Use of stem cells expressing mesenchymal and neuronal markers and compositions thereof to treat neurological disease

ABSTRACT

The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs wherein the hIDPSCs express CD44 and CD13. For example, for treating neurological diseases or conditions including supporting the neuro-protective mechanism in subjects diagnosed with early HD or repairing lost DA neurons in subjects diagnosed with PD.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to and is a Continuation ofInternational Patent Application No. PCT/IB2017/051404, filed on Mar. 9,2017 (published as WO 2017/153956) and claims priority to and is aContinuation-In-Part of U.S. patent application Ser. No. 15/065,259filed on Mar. 9, 2016 (published as US 2016/0184366), which claimspriority to and is a Continuation-In-Part of U.S. patent applicationSer. No. 14/214,016 filed on Mar. 14, 2014 (now U.S. Pat. No.9,790,468), which claims priority to U.S. Provisional Patent ApplicationNo. 61/791,594 filed on Mar. 15, 2013 and to U.S. Provisional PatentApplication No. 61/800,245 filed on Mar. 15, 2013. U.S. application Ser.No. 15/065,259 also claims priority to U.S. Provisional Applications No.62/130,593, filed on Mar. 9, 2015; 62/130,585, filed on Mar. 9, 2015;and 62/220,792, filed on Sep. 18, 2015. Each of the foregoingapplications is hereby incorporated by reference in its entirety.

TECHNICAL FIELD

This application relates to methods of producing stem cells, stem cellsand compositions comprising stem cells suitable for the treatment ofseveral diseases, especially neurological diseases, suitable forsystemic administration.

BACKGROUND

Even though the genes responsible of neurodegenerative diseases and itsprotein have been identified, the mechanism of pathogenesis involved inthese diseases is still unknown, which precludes the development ofefficient therapeutic interventions. What is currently known is thatalthough it is ubiquitously distributed, the mutant form of Huntingtonprotein, for example, causes neurodegeneration and selective loss ofmedium spiny neurons, which preferentially occurs in the striatum and inthe deeper layers of the cerebral cortex during the early phases of thedisease. Thus, cell therapy has been investigated as an additional oralternative treatment which may contribute positively on the course ofthis disease and other similar neurodegenerative diseases. Stem cellsare the essential building blocks of life, and play a crucial role inthe genesis and development of all higher organisms. Due to neuronalcell death caused, for example, by accumulation of the mutatedhuntingtin (mHTT) protein, it is unlikely that such brain damage can betreated solely by drug-based therapies. Stem cell-based therapies areimportant in order to reconstruct morphological design and functionalability of neural tissue in damaged brain areas in patients. Thesetherapies used to have a dual role: transplanted stem cells paracrineaction (anti-apoptotic, anti-inflammatory, anti-scar, anti-bacterial andangiogenic actions), which stimulates local cell survival, inhibitsinflammation and brain tissue regeneration through the production ofbioactive molecules acting in favor of new neurons production from theintrinsic and likely from donor stem cells.

The brain-derived neurotrophic factor (BDNF) is a gene responsible forBDNF protein expression found in the brain and spinal cord. This proteinpromotes the survival of nerve cells (neurons) by playing a role in thegrowth, maturation (differentiation), and maintenance of these cells. Inthe brain, the BDNF protein is active at the connections between nervecells (synapses) where cell-to-cell communication occurs. The BDNFprotein helps regulate synaptic plasticity, which is important forlearning and memory and is found to be expressed in regions of the brainthat control eating, drinking, and body weight. Thus, BDNF hasadditional action in modulating all these functions. Increasing evidencesuggests that synaptic dysfunction is a key pathophysiological hallmarkin neurodegenerative disorders, including Alzheimer's disease. Thedeficits in BDNF signaling contribute to the pathogenesis of severalmajor diseases and disorders such as Huntington's disease anddepression. Thus, manipulating BDNF pathways represents a viabletreatment approach to a variety of neurological and psychiatricdisorders. Administration of BDNF alone offers a viable approach totreating neurodegenerative diseases. However, it is difficult to find anideal dose for each patient because of genetic and individualpolymorphism of neurodegenerative diseases manifestation. Overdoses ofBDNF could induce tumor formation in the brain; on the other hand lowBDNF doses could not provide an efficient treatment. Stem cells aftertransplantation are under the control of the patient biology, which canmodulate BDNF secretion by the cells efficiently for each patient.Additionally, the studies investigating the benefits of stem celltransplantation for treating Alzheimer disease demonstrated thattransplanted nerve stem cells (NSC) support the formation of newconnections between host brain cells. These studies demonstrate thatstrengthening these connections can reverse memory losses in Alzheimerdisease mouse models. It seems that BDNF, a factor naturally secreted byNSC, can replicate the effects produced by stem cell transplantation.

Once NSC is generally difficult to access and cannot be obtained insufficient therapeutic quantities to be applied in stem cell therapythrough intravenous (IV) injection. Typically, two strategies are usedto increase BDNF secretion. First, is the addition of growth factorsinto culture medium of in vitro cultured stem cells in order to induceBDNF secretion. However, this strategy has great limitations due to thefact that stem cells produce this factor only under in vitro conditions.Consequently, when such cells are transplanted to a patient they rapidlyspend the “stock” of BDNF, which prevents long term treatment ofneurodegenerative disease. Another approach is to produce geneticallymanipulated stem cells which are suitably modified to overexpress BDNF.It is important to note that even NSC need to be genetically engineeredto produce therapeutically sufficient levels of BDNF. However, genemodification has its roots in gene therapy—an approach that still has tobe proven. Therefore, there is a great need for new cell types and cellculture methods which can lead to stem cells with elevated secretion ofBDNF.

The subventricular zone (SVZ) is the unique brain area where new neuronsare produced throughout life (Altman J and Das G D 1965) and ingenerating cells to function in repair through adulthood. Blood vesselsimmediately subjacent to the SVZ run parallel to the direction oftangential neuroblast migration, and guide migratory neuroblasts viaBDNF signaling. It is now understood that the organization of the SVZ inthe adult human brain differs significantly from that of any otherstudied vertebrates. Specifically, this region in the adult human braincontains a unique tape of astrocytes that proliferate in vivo and canfunction as NSC in vitro. Astrocytes in the central nervous systemperform many important and diverse functions. They are involved information of the neuro-vascular unit which is composed of a neuron, anastrocyte and a blood vessel. Astrocyte processes extend to and interactwith blood vessels. Astrocytic endfeet are in intimate contact with thebasal lamina that is a component of the vessel wall and together withendothelial cells they form the blood-brain barrier (BBB). Isolation ofstem cells, which have a capacity to migrate and home in a neurogenicniche as well as around blood vessels in the adult human brain, furtherbeing able to differentiate into neurons and glial cells, is a basis forthe development of novel neurodegenerative cell therapies.

Dopamine (DA) is a major neurogenesis factor in the adult SVZ (Baker etal., 2004). The proximity of the SVZ with the striatum makes it aneurodegeneration therapy target for striatum-neurodegenerationassociated disorders such as Huntington's disease (HD) and Parkinson'sdisease (PD). Both pathologies are characterized by different clinicalsymptoms of motor dysfunction, and both are thought to involve theSVZ-striatum DA micro-circuitry path through different mechanisms. Thedisease-generated DA innervation that occurs in HD is a naturalprotective feedback mechanism to compensate for the striatal internalneurons degeneration pathology caused by inherent genetic mutation(Parent M et al., 2013). Dysregulation of DA receptor D2 is a sensitivemeasure for Huntington disease pathology in model mice (Crook et al.,2012; Chen et al., 2013). In contrast, PD is associated with massivedegeneration of DA neurons, due to impaired neurogenesis in thenigrostriatal area and is a major cause of the pathology (Hoglinger et.al., 2004).

The initial inflammatory response occurs in the body to limit theinvasion of foreign bacteria or viruses or parasites and to defendtissues against molecular foes which are further removed from theorganism by anti-inflammatory mechanisms. However, chronic inflammation(CI) is a double-edged sword. CI is long lasting event and itcontinuously harms and kills healthy cells as, for example, inrheumatoid arthritis where the inflammation becomes self-sustaining.

In neurodegenerative diseases several molecules of the protein aretightly aggregated together inside the cell, which pathologists call an“amyloid” structure, and they are apt to clog the brain. Such proteinswere found in Alzheimer's disease—amyloid beta and tau; in Parkinson'sdisease—alpha synuclein, and in Huntington's disease—huntingtin. Theseaggregates often form large insoluble deposits in the brain. However,the truly toxic ones are considered the small, soluble aggregates ofthese proteins. Due to the accumulation of these aggregates in thebrain, chronic inflammatory reactions remained in many age-relatedneurodegenerative disorders among which are aforementioned diseases(Nuzzo et al., 2014).

Degenerated tissue, the presence of damaged neurons and neurites, highlyinsoluble amyloid β peptide deposits, and neurofibrillary tangles in thebrains of Alzheimer disease (AD) carriers provide obvious stimuli forinflammation (Zotova et al., 2010; Schott and Revesz, 2013).

Many studies have suggested that the chronic inflammation observed in ADaccelerates the disease process and may even be a disease trigger. Ahistory of head injury and systemic infections are factors, whichtypically cause brain inflammation and are known to be risk factors forAD. Excessive action of the brain's immune cells, which are glial cells,is another hallmark of Alzheimer's disease. Although it has beensuggested that inflammation is associated with injury and toxicity toneurons, the relationship among glial cells, neurons and amyloid plaquesstill remains unclear. Inflammatory mediators released by glial cellscan be extremely toxic to neurons. Thus, they have been considered asmediators of neurodegeneration.

Two closely related inflammation-promoting proteins, IL-12 and IL-23,are among those pumped out by microglia when the cells becomeimmunologically active. The studies demonstrated that these proteinsexist at elevated levels in the cerebrospinal fluid of AD patients.Blocking these inflammatory proteins in older Alzheimer's mice whosebrains were already plaque-ridden reduced the levels of soluble, moretoxic forms of amyloid beta and reversed the mice's cognitive deficits(Vom Berg et al., 2012; Griffin, 2013).

More recently, other anti-inflammatory approaches such as the blockingof a protein NLRP3 and microglial protein MRP14 have been described andalso seem to work well in the same Alzheimer's mouse model. Theseapproaches reduce brain inflammation, amyloid beta deposition, andcognitive impairments. In Alzheimer's mice that were geneticallyengineered to lack NLRP3, microglia were reversed back towards anon-inflammatory state in which they consume much more amyloid beta andsecrete neuron beneficial proteins. In another study, a microgliaprotein MRP14 was targeted, which also helped to reverse microglia to anon-inflammatory state (Heneka et al., 2013; Zhang et al., 2012).

The other factor which is critical for AD is aging. Aging may helptrigger Alzheimer's by worsening common age-related problems withneurons, which become functionally deficient and lose their ability totransport and appropriately place proteins. Inflammation worsens thisproblem by increasing the production of amyloid-beta in inflamedregions, stressing neurons, and hastening the age-related decline oftheir protein-transport and disposal systems. Inflammation reactivatesmicroglia into an inflammatory state and thus reduces their ability toclear up the brain (Swindell et al., 2013).

Currently, it is assumed that inflammation helps to start the AD processby increasing the production of amyloid beta. The inflammation seems tobe self-sustaining in AD because it reduces the ability of microglia toremove amyloid beta. Therefore, constant deposition of amyloid beta doesnot allow the inflammation to resolve, which gets worse in aged ADcarriers (Akiyama et al., 2000; Vom Berg et al., 2012; Zang et al.,2012; Griffin, 2013; Heneka et al., 2013; Swindell et al., 2013; Schottand Revesz, 2013).

The contribution of inflammation to neurodegeneration in Huntingtondisease (HD) is strongly suggested; however it is less studied then inAD (Soulet and Cicchetti, 2011; Ellrichmann et al., 2013). Thus, anactivation of the immune system in HD was clearly proven by the elevatedexpression of pro-inflammatory cytokines, which are crucial to thebody's immune response, such as, IL-6 and TNF-alpha. Thesepro-inflammatory cytokines were significantly increased in the striatum,plasma and CSF in mouse models and in symptomatic as well aspresymptomatic HD patients. Additionally, innate immune cellhyperactivity was detected through elevated IL-6 production in mutantmHTT expressing myeloid cells of the central (microglia) and peripheralinnate immune system (monocytes and macrophages) both in HD patients andmouse models. It has also been reported that abnormally high levels ofcytokines were present in the blood of people carrying the HD gene manyyears before the onset of symptoms (Björkqvist et al., 2008; Träger etal., 2014a, b). The composition of cytokines and levels of theirexpression, which can be measured in a blood of patients, could beuseful to establish the need to initiate intervention for therapies aswell as the timing of therapies.

Blood cells, due to the presence of the abnormal HD protein (huntingtin)inside the cells, were hyperactive in HD patients, as well as microgliain the brain, thus suggesting that abnormal immune activation could beone of the earliest abnormalities in HD. The patient's blood signaturecould provide a new insight into the effects of the HD in the brain aswell as markers of HD severity. Anomalous immune activation could be atarget for future treatments aimed at slowing down HD (Soulet andCicchetti, 2011, Ellrichmann et al., 2013).

Parkinson's disease is characterized by a slow and progressivedegeneration of dopaminergic neurons in the substantia nigra. Usinganimal models researchers have obtained consistent findings aboutinvolvement of both the peripheral and the central nervous system immunecomponents in response to inflammation, which initiates an immuneresponse in PD. The presence of continuing and increasingpro-inflammatory mechanisms results in a process whereby cellularprotective mechanisms are overcome and the more susceptible cells, suchas the dopaminergic neurons, enter into cell death pathways, which leadsto a series of events that are a crucial for the progression of PD(Doursout et al., 2013). Inflammatory responses also manifested by glialreactions, T cell infiltration, and increased expression of inflammatorycytokines, as well as other toxic mediators derived from activated glialcells, are well known features of PD. More recent in vitro studies,however, proposed that activation of microglia and subsequentlyastrocytes via mediators released by injured dopaminergic neurons isinvolved, even though they are unlikely to be a primary cause forneuronal loss (Hirsch et al., 2003). In patients the epidemiological andgenetic studies support a role of neuroinflammation in thepathophysiology of PD. Post mortem studies confirm the involvement ofinnate as well as adaptive immunity in the affected brain regions inpatients with PD. Activated microglial cells and T lymphocytes have beendetected in the substantia nigra of patients concomitantly with anincreased expression of pro-inflammatory mediators (Tufekci et al.,2012; Hirsch et al., 2012). Another study, which enrolled 87 Parkinson'spatients between 2008 and 2012, together with 37 healthy controlsmeasured markers of inflammation such as C-reactive protein (CRP),interleukin-6, tumor necrosis factor-alpha, eotaxin, interferongamma-induced protein-10, monocyte chemotactic protein-1 (MCP-1) andmacrophage inflammatory protein 1-beta in routine blood tests. Allparticipants underwent physical exams as well. This study demonstratedthat the degree of neuroinflammation was significantly associated withmore severe depression, fatigue, and cognitive impairment even aftercontrolling for factors such as age, gender and disease duration(Lindqvist et al., 2013). Neuroinflammatory processes might represent atarget for neuroprotection, and anti-inflammatory strategies may be oneof the principal approaches in the treatment of PD.

Multiple approaches have been tested to repairneurodegeneration-associated CNS diseases, including clinical motordysfunction diseases (Wernig M, et al., 2011). Stem cells sources usedfor neuro-regeneration cell therapy include mesenchymal stem cells(MSC), neural progenitor cells (NP), human fetal neuronal stem cells(huNSC), and pluripotent stem cells (both embryonic (ESCs) and induced(iPSC)). Most of the studies on cell therapy for neurological conditionsused neuronal-like cells through major cellular manipulation and/orhighly invasive methods of delivery. For example, WO 2008/132722 and USPatent Application Publication No. 2013/0344041 disclose geneticallymanipulated stem cells to induce stem cell traits or to releaseneurotrophic factors; WO 2009/144718 and US Patent ApplicationsPublication Nos. 2014/0335059 and 2014/0154222 disclose inducing therelease of neurotrophic factors at levels higher than at non-inducedstage via exposure to biological, natural or chemical compounds inculture; and other studies use immortalized cell line of fetal stemcells that express early markers of neuronal differentiation. In spiteof the studies on stem cell therapy, no data have shown that stem celltherapy through intravenous (IV) injection can result in directneurogenesis via BDNF secretion or D2 expression in brain compartmentssuffering from neurodegenerative disease.

SUMMARY OF THE INVENTION

In some aspects, the present invention refers to immature dental pulpstem cells (IDPSCs).

In one embodiment, the present invention refers human immature dentalpulp stem cells (hIDPSCs) expressing CD44 and CD13 and lackingexpression of CD146, obtained by method comprising: a) obtaining dentalpulp (DP) from a human deciduous tooth; b) washing the DP with asolution containing antibiotics and placing the DP in a container with aculture medium; c) mechanically transferring the DP into anothercontainer with the culture medium after outgrowth and adherence of thehIDPSCs is observed to establish an explant culture; d) repeating stepsb) and c) collecting hIDPSCs expressing CD44 and CD13 and lackingexpression of CD146.

In another embodiment, the present invention is directed human immaturedental pulp stem cells (hIDPSCs) expressing CD44 and CD13 and lackingexpression of CD146, HLA-DR, and HLA-ABC, obtained by the methodcomprising: a) obtaining dental pulp (DP) from a human deciduous tooth;b) washing the DP with a solution containing antibiotics and placing theDP in a container with a culture medium; c) mechanically transferringthe DP into another container with the culture medium after outgrowthand adherence of the hIDPSCs is observed to establish an explantculture; d) repeating steps b) and c) to collect hIDPSCs expressing CD44and CD13 and lacking expression of CD146, HLA-DR, and HLA-ABC.

In some aspects, the hIDPSCs are obtained by a method that furthercomprises: e) confirming expression of CD44 and CD13 and lack ofexpression of CD146 in the hIDPSC by immunostaining a sample of thehIDPSC to detect the CD44, CD13, CD146, HLA-DR, and/or HLA-ABC.

In other aspects, the immunostaining involves analysis of the samplewith flow cytometry.

In certain embodiments, steps b) and c) are repeated more than 5 timesand hIDPSC are collected from explant cultures produced after 5transfers of the DP. In other embodiments, steps b) and c) are repeatedmore than 10 times and hIDPSC are collected from explant culturesproduced after 10 transfers of the DP.

In one aspect, the explant culture comprises semi-confluent colonies ofhIDPSCs. In another aspect, the explant culture of hIDPSCs from step c)are passaged prior to collection. In yet another aspect, passaging ofthe explant culture of hIDPSCs comprises enzymatic treatment of thehIDPSCs and transfer of the hIDPSCs to expand the explant culture.

In some embodiments, the hIDPSCs of the present invention are obtainedby a method comprising: extracting dental pulp (DP) from a tooth;culturing the DP in basal culture medium in a first container toestablish a DP explant culture, wherein the DP explant culture iscultured without or with at least one extracellular matrix componentsselected from the group consisting of: fibronectin, collagen, laminin,vitronectin, polylysine, heparan sulfate proteoglycans, and enactin;mechanically transferring the DP to a second container to establish asecond DP explant culture; repeating the step of mechanicallytransferring the DP until at least 15 DP explant cultures have beenestablished; passaging the DP explant culture to produce a passaged DPculture; and combining the passaged DP culture of an early harvestpopulation and an late harvest population to produce the pharmaceuticalcomposition, wherein the early harvest population comprises passaged DPculture established from at least one of the first 15 DP explantcultures and the late harvest population comprises passaged DP cultureestablished from at least one of the DP explant cultures after the 15thDP explant culture. In some implementations, the culturing step occursunder hypoxic conditions. In some implementations, the step of combiningthe passaged DP culture of the early harvest population and the lateharvest population to produce the pharmaceutical composition comprises:simultaneously thawing the frozen stock of passaged DP cultures of theearly harvest population and the late harvest population; and poolingthe thawed passaged DP culture to produce a pharmaceutical composition.

For some embodiments culturing the DP in basal culture medium in themethod of production persists for at least three days before the DP ismechanically transferred. In some implementations, the method ofproduction further comprises creating a frozen stock of the passaged DPculture. In some aspects, the frozen stock of the passaged DP culture iscreated at the third passage of the DP explant culture.

In some embodiments, the invention is directed to hIDPSCs obtained bymethod comprising: extracting dental pulp (DP) from a tooth; culturingthe DP in basal culture medium in a first container to establish a DPexplant culture, wherein the stem cells comprising late harvest enrichedfrom tissue of neural crest origin are double positive for CD44 andCD13. In some aspects, the stem cells enriched from tissue of neuralcrest origin and double positive for CD44 and CD13 are immature dentalpulp stem cells (IDPSCs).

In some embodiments, the invention is directed to is directed to hIDPSCsobtained by a method comprising: extracting dental pulp (DP) from atooth; culturing the DP in basal culture medium in a first container toestablish a DP explant culture, wherein the stem cells comprising lateharvest enriched from tissue of neural crest origin demonstratedincreasing level of secretion of endogenous BDNF and/or otherneurotrophic factors (NF3, NF4 and NF5), when compared to stem cellsobtained from early harvest. In some aspects, the stem cells enrichedfrom tissue of neural crest origin and secreting high level ofendogenous BDNF and/or other neurotrophic factors (NF3, NF4 and NF5) areimmature dental pulp stem cells (IDPSCs).

In yet other embodiments, the hIDPSCs of the present invention areobtained by methods that produce hIDPSCs which express of CD44 and CD13and lack expression of CD146 which enables the hIDPSCs to cross the BBBand/or lack of expression of CD146, HLA-DR, and/or HLA-ABC whichprevents rejection of the hIDPSCs by immune cells.

In one embodiment, the hIDPSCs of the present invention are obtained bymethods that produce stem cells expressing at least one safety markerselected from the group consisting of ATP-binding cassette sub-family Gmember 2 (ABCG2), p53, and inactive nanog. Inactive nanog is expressednanog localizing predominantly in the cytoplasm of the stem cell. Insome aspects, at least 75% of the stem cells express ABCG2, at least 75%of the stem cells express p53, or no more than 5% of the stem cellsexpress inactive nanog. Some stem cells further express the safetymarker SOX2. In some such embodiments, no more than 30% of the stemcells express SOX2.

The hIDPSCs of the present invention are further obtained by methodsthat produce stem cells that may further secrete at least one markerselected from the group consisting of brain-derived neurotrophic factor(BDNF), neutrotrophin-3 (NT3), neutrotrophin-4 (NT4), neutrotrophin-5(NT5), and p75. In some such embodiments, the stem cells of thepharmaceutical composition express BDNF, NT3, NT4, NT5, and p75 (CD271).

In another embodiment, the hIDPSCs of the present invention are obtainedby methods that produce stem cells that express at least oneneuroepithelial stem cell marker selected from the group consisting ofBDNF, NT3, NT4, NT5, and p75. In some aspects, the stem cells producedby the methods of the present invention express BDNF, NT3, NT4, NT5, andp75. These cells may further express at least one safety marker selectedfrom the group consisting of ABCG2, inactive nanog, p53, and SOX2. Insome aspects, at least 75% of stem cells express the at least one markerwhen the at least one marker is ABCG2. In some aspects, at least 75% ofthe stem cells express p53. In some aspects, no more than 5% of the stemcells express inactive nanog. In some aspects, no more than 30% of thestem cells express SOX2.

In one embodiment, the invention is directed to stem cells, wherein thestem cells comprise late harvest enriched from tissue of neural crestorigin. In some implementations, the tissue of neural crest origin isdental pulp. In some aspects, the stem cells enriched from tissue ofneural crest origin are immature dental pulp stem cells (IDPSCs). Earlyharvest stem cells enriched from tissue of neural crest origin compriseIDPSCs of the first fifteen or the first 25 harvest cycles whereas lateharvest stem cells comprise IDPSCs from the sixty or later or the 26thor later harvest cycle.

In yet other embodiments, the invention comprises hIDPSCs which expressof CD44 and CD13 and lack expression of CD146 which enables the hIDPSCsto cross the BBB and/or lack of expression of CD146, HLA-DR, and/orHLA-ABC which prevents rejection of the hIDPSCs by immune cells.

In one embodiment, the invention refers to stem cells expressing atleast one safety marker selected from the group consisting ofATP-binding cassette sub-family G member 2 (ABCG2), p53, and inactivenanog. Inactive nanog is expressed nanog localizing predominantly in thecytoplasm of the stem cell. In some aspects, at least 75% of the stemcells express ABCG2, at least 75% of the stem cells express p53, or nomore than 5% of the stem cells express inactive nanog. Some stem cellsfurther express the safety marker SOX2. In some such embodiments, nomore than 30% of the stem cells express SOX2.

The stem cells of the present invention may further secrete at least onemarker selected from the group consisting of brain-derived neurotrophicfactor (BDNF), neutrotrophin-3 (NT3), neutrotrophin-4 (NT4),neutrotrophin-5 (NT5), and p75. In some such embodiments, the stem cellsof the pharmaceutical composition express BDNF, NT3, NT4, NT5, and p75(CD271).

In another embodiment, the stem cells of the present invention expressat least one neuroepithelial stem cell marker selected from the groupconsisting of BDNF, NT3, NT4, NT5, and p75. In some aspects, stem cellsof the present invention express BDNF, NT3, NT4, NT5, and p75. Thesecells may further express at least one safety marker selected from thegroup consisting of ABCG2, inactive nanog, p53, and SOX2. In someaspects, at least 75% of stem cells express the at least one marker whenthe at least one marker is ABCG2. In some aspects, at least 75% of thestem cells express p53. In some aspects, no more than 5% of the stemcells express inactive nanog. In some aspects, no more than 30% of thestem cells express SOX2.

In some embodiments, the present invention is directed to compositionscomprising hIDPSCs produced according to the methods disclosed herein.

In some embodiments, the present invention is directed to a compositioncomprising the hIDPSCs disclosed herein.

In other embodiments, the present invention relates to pharmaceuticalcompositions for use in the treatment of a neurological disease orcondition selected from the group consisting of Parkinson's disease(PD), multiple sclerosis, epilepsy, amyotrophic lateral sclerosis (ALS),stroke, ischemia, autoimmune encephalomyelitis, diabetic neuropathy,glaucomatous neuropathy, Alzheimer's disease, Huntington's disease (HD),autism, schizophrenia, a motor disorder, and a convulsive disorder.

The present invention further relates to pharmaceutical compositions forsystemic administration to a subject to treat a neurological condition.The neurological disease or condition may be a neurodegenerative diseaseor condition, autism, schizophrenia, epilepsy, stroke, ischemia, a motordisorder, or a convulsive disorder. Neurodegenerative disease orcondition may be Parkinson's disease (PD), multiple sclerosis, epilepsy,amyotrophic lateral sclerosis (ALS), stroke, autoimmuneencephalomyelitis, diabetic neuropathy, glaucomatous neuropathy,Alzheimer's disease, or Huntington's disease (HD).

The present invention also relates to methods of using the hIDPSCsand/or pharmaceutical compositions of the present invention to treatneurological diseases or conditions.

The present invention also relates a method of treating a neurologicaldisease or condition comprising administering to a subject the hIDPSCsand/or pharmaceutical compositions of the present invention.

In some embodiments, the administration of the hIDPSCs and/orpharmaceutical compositions of the present invention is systemic and isadministered to a subject in need thereof.

In some embodiments of the invention, such methods support the naturalneuro-protective mechanism in subjects diagnosed with early HD orrepairing lost DA neurons in subjects diagnosed with PD. The methods mayalso be used as a preventive therapy for subjects at risk of HD.

In one embodiment of the methods, the neurological disease or conditionis treated by the stem cells and/or pharmaceutical compositions of thepresent invention crossing the blood/brain barrier (BBB) and inducingneurogenesis. In some aspects, the hIDPSCs are directly transplantedinto the brain parenchyma, including striatum, following crossing of theBBB. In some embodiments, the induced neurogenesis isdopamine-associated. For example, dopamine-associated neurogenesisoccurs through self-differentiation of the stem cells or activation ofmigration and differentiation of intrinsic stem cells by the extrinsicstem cells. In some aspects, massive dopamine-associated neurogenesistakes place in the subventricular zone (SVZ).

In some embodiments of the methods, hIDPSCs and/or the pharmaceuticalcomposition provide neuroprotection. For example, systemicneuroprotection is provided with the high basal level of neurotrophicand immunoprotective factors expression and release pattern of the stemcells of the pharmaceutical composition. In some aspects, these stemcells of the pharmaceutical composition are IDPSCs.

In some implementations, the methods further comprise measuring theamount of DA receptor in the subject. In some aspects, the DA receptoris receptor D2. In some embodiments, measuring the amount of DAreceptor, for example receptor D2, in the subject comprises imaging thesubject to detect presence of DA receptor.

In some aspects, the subject is administered a single administration ora first and second administrations of the pharmaceutical composition.The repetitive (from 1 to six) administrations of the hIDPSCs and/orpharmaceutical composition take place at least seven days, at least 14days, at least 21 days, or at least 30 days after the firstadministration, as well as one time per year, or twice per year. In someimplementations, administration of the hIDPSCs and/or pharmaceuticalcompositions is through intravenous injection. In some implementations,the administration of the pharmaceutical composition may be repeatedannually, for example, repeated three times.

In some implementations of the methods, the hIDPSCs and/orpharmaceutical composition comprising stem cells, comprise stem cellsthat are autologous to the subject. For example, stem cells autologousto the subject are collected from the subject before diseasemanifestation from contingently “healthy cells”, given that most ofthese diseases are genetic and age dependent. In other implementations,the hIDPSCs and/or pharmaceutical composition comprising hIDPSCs thatare allogeneic to the subject regardless of whether the majorhistocompatibility complex expressed by the stem cells match the majorhistocompatibility complex expressed by subject. The pharmaceuticalcomposition may also comprise a combination of stem cells that areautologous to the subject and stem cells that are allogeneic to thesubject.

In one aspect, the present invention is directed to a method ofpreventing neuron loss in the central nervous system (CNS) of a subject,the method comprising administering to the subject hIDPSCs and/or apharmaceutical composition comprising hIDPSCs, wherein the hIDPSCsexpress CD44 and CD13.

In another aspect, the present invention provides a method of promotingneuron cell growth and repair in the CNS of a subject, the methodcomprising administering to the subject hIDPSCs and/or a pharmaceuticalcomposition comprising hIDPSCs, wherein the hIDPSCs express CD44 andCD13.

In yet another aspect, the present invention is directed to a method ofincreasing expression of dopamine- and cAMP-regulated neuronalphosphoprotein (DARPP-32), dopamine receptor D2, and/or brain-derivedneurotrophic factor (BDNF) in the CNS of a subject, the methodcomprising administering to the subject hIDPSCs and/or a pharmaceuticalcomposition comprising hIDPSCs, wherein the hIDPSCs express CD44 andCD13.

In certain aspects, administration of the hIDPSCs and/or pharmaceuticalcomposition is systemic. In one aspect, the systemic administration isintravenous or intraperitoneal.

In other aspects, the present invention relates to hIDPSCs and/or apharmaceutical composition comprising hIDPSCs expressing CD44 and CD13for use in the treatment of a neurological disease or condition selectedfrom the group consisting of Parkinson's disease (PD), multiplesclerosis, amyotrophic lateral sclerosis (ALS), stroke, autoimmuneencephalomyelitis, diabetic neuropathy, glaucomatous neuropathy,Alzheimer's disease, Huntington's disease (HD), autism, schizophrenia,stroke, ischemia, a motor disorder, and a convulsive disorder.

In yet other aspects, the present invention is directed to the use ofhIDPSCs and/or a pharmaceutical composition comprising hIDPSCsexpressing CD44 and CD13 for the treatment of a neurological disease orcondition selected from the group consisting of Parkinson's disease(PD), multiple sclerosis, amyotrophic lateral sclerosis (ALS), stroke,autoimmune encephalomyelitis, diabetic neuropathy, glaucomatousneuropathy, Alzheimer's disease, Huntington's disease (HD), autism,schizophrenia, stroke, ischemia, a motor disorder, and a convulsivedisorder.

The present invention also relates to methods of using the hIDPSCsand/or pharmaceutical compositions of the present invention to preparemedicaments to treat neurological diseases or conditions.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts immunophenotyping of hIDPSC from early and late harvests.Harvests 0-10 were defined as early harvests. All harvests that had morethan 10 harvests were defined as late harvests.

FIG. 2 depicts IDPSC at late harvest (13 harvests) and at passage 3. Thecells were immunopositive for P75 (CD271) (A, C, D), nestin (E-G), CD13(H) and CD73 (I), and they did not react with CD146 (J) and HLA-ABC (K).Insets, depict the control for respective secondary antibodies. A-GLight Microscopy. H-L Epi-Fluorescence. Magnification: A,J-20×;C,E-G,H,I,L-10×; D,K-40×.

FIG. 3 depicts in a) CFU-F assay performed in triplicate at T20, passage3, demonstrating high clonogenic capacity of a LP population of IDPSCs.In b) and c) FACS analysis performed to show that LP (late population)IDPSCs (batch #11) comprise approximately 80% cells that express BDNFand DARPP 32 while EP early population IDPSCs are negative for thesemarkers (data not shown) and comprise a very low number of the cellswhich express D2.

FIG. 4A depicts positive immunostaining for BrdU (B-J) in control cellswith a secondary antibody. FIGS. 4B and 4C depict quantification of LP(late population) IDPSCs which react positively with a BrdU antibody.(A)—Epi-fluorescence, (B) and (C)—FACS analysis. Magnification (A)—200×.(B, E and H)—400×. (C, F, I, D, G and J)—1000×.

FIG. 5 depicts quantitative PCR for expression of endogenous Oct4, Nanogand Sox2 genes observed in hIDPSCs before (black color) and afterreprogramming (white color) as well as in human embryonic stem cells(hESC) (striped).

FIG. 6 depicts the quantification of GFAP (glial fibrillary acidicprotein) and beta-III-tubulin expression in EP (early population) and LP(late population) IDPSCs by flow cytometry.

FIG. 7 depicts a flow cytometry analysis of EP (early population) and LP(late population) hIDPSC. Changes in CD146 and CD13 expression wereobserved following in vitro DP harvesting and hIDPSC passing. ForEP-hIDPSC, ˜33% of CD146 positive cells were observed, while forLP-hIDPSC, less than 1% of the cells were positive for this marker. ForEP-hIDPSC ˜52% of CD13 positive cells were observed, while for LP-hIDPSC95% of the cells were positive for this marker.

FIG. 8 depicts immunostaining of IDPSC isolated from dental pulp ofC57BL-6 mice. IDPSC are positive for Oct4 (A-B) with the expressionmainly located in the nucleus. The cells are also positive for Nanog,although the expression is limited in the (C). Symmetrical division wasobserved in Nanog+ cells (D). Two Sox2+ IDPSC and one Sox2− cellresulted from symmetric and asymmetric division (E). Symmetricaldivision of Sox2+ cell, nuclear protein localization can be observed(F). Asymmetrical division of cells Sox2+ more committed daughter lossSox2 expression (G). A-C: 200×. D-G: 400×.

FIG. 9 depicts the switch from symmetric to asymmetric neural stem celldivisions in the optic lobe.

FIG. 10 depicts the expression of undifferentiated LSCs anddifferentiated corneal cells proteins (as an example of limbalneuroectodermal lineage) in IDPSCs grown on plastic substrate for sevendays in different culture media. IDPSCs cultured in Epilife, DMEM/KO,KSFM, and SHEM culture media lacked expression of ABCG2 (A1-A4).However, expression of ABCG2 was detected in IDPSCs cultured inDMEM/F12, also known as basal culture medium (A5). These cells developeda fibroblast-like morphology. IDPSCs cultured in Epilife, KSFM, andDMEM/F12 lacked expression of CK3/12 (B1, B3, B5). However, IDPSCcultured DMEM/KO and SHEM expressed CK3/12 and had an epithelialcell-like morphology (B2, B4). Epi-fluorescence (EF). Nucleus stainedwith DAPI (blue). Scale bars: 10 μm for A1-A4, B1, B2, and B4; 5 μm forA5, B3, and B5.

FIG. 11 depicts the expression of undifferentiated LSCs anddifferentiated corneal cells markers in IDPSCs grown during seven daysin different culture media on amniotic membrane (AM). Vimentin wasdetected in IDPSCs grown in DMEM/F12, SHEM, KSFM and DMEM/KO culturemedia (A and A1-A3). ABCG2 was detected in IDPSCs grown in basal culturemedia and SHEM (B and B1) but not in IDPSC grown in KSFM and DMEM/KO (B2and B3). CK3/12 expression was not detected in IDPSC cultured DMEM/F12,SHEM and KSFM (C, C1, and C2). Some IDPSCs expressing CK3/12 weredetected in IDPSCs grown in DMEM/KO (C3). These IDPSCs expressing CK3/12have fibroblast-like morphology. Nucleus stained with DAPI (blue). EF.Scale bars: A1-A4, B1, B2, B4=10 μm; A5, B3, B5=5 μm.

FIG. 12 depicts pharmacological efficacy studies of investigationalproduct CELLAVITA™ (stem cells).

FIG. 13 depicts a scheme for the manufacturing process of compositionsof IDPSCs comprising both early and late population IDPSCs suitable forthe treatment of neurological diseases and conditions.

FIG. 14 depicts a time line of stability studies of hIDPSC during longterm cryopreservation, following thawing and shipping before local ofapplication in animal models of human diseases.

FIG. 15 depicts the timeline of the pilot study in the HD disease model.HD was induced during the first four days, day 0 (DO) to day 4 (D4) byadministering 3-NP. On the fifth day (D5), IDPSC transplantation wasadministered via intravenous injection. Animals were euthanized on day 9(D9) followed by fixation of brain tissues and histological analysis ofthe lesions for the detection of IDPSCs biodistribution and engraftment(Vybrant+immunohistochemistry using specific antibodies).

FIG. 16 depicts the timeline for the Group I study in the HD diseasemodel. HD was induced during the first four days, day 0 (DO) to day 4(D4). On the fifth day (D5), IDPSC transplantation was administered viaintravenous injection. Animals were euthanized on day 35 (D35) followedby brain tissues fixation and histological analysis of lesion fordetection of IDPSC biodistribution and engraftment(Vybrant+immunohistochemistry using specific antibodies).

FIG. 17 lists the “global biomarkers” (i.e. internationally-accepted)used for the evaluation of 3-NP-induced neurodegeneration process aswell as the effect of IDPSCw transplantation on this process.

FIG. 18 depicts the localization of markers used for evaluation ofneurodegeneration. The red circles point to the usual locations of HDlesions and form scar tissue, which marked with positive expression ofcollagen I. In health areas, the expression of GABAergic and receptor D2proteins can be observed. Engraftment of hIDPSCs after IV administrationis shown by detection of human nucleus using immunohistochemistry and bycolocalization of CD73 and hIDPSC using immunofluorescence.

FIG. 19 depicts the engraftment of hIDPSCs after intravenous injectioninto the animals. Optical cuts demonstrate at different depth of focus(A1-A4) the presence of hIDPSC stained with Vybrant (green), nucleistained with PI (red). The cells demonstrate capillary predominantassociation and different morphological types: neuron-like cells andpericytes (A6). On A2-A4, two pericytes at different location alongcapillary can be observed. Both present similar morphology. On A4,embranchment of axon is also shown. A5 presents a scheme of neuronmorphology inside brain tissues showed in A2-A4. Neurons nuclei arelight with nucleolus, which has observably differences than nuclei thatare strongly stained. Blue-artificial color of confocal microscope.Epifluorescence+Digital Interference contrast (DIC). Scale bar=10 μm.

FIG. 20 depicts the engraftment of hIDPSCs four days after IVadministration. Optical cut demonstrates hIDPSC stained with Vybrant(green) and positively reacted with anti-hIDPSC antibody (red).Superposition of both produces yellow color. The cells demonstrate nearcapillary localization. Two markers for MSC were used: CD73 and CD105demonstrating positive reaction with hIDPSC (A-D). E. Positive controlhIDPSC cultured in vitro. Confocal microscope. Epifluorescence+DigitalInterference contrast (DIC). Scale bar: A=5 μm; B=10 μm; C=20 μm; D=5μm.

FIG. 21 depicts immunohistochemistry results using anti-human nuclei(hNu) anti-body. Few hIDPSCs cells can be observed in the cortex of therat brain while multiple cells can be observed in the striatum. Lightmicroscopy. 90×. Scale bars: 5 μm (left) and 25 μm (right).

FIG. 22 depicts immunohistochemistry results of the brain 30 days afterIDPSCs injection using anti-human nuclei (hNu) anti-body. The bluecircles point to cells that present triangular neuron-like body. Thesize of the triangular-bodied cells is indicative of the cells being“neurons.” The white circle point to a fibroblast-like cell. Lightmicroscopy. 90×.

FIG. 23 depicts immunohistochemistry results of the brain usinganti-human nuclei (hNu) anti-body. In blue circles hIDPSCs localized instriatum and in SVZ are shown. Light microscopy. 90×

FIG. 24 depicts positive DARPP32 immunostaining for neurons inCELLAVITA™ (stem cells)-treated animals 30 days after hIDPSCtransplantation (A, B) Untreated animals (3-NP+saline) showing noDARPP32 immunostaining in the striatum or cortex. (C, D) Rat neuronproduction in the cortex and striatum of hIDPSC-treated animals. Circledin blue, area with neurons in (C) and higher magnification in (D). Lightmicroscopy. Magnification: 20× and 90×.

FIG. 25 depicts the expression of receptor D2 in the striatum of HD ratmodel before administration of IDPSC and 30 days after administration ofIDPSC. Samples from animals with scores 3 and 2 are of animals treatedwith 3-NP but did not receive IDPSC treatment. In the score 2 sample,only a few receptor D2 positive cells could be observed while no suchcells could be observed in the score 3 sample. Sample from animals withscore 1 is of an animal treated with 3-NP and IDPSC. In the score 1sample, multiple receptor D2 positive cells could be seen. Inset highmagnification demonstrated the details of immunostaining and neuronmorphology.

FIG. 26 depicts the experimental design for Group II and III in order tostudy the effects of multiple IDPSC transplantations and elevated celldoses in HD disease model.

FIG. 27 depicts an example scheme of how to determine the extent ofmotor deterioration in rats with HD induced by 3-NP.

FIG. 28 depicts the body weight of pilot study animals before 3-NPinduction, after 3-NP induction (day 4), and after treatment with IDPSCs(hIDPSCs).

FIG. 29 depicts the body weight of Group II and Group III animals before3-NP induction and after 3-NP induction.

FIG. 30 depicts the body weight of Group II animals after 3-NP inductionand 30 days after treatment with hIDPSCs.

FIG. 31 depicts the body weight of Group III animals after 3-NPinduction and 30 days after treatment with hIDPSCs.

FIG. 32 depicts the timeline of the pilot study in the HD disease model(groups I, II, III, and IV). HD was induced during the first four days,day 0 (DO) to day 4 (D4) by 3-NP. On the fifth day (D5), IDPSCtransplantation was administered via intravenous injection. Animals wereeuthanized on day 9 (D9) followed by brain tissue fixation andhistological analysis of lesion for detection of IDPSC biodistributionand engraftment (Vybrant+immunohistochemistry using specificantibodies). Group I and III were euthanized on day 35 (D35) and groupsII and IV on day 95 followed by brain tissues fixation and histologicalanalysis of lesion for detection of IDPSC biodistribution andengraftment (Vybrant+immunohistochemistry using specific antibodies).

FIG. 33 presents localization of hIDPSC in rat brain tissue four daysafter hIDPSC administration. hIDPSC cells were stained green (Vybrant)and nuclei were stained red (PI) (A1-A4). Cells were localized mainly incapillaries and two morphological types were observed: neuron-like cellsand pericytes. Note the different localization of pericytes incapillaries in A2, A3, and A4; in A4, hIDPSCs are localized in the axonbifurcation. A5: neuron morphology in brain tissues (A2-A4); A6:schematic figure of brain capillary showing pericyte localization.Confocal microscopy. Epifluorescence+Digital interference contrast (DIC)microscopy. Scale bar=10 μm.

FIG. 34 depicts the engraftment of hIDPSCs four days after IVadministration. Optical cut demonstrates hIDPSC stained with Vybrant(green) and positively reacted with anti-hIDPSC antibody (red).Superposition of both produces yellow color. The cells demonstrate nearcapillary localization. Two markers for MSC were used: CD73 and CD105demonstrating positive reaction with hIDPSC (A-D). E. Positive controlhIDPSC cultured in vitro. Confocal microscope. Epifluorescence+DigitalInterference contrast (DIC). Scale bar: A=5 μm; B=10 μm; C=20 μm; D=5μm.

FIG. 35 depicts immunohistochemical images showing positive anti-humannuclei (hNu) staining of hIDPSCs and their localization in rat braintissue 30 days after hIDPSC administration. Note: A few hIDPSCs in thecortex (left) and a large number of hIDPSCs in the corpus striatum(right). Light microscopy. 90× magnification. Scale bars: 5 μm and 25μm, respectively.

FIG. 36 shows an immunohistochemical image of rat brain tissue after theinjection of 3-NP and the administration of hIDPSC. Note: positiveanti-human nuclei (hNu) immunostaining in cells. Neuron-like cells arecircled in blue, and fibroblast-like cells are circled in white. Lightmicroscopy, 90× magnification.

FIG. 37 depicts Nissl Staining in the Striatum of Untreated Animals(3-NP+saline) (a-bl); Control Animals (no 3-NP or hIDPSC) (c, cl); andTreated Animals (3-NP+hIDPSC) (d-fl). Different scores were observed inthe experimental groups: score 1 (a, al, d, and dl); score 2 (b, bl, e,and el); and score 3 (c, cl, f, and fl). Area of extensive degeneration(a, al); severe (d, dl), moderate (b, bl, e, and el), mild (f, fl), andno (c, cl) neuron loss. Magnification: 10× (a-f) and 20× (a-fl). Insetsin (b, c, e, and f) show typical Nissl-stained neuron morphology (40×).Light microscopy (a-f).

FIG. 38 depicts DARPP32 immunostaining in the corpus striatum ofuntreated animals (3-NP+saline) (a-b), Controls (no 3-NP or hIDPSC) (c),and Treated Animals (3-NP+hIDPSC) (d-el). In (a) no immunostaining (bluearrow, score 1), (b) few DARPP32+ cells (score 2), and (c) Controlanimals (no 3-NP or hIDPSC) showing positive DARPP32 immunostaining(score 3). In (d, dl), neuron loss in Treated animals (3-NP+hIDPSC),with few DARPP32-stained cells (score 2) (black arrow). In (e, el),strong anti-DARPP-32 immunostaining (score 3). Insets (a, b, c, dl) showDARPP32+ neurons (black arrow) (40×). HE (hematoxylin and eosin)-stainednuclei in blue. Magnification: 10× (a, c, d, and e) and 20× (d, el).

FIG. 39 depicts neuronal growth in the striatum of rats after hIDPSC.Administration of hIDPSC resulted in a neuroreparative effect inhIDPSC-treated animals by (A) Nissl staining and (B) DARPP32 expression.(C) Number of animals showing neuron recovery after hIDPSCadministration compared to the Controls. Most hIDPSC-treated animals(3-NP+hIDPSC) had scores 3 and 2 (moderate and mild), whereas mostUntreated animals (3 NP+saline) had scores 2 and 1 (severe andmoderate).

FIG. 40 depicts BDNF expression in rat brain tissue after (a-f) 3-NPinjection and (g j) CELLAVITA™ (stem cells) administration (a, b).Absence of BDNF expression seven days after 3-NP injection and (c, d)low expression after 30 days (e, f). Control animals (no 3-NP orCELLAVITA™ (stem cells). BDNF expression 7 (g, h) and 30 (i, j) daysafter CELLAVITA™ (stem cells) administration. Magnification: 10× (a, c,e, f, g, and h) and 20× (b, d, i, and j).

FIG. 41 depicts DARPP32 expression in the striatum of rats 30 days afterCELLAVITA™ (stem cells) administration in a 3-NP model of HD. Confocalmicroscopy, overlapping images in A. Epifluorescence+Digitalinterference contrast (DIC) microscopy. B-D: Epifluorescence. Scale bar:10 μm.

FIG. 42 depicts the effect of hIDPSC administration on body weight intreated (3-NP+hIDPSC) and untreated animals (3-NP+Saline). Body weightwas recorded before and 4 days after 3-NP administration and after eachhIDPSC administration (every 30 days). No increase in body weight wasobserved in 3-NP-treated animals 30, 60, and 90 days after 3-NPadministration. Body weight in hIDPSC-treated animals (1×10⁶ dose)increased after the first hIDPSC administration.

FIG. 43 depicts representative figures of BDNF expression in the brainof 3-NP treated animals 4 days after hIDPSC intravenous transplantation.Strong BDNF secretion observed in cortex (1a,1b). Lower BDNF secretionshowed in hippocampus (1c,1d). Strong BDNF expression observed instriatum (1e, 10. Control 3-NP group did not show BDNF secretion in thesame brain regions (2a-2f). Light microscopy. Magnification 20× in 1a,1c, 1e, 2a, 2c, 2e; Magnification 40× in 1b, 1d, 1f, 2b, 2d, 2f Arrowsin 1b and 1d and asterisks in 1e and 1f demonstrate BDNF secretingcells. Nuclei counterstained with HE (hematoxylin and eosin).

FIG. 44 depicts representative BDNF expression in the brain of 3-NPtreated animals 30 days after hIDPSC intravenous transplantation. StrongBDNF secretion was observed in cortex (1a, 1b). Lower BDNF secretion wasobserved in the hippocampus (1c, 1d). Strong BDNF expression wasobserved in the striatum (1e, 1f). The control 3-NP group did not showBDNF secretion in the same brain regions (2a-2f). Light microscopy.Magnification 20× in 1a, 1c, 1e, 2a, 2c, 2e; Magnification 40× in 1b,1d, 1f, 2b, 2d, 2f Arrows in 1b and 1d and asterisks in 1e and 1fdemonstrate BDNF secreting cells.

FIG. 45 depicts the experimental designs for all HD disease modelstudies in order to evaluate functional characteristics of HD-inducedrats after IDPSC transplantation.

FIG. 46 depicts the principle difference between normal MSC and ES (oriPS) cells. Tumor formation is correlation with ES and iPS cells but notwith normal MSC.

FIG. 47 depicts a scheme for the mechanism of the efficacy of hIDPSC ininducing neurogenesis and providing neuroprotection.

FIG. 48 depicts an early phase development process for CELLAVITA™ (stemcells) isolation and batch formulation.

FIG. 49 depicts another early phase development manufacturing processfor CELLAVITA™ (stem cells).

FIG. 50 depicts a CELLAVITA™ (stem cells) production process composed ofseveral major steps.

FIG. 51 depicts safety studies of investigational product CELLAVITA™(stem cells).

DETAILED DESCRIPTION

As used herein, the verb “comprise” as is used in this description andin the claims and its conjugations are used in its non-limiting sense tomean that items following the word are included, but items notspecifically mentioned are not excluded. In addition, reference to anelement by the indefinite article “a” or “an” does not exclude thepossibility that more than one of the elements are present, unless thecontext clearly requires that there is one and only one of the elements.The indefinite article “a” or “an” thus usually means “at least one”.

As used herein, the term “high expression” in reference to theexpression level (strongly immunopositive for antigen of interest) of agene in a population of cells refers at least 75% of the populationexpressing the gene.

As used herein, the term “low expression” in reference to the expressionlevel of a gene in a population of cells refers no more than 30% of thepopulation expressing the gene. In preferred embodiments, low expressionrefers no more than 25% of the population expressing the gene.

As used herein, the term “no expression” in reference to the expressionlevel of a gene in a population of cells refers no detectable cells thatexpress the gene of interest in the population. No detectable expressionincludes an expression level that is within the realm of error for themethod of measuring expression.

As used herein, the term “subject” or “patient” refers to any vertebrateincluding, without limitation, humans and other primates (e.g.,chimpanzees and other apes and monkey species), farm animals (e.g.,cattle, sheep, pigs, goats and horses), domestic mammals (e.g., dogs andcats), laboratory animals (e.g., rodents such as mice, rats, and guineapigs), and birds (e.g., domestic, wild and game birds such as chickens,turkeys and other gallinaceous birds, ducks, geese, and the like). Insome implementations, the subject may be a mammal. In otherimplementations, the subject may be a human.

As used herein, the term, “stem cell” refers immature, unspecializedcells that, under certain conditions, may differentiate into mature,functional cells.

As used herein, the term, “neural stem cell” or “NSC” refers tomultipotent cells that self-renewable and able to terminallydifferentiate into neurons, astrocytes, and oligodendrocytes.

As used herein, the term “neural progenitor cells” refer toundifferentiated cells further along the stage of cell differentiationthan neural stem cells. Thus these cells are derived from neural stemcells and can produce progeny that are capable of differentiating intomore than one cell type of central nervous system (CNS) and peripheralnervous system (PNS).

As used herein, the term “neural precursor cell” or “NPC” refers to amixed population of cells consisting of neural stem cells and all of itsundifferentiated progeny. Therefore NPCs include both NPC and NSC. TheNPCs can also be categorized into neuronal NPCs and glial NPCs, whichproduce neurons and glial cells, respectively.

As used herein, the term “harvest cycle” constitutes a transfer of theorgão (e.g. of neural crest origin like dental pulp) or tissue to a newcell culture container after adherence and outgrowth of the stems cellsin the tissue followed by preservation (e.g. cryopreservation) and/orsub-culturing of the outgrowth of IDPSCs. Stem cells isolated from thefirst time from organ culture (dental pulp) using explant technology areearly populations, thus stem cells isolated from the first harvest cycle(first transfer of organ culture) are early population cells. Forexample, of stem cells isolate from dental pulp tissue, stem cells fromhuman exfoliated deciduous teeth (SHED) cannot be divided in early andlate population, as these cells are isolated using enzymatic method onlyonce from dental pulp, which are discarded after SHED isolation. Thus,only one SHED cell population can be isolated. Further, followingenzymatic digestion, SHED can be passed from one to other cell cultureflask thus counting cell passages, which generally are performed whenSHED reach semi-confluence.

In contrast to SHED for immature dental pulp stem cells (IPDSCs)enzymatic method is not used. IDPSCs can be isolated as from explantculture of the dental pulp after the first adherence of DP to plasticand cells outgrowth—early population cells. At this stage dental pulp isnot discarded and used for subsequent explant dental pulp cultures—latepopulations. Thus, IDPSC isolated from the second or later harvest cycleare late population cells. For example, IPDSCs that are isolated fromthe second harvest cycle or later are late population undifferentiatedstem cells. As used herein, the term “early passage” refers to the cellsfrom the first five passages of an explant culture. As used herein, theterm “late passage” refers to the cells from passages after the fifthpassage, e.g. in the sixth passage or later, of an explant culture.Thus, the IDPSC may be from an early or late population and additionallycategorized as an early or late passage.

The present invention relates to the discovery that a particularcomposition of IDPSC, the unique stem cells population, which composedby early and late stem cells populations, from tissue of neural crestorigin can cross the blood/brain barrier (BBB) and induce neurogenesis.Tissue of neural crest origin include, for example, dental, periodontal,and hair follicular tissue. Hair follicular tissue includes folliculartissue of the vibrissa.

The hIDPSC was evaluated in the 3-NP (three nitropropionic acid) HD ratmodel. The hIDPSC showed engraftment into the rat brain after 1 monthfollowing intravenous injection of 1×10⁶ and 1×10⁷ cell/transplant(3×10⁶ cell/kg and 3×10⁷ cell/kg) labeled with fluorescent protein(Vibrant), as well as, following immunohistochemistry analysis usingspecific anti-human antibody. Cell engraftment was observed in differentbrain compartments (cortex, striatum and Subventricular zone-SVZ).

The ability to cross the BBB enables systemic administration (e.g. IVadministration) of stem cell therapy to treat neurological conditions,which provides a significant advantage over more localized methods ofadministration. In addition to systemically administration being lessinvasive, leaving stem cells to migrate to locations that require aidreduces the risk of harmful cell masses developing at the site ofadministration. For example, while intrathecal (IT) administration ofstem cell therapy is commonly contemplated in preclinical and clinicalstudies, this method can have significant risk when the stem cells areMSCs. It has been reported that depending on cellular density, bonemarrow-derived MSCs that were drawn into brain parenchyma (presumably inresponse to chemoattractant signals from this inflammation) viaintracerebroventricular (ICV) formed cellular masses in 64% of severeexperimental allergic encephalomyelitis animals. Karyotypically normalMSCs at early passages also induced masses in naïve animals (Grigoriadiset al., 2011). Therefore, MSCs implanted directly within the CNS may bythemselves produce local pathology of yet unknown consequences (Snyderet al., 2011). The volume of these masses appeared to correlate withcellular density. Therefore cell number as well as number of applicationcan be limited and risky factors for IT and ICV applications in contrastto IV.

The composition of IDPSC may be in the form of a pharmaceuticalcomposition comprising stem cells expressing a mesenchymal andneuroepithelial stem cell immunophenotypes. In some implementations,expressing a mesenchymal and a neuroepithelial stem cell molecularprofile is the expression of markers of MSC and neuroepithelialcells/progenitor cells and genes encoding neuro-protective andimmunoprotective factors.

Cells expressing a MSC immunophenotype include expression of CD44. Prioranimal models of multiple sclerosis found that NCS adhesion to inflamedendothelial cells and then trans-endothelial migration across the BBBinto the inflamed CNS areas are sequentially mediated by theconstitutive expression of functional cell adhesion molecules (CAM),especially CD44 (Rampon C et al., 2008). Although the exact mechanism ofhow hIDPSC are able to cross BBB is not clear, it is believed that thesecells have this capacity because they have perycite-like characteristics(Barros et al., 2014). Perycites are known to play a critical role inthe integration of endothelial and astrocyte functions at theneurovascular unit, and in the regulation of the BBB (Armulik et al.,2010; Liu et al., 2012). According to a previous study (Yilmaz et al.,2011), mesenchymal stem cells (MSC) can engraft into brain aftersystemic administration due to expression of CD44, which is a ligand ofE and L blood vessel endothelial selectins (Dimitroff, et al., 2001).MSC present similar homing mechanisms as leukocytes. The first step ofleukocyte migration involves capture of leukocytes flowing freely in theblood stream, mediated by glycoproteins known as selectins. P- andE-selectins are expressed by the vascular endothelium and are theprincipal mediators for the rolling response in leukocyte migrationthrough blood vessels (Luster et al., 2005). MSC may use this or similarmechanisms to engraft in several organs (Sackstein et al., 2008) such asthe brain. Thus, CD44 is considered a pivotal factor for MSC migrationinto the brain. Similarly to BM MSC, hIDPSC express CD44, which suggeststhat CD44 is also involved in hIDPSC migration towards several organs(Barros et al., 2014, Castanheira et al., 2013) including the brainafter intravenous administration. Surprisingly, that, hIDPSC expressalso CD13, (aminopeptidase N) (Kerkis et al., 2006; Kerkis and Caplan,2012), which is multifunctional protein and plays varying roles in cellmigration, cell proliferation, cell differentiation (Taylor et al.,1993; Mina-Osorio et al., 2008a/b). CD13 participates in angiogenesisgenerating and modulating angiogenic signals, in the process ofcapillary tube formation, and as a marker of angiogenic vessels (Bhagwatet al., 2001). This suggests its possible role in hIDPSC capacity tomigrate and to target brain vasculature. In the 3-NP rat study, hIDPSCdemonstrated tight association with brain capillaries.

In some embodiments, the IDPSC lack expression of CD146, HLA-DR, and/orHLA-ABC. Lack of expression of these markers facilitates the use ofhIDPSC as a safe, heterologous therapy. The endothelium plays animportant role in the exchange of molecules, but also of immune cellsbetween blood and the underlying tissue. The endothelial molecule S-Endo1 antigen (CD146) is preferentially located at endothelial junctions andhas been claimed to support endothelial integrity. Thus, in humans, MCAM(CD146) is expressed in T cells (3%) in the peripheral circulation ofhealthy individuals. MCAM positive T cells also demonstrate an increasedability to bind to endothelial monolayers and these cells couldrepresent early components of the adaptive immune response (Dagur etal., 2015). Therefore, stem cells, which express this marker may bind toBBB and not cross BBB, as well as being immune reactive.

The mesenchymal stem cell genotype pattern also includes low expressionof pluripotent markers OCT3/4 and nanog. Interesting, theundifferentiated stem cells of pharmaceutical composition of theinvention need not express c-Myc, KLf-4, and REX-1. In fact, these stemcells may be negative for c-Myc, KLf-4, and REX-1.

Stem cells expressing a neuroepithelial stem cell molecular profileexpress at least one, preferably two, more preferably more than two NPC-and NSC-biomarkers selected from the group consisting of vimentin,nestin, SOX2, p75, and other neurotrophic factors essential for neuralcells development and survival. p75 is a neurotrophic receptor marker.In the recent works, it was hypothesized that normalization of p75NTRand/or TrkB expression or their signaling will improve BDNF(brain-derived neurotrophic factor) neuroprotective therapies inHuntington's disease (Brito et al., 2013).

Exemplary neurotrophic factors essential for neuronal development andsurvival include BDNF (brain-derived neurotrophic factor), GNDF (glialcell line-derived neurotrophic factor), NGF (nerve growth factor), andNTs (neurotrophins). BNDF plays a critical role in Huntington's disease(Gauthier et al.; Strand et al.) and Parkinson's disease (Mogi et al.),both of which are dopamine-associated neurodegenerative diseases.Several studies demonstrate that wild-type HD-overexpressed htt proteinincreases BDNF expression in CNS cells, whereas the mutated htt proteinleads to down-regulation of BDNF, resulting in insufficient neurotrophicsupport and neuronal cell death (Zuccato et al., 2001). The brains of ADpatients have reduced NGF levels (Calissano et al.); however, NGFadministration can partially reduce cholinergic atrophy in aged rodents(Fischer W et. al). In some embodiments, the preferred NGF is NGF-β. NTsessential for neuronal development and survival include NT3, NT4, orNT5. NT4 and NT5 are known to promote sensory and motor axon growth.

In some implementations, the stem cells comprise cells autologous to asubject in need of the pharmaceutical composition. In otherimplementations, the stem cells comprise cells allogeneic to the subjectin need of the pharmaceutical composition. In some implementations, stemcells comprise a combination of cells autologous to and allogeneic tothe subject in need of the pharmaceutical composition.

In one embodiment, the composition of stem cells is isolated from tissueof neural crest origin selected from the group consisting of dentaltissue, periodontal tissue, and hair follicular tissue. In preferredembodiments, the tissue of neural crest origin is dental pulp. In a mostpreferred embodiment, the stem cells are from immature dental pulp, forexample, human immature dental pulp stem cells (IDPSCs) as disclosed inInternational Application no. PCT/IB14/59850 and U.S. patent applicationSer. No. 14/2140,016. IDPSCs carry multiple neuronal markers and undergorobust differentiation into neurons. The novelty of IDPSCimmunophenotype is unexpected expression of these markers and at thesame time markers typical for MSC, presenting immunophenotype inaccordance with the International Society for Cellular Therapy's minimalcriteria for defining multipotent mesenchymal stromal cells (Dominici etal., 2006). This combination of expression by IDPSC of MSC and multipleneuronal markers is not typical for MSCs (Dominici et al., 2006) andwhich has not been disclosed for MSCs.

Pharmaceutical compositions contemplated in the invention are preferablyisotonic. For intravenous injection, the population of immature stemcells should be between 10⁴-10¹⁰ cells per injection, for example, 10⁴,10⁵, 10⁶ and 10⁷ cells per kg of body weight. The pharmaceuticalcomposition comprising a population of stem cells may be used inadjunction to other pharmaceutically active compounds or modalities.Thus in some embodiments, the pharmaceutical composition may furthercomprise another pharmaceutically active compound or therapeuticmodality.

Mesenchymal Stem Cells

In the body, MSCs are found in bone marrow, umbilical cord tissue,dental pulp and fat pads. However, in bone marrow MSCs are relativelyrare, comprising only one out of every 10,000 cells, while other sourcesare significantly richer in these cells. In organism MSCs areresponsible for tissue regeneration in cases of disease, trauma orinjury throughout human life. This function of MSCs is mediated by theircapacities for self-renewal and plasticity (the capacity fordifferentiation—production of diverse cell types). MSCs can be isolatedfrom aforementioned tissues and cultured easily in the laboratory. Afterobtaining a limited number of the cells from a patient, MSCs can bemultiplied rapidly in vitro and cryopreserved for the future clinicalapplications.

MSCs are able to secrete a variety of bioactive molecules, such ascytokines, which provide “trophic activities” by structuring aregenerative microenvironment, and other molecules that contribute toimmunomodulatory cell functions and even to transfer products as largeas mitochondria to damaged cells that need help. When transplanted invivo, MSCs in response to chemotactic stimuli, can migrate to the focalinjury from both local and surrounding sites. Additionally, MSCs can actto reduce chronic inflammation, to inhibit apoptosis, to provide theappearance of myofibroblasts, to inhibit scar formation and to stimulatethe mitosis of tissue-intrinsic progenitors, thus remodeling damagedtissue. That is why MSCs are also called “Medicinal Signaling Cells.”They stimulate angiogenesis, the process of new blood vessel formation,which is closely linked to neurogenesis, the process by which new nervecells are produced. Blood vessels play an important role as a frameworkfor neuronal progenitor cells migration toward the damaged brain regionThe factors secreted by MSCs also reduce the destructive effects ofoxidative harm. Using all these mechanisms of action MSCs cansignificantly improve lesioned microenvironment that leads torestoration of the damaged cells. Therefore, MSCs are believed to be“cellular paramedics”.

When MSCs obtained from humans were labeled, in order to track them, andinjected into mice that had some type of tissue damage, they migratedthroughout the damaged tissues apparently evenly. These cells can or notto be present in the tissue for a substantial period of time, whichdepends on disease model. The continued presence of MSCs is important,but not essential, to therapeutic development because it indicates thatpotential positive long-term effects of a treatment might be capable ofpersisting.

It is important to understand, that temporary presence of MSCs is not aresult of the host immune system action, because the experiment ininjured mice, with or without functional immune systems yielded the sameresults. Further investigations demonstrated that MSCs suppress theimmune system and reduce inflammation. In other words, MSCs can betransferred between organisms demonstrating very low immune rejection,which occurs when the immune system of the organism attacks the foreigntissue, receiving the transplant. This finding makes MSCs goodcandidates for transplantation or injection into a host because they canavoid rejection by the host's immune system (Le Blank, Ringdén, 2006;English, 2012; Miguel et al., 2012; Griffin et al., 2012; Ankrum et al.,2014).

The crucial question of cellular therapies is a route of MSCs deliveryinto the brain, which has been approached in a number of different ways.Several approaches have been proposed to deliver MSCs into the brainsuch as, intrathecal, intravenous, an injection into the spacesurrounding the spinal cord and even a route through the nose. In earlydevelopment, as a result of complex multicellular interactions betweenimmature endothelial cells and neural progenitors, neurons, radial glia,and pericytes, which shared similar features with MSCs, the blood/brainbarrier (BBB) is formed and it controls selective molecular or cellstrafficking between the bloodstream and brain interstitial space. TheBBB present significant problems for the delivery of therapeutic agents(drugs or cells) for treating brain malignancies and neurodegenerativedisorders. Systemically-infused MSCs may treat acute injuries,inflammatory diseases, stroke of the central nervous system (CNS) andeven brain tumors because of their regenerative capacity and ability tosecrete trophic, immune modulatory, or other engineered therapeuticfactors. However, whether MSCs possess the ability to migrate across theBBB in normal and pathological conditions remains unresolved (Liu etal., 2013).

Systemic infusion (e.g. IV) of MSCs expanded in vitro is minimallyinvasive and convenient procedure that is used in the large number ofongoing clinical trials. Therefore, it is essential to understand iftransplanted MSCs can home and engraft at ischemic and injured sites inthe brain to exert their therapeutic effects. No data has yet to suggestor disclosed that systemic delivery of minimally manipulated MSCs mayresult in direct transplantation of cells into the brain through theBBB.

The simplicity with which MSCs can be obtained, cultured, as well astheir unique “trophic activities” and possibility of their transfer intoa host without immune rejection are the reasons why stem cell therapywith MSCs is a promising avenue to for treating neurological diseasesand conditions, for example neurodegeneration. According to recentpublications, MSCs can support repair neurodegeneration by secretingtrophic factors, which are proteins that stimulates differentiation andsurvival of cells. The effects of these factors allow nerve cells tocarry out several processes that can support survival: axon extension,growth, and cells attachment. Although are evidences that MSCs canpromote cell growth and repair in the brain, it is not yet definitivelyconfirmed that MSCs can become mature nerve cells with the ability tosignal, or communicate with, other nerve cells.

Previous studies have tested the potential of MSC therapy in HD animalmodels (chemical models where HD is induced by QA or 3-NP and transgenicmouse lines R6/2-J2, N171-82Q, and R6/2). However, while the authorscalled the cells tested MSCs, these cells were not confirmed as havingthe immunophenotype typical for MSCs as defined by the InternationalSociety for Cellular Therapy (Dominici et al., 2006). These pre-clinicalstudies used allogeneic and xenogeneic primary culture and immortalizedcell lines from the bone marrow, adipose tissue, and umbilical cordblood grown under normal levels of oxygen (normoxia) or under low levelsof oxygen (hypoxia), as well as, mononuclear cells. Thus these studieshave not established that cells considered as MSCs by the InternationalSociety for Cellular Therapy may be successfully employed to treatneurological diseases without previous special manipulation in culture.

The number of cells used in these experiments varied from 10⁵, 2×10⁵,4×10⁵, 5×10⁵, and up to 10⁶ per hemisphere/striatum. The time ofadministering MSCs transplantation varied significantly across thestudies with the time being 1-3 days, 2-4 weeks, and 8 weeks. Thesecells were found in the brain after direct grafting, but directintrabrain delivery is a highly invasive and risky procedure. Thus thesestudies have not demonstrated that minimally invasion methods ofadministering stem cell therapy, such as systemic administration by IVinjection, could be used.

All but one of the studies used the cells at passages no higher than 10.The exclude study used mouse umbilical cord blood-derived (mUBC-derived)MSCs at passages 40 and 50. Interestingly, the study observed thatexpression of marker of pluripotent stem cells, such as stage specificembryonic antigen-4 (SSEA4) increased with passaging and thattransplantation of high-passage mUCB-derived MSCs confer significantmotor benefits unlike transplantation with low-passage mUCB-derivedMSCs. Unfortunately, potential pluripotent origin and high risk ofkaryotype mutation due to higher passage numbers put clinicalapplications at risk.

In contrast to these studies, the present invention provides a method oftreating neurological diseases and condition that uses a uniquepopulation of IDPSC having the immunophenotype typical for MSCs asdefined by the International Society for Cellular Therapy effective evenwith a minimally invasive administration, for example through classic IVroute of delivery.

As demonstrated by these previous studies on treating HD with supposedMSCs, one hope for treating neurodegenerative diseases is using stemcells. Unfortunately, only treatment with administering fetal donortissue to the striatum proceeded to clinical trial, and it was only asmall trial.

Cell therapies in HD are intended to protect neuronal populationssusceptible to disease and/or replace dysfunctional or dying neurons.Thus clinical progress in HD cell therapy has been centered onestablishing protocols for transplanting fetal-derived cells into thediseased striatum. This strategy is helping the development for stemcell therapy in the clinic and provides a period of several years ofimprovements and stability, but not permanent cure for disease(Bachoud-Levi et al., 2006). The long-term follow up over a 3- to10-year postoperative period of the patients concludes that fetalstriatal allografting in HD is safe. However, no sustained functionalbenefit was seen, perhaps due to the small amount of cells that wasgrafted in this safety study compared with other reports of moresuccessful transplants in patients with HD (Barker et al., 2013).

Use of stem cells therapies is inevitable since intracellular andcellular mechanisms are involved into HD phenotype. Stem cell therapymay also accelerate the process of brain tissue regeneration. Stem cellsare an important therapy, which will help to rebuild an area of thebrain that was most damaged in HD. Only drugs approach will not be ableto reconstruct damaged brain areas especially in late stages of HD.

MSCs may be obtained from extracted human teeth, both permanent anddeciduous, by enzymatic digestion (Gronthos et al. 2000; Miura et al.,2003), or by organ culture followed by explant (immature dental pulpstem cells, IDPSCs) technology as disclosed in International Applicationno. PCT/IB14/59850 and U.S. patent application Ser. No. 14/2140,016. TheIDPSCs are obtained from dental pulp tissue, which anatomicallyoriginated from ectomesenchymal tissue, more precisely from neuralcrest, which is a mass of tissue present in the early formation of anembryo. It eventually forms the hard and soft tissues of the neck andcranium.

IDPSCs, which are of neural crest origin, are known to migratepre-natally into various, mainly ectodermal tissues and have thecapacity to self-renewal and display a developmental potential almostthe same as embryonic stem (ES) cells, but without risk of formation ofembryonic bodies in vitro and teratomas in vivo (Kerkis and Caplan,2012). The postmigratory stem cells of neural crest origin generate allcraniofacial bones, the majority of cells and tissues of the central andperipheral nervous systems, as well as several non-neural cell types,such as smooth muscle cells of the cardiovascular system, pigment cellsin the skin, cartilage, connective tissue, corneal epithelium and dentalpulp among them. Although postmigratory postnatal stem cells of neuralcrest origin are of restricted developmental potential, they maintainfunctional characteristics resembling their embryonic counterparts andan ability to differentiate into a broad spectrum of cell types (LeDouarin et al., 2004, 2007, 2008; Dupin et al., 2007; Le Douarin &Dupin, 2003, 2012).

In vitro IDPSCs undergo uniform differentiation into neurons and glialcells. In vivo transplantation of human IDPSCs showed dense engraftmentin various tissues, including neurons. Neuronal fate differentiation isbased upon epigenetic “memory” of orofacial bones, including dentalpulp, compared with those in axial and appendicular bone (bone marrowand ileac crest) based on their different embryological origins.Maxillas, mandible, including the alveolar bone (i.e. dentine, dentalpulp and periodontal ligament), are formed exclusively by neural crestcells while axial and appendicular bones develop from mesoderm. ThusIDPSCs have the potential for neural regeneration and neuroprotection.

Logan A et al. described that multiple NTFs (neurotrophic factors)should be produced by cells in order to result in synergistic effect onneuroprotection. Therefore it is important that hIDPSCs cells areexpressing and releasing multiple NTFs. Recent publications report theevidence for a paracrine mechanism of dental pulp stem cells (DPSC)action in neural support, with the gene expression of many NTFs, such asNGF (nerve growth factor), BDNF and NT3, the results demonstrated thathIDPSC promoted significantly more neuroprotection and neurogenesis ofaxotomised RGC than either hBMSC (bone marrow derived MSC) or hAMSC(adipose tissue derived MSC) (Mead B et al. 2013; Mead B et al., 2014;Martens W et al., 2013). Intravitreally transplanted DPSCs weresuggested as a more appropriate cell type than BMSCs for retinal therapy(Mead B et al., 2014). These studies used DPSC (=SHED) enzymaticallyderived from adult rats using trypsin.

In addition, it has recently been strengthened by the results of anstudy using a rodent model of spinal cord injury with transplantation ofSHED by direct dura transplantation in proximity and directly to thelesion site, wherein SHED was superior to three human skin fibroblastlines in terms of neuroprotection and neuroregeneration through bothcell-autonomous and paracrine neuroregenerative activities (Sakai etal., 2012). These studies used cultured DPSC enzymatically derived fromimmature and adult wisdom using collagenase. During transplantation ofDPSCs, animals were also treated with cyclosporine forimmunosuppression.

Safety of Systemically Administering Stem Cells

Unless the transplant is an autograft, there is always a risk that thehost's immune system will attack the transplant. Even a well-matchedallograft requires immunosuppression pretreatment. This remains true forstem cell transplantation.

In order to avoid the host's immune system attacking the transplantedcells, the therapeutic stem cell population should be not beimmunogenic. Immunogenicity is the ability of allogeneic stem cells toprovoke an immune response when facing the host immune system aftertransplantation (Schu S et al., 2012). The transplantation of NPCs withmismatched major histocompatibility complex (MHC) into mice with mousehepatitis virus-induced CNS demyelination resulted in increased T cellinfiltration and NPC rejection (Weinger J G et al., 2012). However,recent evidence supports the possibility that undifferentiated adultstem cells are endowed with an immunologically privileged status and arecapable of escaping the normal processes of allogeneic rejection (BifariF et al. 2010). Immunologically privileged status is possible for apopulation of cells if the cells lack the expression of MHCs. Forexample, no immunogenicity in humans can occur by the population of stemcells being essentially negative for human leukocyte antigen (HLA),which is the human version of MHC. Therefore, the absence of HLA-DR,which is a quality control characteristic of IDPSCs is an essentialmarker for cell to be used in for systemic cell therapy without need oftoxic immunosuppression pre-treatment to the patient.

Another risk of stem cell transplantation is the increased risk of tumordevelopment, especially for undifferentiated cells, because of thesecell's potential for differentiation into other cell types. Pluripotentstem cells, especially hESCs and iPSCs cells are able to form spheresthat resemble embryoid bodies in vitro and teratomas in vivo. Allcurrently available technologies to apply pluripotent cells holdtumorigenicity risk. Expression and lack of expression of certain genesreduces risks to enable systemic administration of a population of stemcells.

Nanog is transcription factor associated with the maintenance of thepluripotent cells of the inner cell mass and the formation of embryonicstem cells. Nanog is a leukemia inhibitory factor (LIF) and activator oftranscription-independent factor-3 (STAT-3). It is regulated by OCT4 andSOX2 and in turn positively regulates the expression of OCT4, SOX2 anditself by binding to the respective promoter gene regions (Boyer et al,2005; Loh et al., 2006; Li, 2010). Together, these three transcriptionfactors play an essential role in preventing differentiation ofpluripotent stem cells (Boyer et al., 2005). The transfection cellularnucleus with OCT3/4, SOX2, NANOG was previously to be sufficient forinducing pluripotency in adult somatic cells (the creation of iPSC) andthen lead to full pattern of embryonic stem cells theoreticalcharacteristics: differentiation into 200 types of cells in the body,unlimited expansion, renewal potential, embryonic body formation,teratoma formation. Teratoma formation is a main threat of safety incellular therapy. However, absence expression of nanog in nucleus is anessential safety marker to determine whether a population of stem cellis suitable for systemic administration. The lack of tumorigenicity ofundifferentiated stem cells in vivo requires the absence of nanog innucleus. Thus undifferentiated stem cells expressing inactive nanog,i.e. nanog localized in the cytoplasm, also lack tumorigenicity in vivo.

Another important safety marker for a population of stem cells suitablefor systemic administration is the expression of p53. This protein iscrucial in multicellular organisms, where it regulates the cell cycleand thus prevents cancer by functioning as a tumor suppressor.

ABCG2 protein expression is also safety marker that indicates apopulation of stem cells is suitable for systemic administration.ATP-binding cassette (ABC), ABCG2 protein (BCRP) expression is animportant determinant of the MSC undifferentiated population phenotype.ABCG2 might serve as a marker for undifferentiated stem cells fromvarious sources, as its expression is sharply downregulated withdifferentiation. Notably, ABCG2 transporters with Alzheimer's disease(AD), actively transport Aβ as confirmed histopathologically in AD casesand controls. Genome-wide association studies (Bertram L et al., 2007)have implicated a have identified genes the modulate AD risk, includinggenetic variants in ABCA7, a variant of ABC gene. It was concluded thatincrease in ABCA7 expression reduces AD risk, though increased ABCA7expression during AD is insufficient to block disease progression (JaredB et al., 2014).

Thus some embodiments of the pharmaceutical composition of the inventioncomprises stem cells from tissue of neural crest origin expressing atleast one safety markers selected from the group consisting ofATP-binding cassette sub-family G member 2 (ABCG2), inactive nanog, p53,and SOX2. In some aspects, the at least one safety marker is electedfrom the group consisting of ATP-binding cassette sub-family G member 2(ABCG2), inactive nanog, and p53. The IDPSC have high expression ofABCG2 and p53 but low expression of inactive nanog and SOX2. Forexample, when the at least one safety marker is ABCG2 or p53, at least75%, 80%, 85%, 90%, 95% or 98% of the stem cells of the pharmaceuticalcomposition express the at least one safety marker. On the other hand,if the at least one safety marker is inactive nanog or SOX2, no morethan 30%, 25%, 20%, 15%, 10%, 5%, or 5% of the stem cells express the atleast one safety marker. In some aspects, the stem cells of thepharmaceutical composition coexpress ABCG3, p53, inactive nanog, andSOX2, wherein at least 75% of the stem cells express ABCG2, at least 75%of the stem cells express p53, no more than 5% of the stem cells expressinactive nanog, and no more than 30% of the stem cells express SOX2.

Another embodiment of the pharmaceutical composition comprises stemcells from tissue of neural crest origin expressing at least oneneuroepithelial stem cell marker selected from the group consisting ofbrain-derived neurotrophic factor (BDNF), neutrotrophin-3 (NT3),neutrotrophin-4 (NT4), neutrotrophin-5 (NT5), and p75. In some aspects,the stem cells have high expression of the at least one neuroepithelialstem cell marker. For example, at least 75%, 80%, 85%, or 90% of thecells express at least one neuroepithelial stem cell marker. In someembodiments, the stem cells of the pharmaceutical composition coexpressBDNF, NT3, NT4, NT5, and p75.

In some aspects, these embodiments pharmaceutical composition comprisestem cells from tissue of neural crest origin that are negative forHLA-DR. The stem cells of the pharmaceutical composition may also benegative for certain MSC markers selected from the group consisting ofc-Myc, KLf-4, and REX-1. In preferred embodiments, the stem cells of thepharmaceutical composition are negative for HLA-DR, c-Myc, KLf-4, andREX-1.

The various embodiments of the pharmaceutical composition may also becombined. For example, the pharmaceutical composition may comprise stemcells from tissue of neural crest origin expressing at least one safetymarkers selected ABCG2, inactive nanog, and p53 and further express atleast one neuroepithelial stem cell marker selected from the groupconsisting of BDNF, NT3, NT4, NT5, and p75. As another example, thepharmaceutical may comprise stem cells from tissue of neural crestorigin expressing express at least one neuroepithelial stem cell markerselected from the group consisting of BDNF, NT3, NT4, NT5, and p75 whilefurther expressing at least one safety markers selected ABCG2, inactivenanog, p53 and SOX2.

Methods of Using the Pharmaceutical Compositions

The present invention provides for methods for treating neurologicaldiseases and conditions comprising systemically administering thepharmaceutical composition of the invention to a subject. In someimplementations, these methods of treating neurological diseases andcondition promote neurogenesis and are protective in models ofneurodegenerative diseases. In some embodiments, systemic administrationthe population of stem cells, such as by IV administration, results indirect delivery of the cells to the brain. In some aspects, neurogenesisoccurs by the population of stem cells self-differentiating and/oractivating intrinsic stem cells to migrate and differentiate. In someaspects, neurogenesis is preferably dopamine-associated.

In some embodiments of the methods, the neurological disease orcondition is treated by the stem cells crossing the blood/brain barrier(BBB) and inducing neurogenesis. In some aspects, the stem cells aredirectly transplanted into the brain parenchyma, including striatum,following crossing of the BBB. In some embodiments, the inducedneurogenesis is dopamine-associated. For example, dopamine-associatedneurogenesis occurs through self-differentiation of the stem cells oractivation of migration and differentiation of intrinsic stem cells bythe extrinsic stem cells. In some aspects, massive dopamine-associatedneurogenesis takes place in the subventricular zone (SVZ).

In some implementations, the methods further comprise measuring theamount of DA receptor in the subject. In some embodiments, measuring theamount of DA receptor in the subject comprises imaging the subject todetect DA receptor. In most preferred embodiments of the methods,neurogenesis is mediated by dopamine receptor D2, thus in someembodiments, the DA receptor measured is receptor D2.

In some embodiments of the methods, the pharmaceutical compositionprovides neuroprotection. For example, systemic neuroprotection isprovided with the high basal level of neurotrophic and immunoprotectivefactors expression and release pattern of the stem cells of thepharmaceutical composition. In some aspects, these stem cells of thepharmaceutical composition are IDPSCs.

The neurological diseases and conditions include, for example, autism,schizophrenia, epilepsy, stroke and ischemia, a neurodegenerativedisease or condition, a motor disorder, or a convulsive disorder. Theneurodegenerative disease or condition may be, for example, Parkinson'sdisease, multiple sclerosis, amyotrophic lateral sclerosis (ALS),stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatousneuropathy, Alzheimer's disease, and Huntingdon's disease. Motordisorders include, for example, Tourette syndrome, amyotrophic lateralsclerosis (ALS), progressive bulbar palsy, spinal muscular atrophy(SMA), post-polio syndrome (PPS). Convulsive disorders include, forexample, epilepsy.

In some implementations, the methods for treating neurological diseasesand conditions support the natural neuro-protective mechanism insubjects diagnosed with early HD. In other implementations, the methodsfor treating neurological diseases and conditions repairs lost DAneurons in subjects diagnosed with PD.

The present invention also provides for methods of using thepharmaceutical composition as a preventive therapy for subjects at riskof HD.

In one embodiment, the present invention is directed to a pharmaceuticalcomposition for systemic administration to a subject to treat aneurological condition comprising undifferentiated stem cells fromtissue of neural crest origin expressing at least one safety markersselected from the group consisting of ATP-binding cassette sub-family Gmember 2 (ABCG2), inactive nanog, and p53. In certain aspects, inactivenanog is expressed nanog localizing predominantly in the cytoplasma ofthe undifferentiated stem cell. In another aspect, at least 75% of theundifferentiated stem cells express the at least one marker when the atleast one marker is ABCG2 or p53. In yet another aspect, no more than 5%of the undifferentiated stem cells express the at least one marker whenthe at least one biomarker is nanog.

In some embodiments, the undifferentiated stem cells express ABCG2,inactive nanog, and p53. In one aspect, at least least 75% of theundifferentiated stem cells express ABCG2, at least least 75% of theundifferentiated stem cells express p53, and no more than 5% of theundifferentiated stem cells express inactive nanog. In another aspect,the undifferentiated stem cells further express SOX2, and wherein nomore than 30% of the undifferentiated stem cells express SOX2. In yetanother aspect, the undifferentiated stem cells further express at leastone neuroepithelial stem cell marker selected from the group consistingof brain-derived neurotrophic factor (BDNF), neutrotrophin-3 (NT3),neutrotrophin-4 (NT4), neutrotrophin-5 (NT5), and p75.

In other embodiments, the undifferentiated stem cells express BDNF, NT3,NT4, NT5, and p75. In one embodiment, the present invention is directedto a pharmaceutical composition for systemic administration to a subjectto treat a neurological condition comprising undifferentiated stem cellsfrom tissue of neural crest origin at least one neuroepithelial stemcell marker selected from the group consisting of BDNF, NT3, NT4, NT5,and p75.

In certain aspects, the undifferentiated stem cells express BDNF, NT3,NT4, NT5, and p75. In other aspects, the undifferentiated stem cellsfurther express at least one safety markers selected from the groupconsisting of ABCG2, inactive nanog, p53, and SOX2. In certain aspects,inactive nanog is expressed nanog localizing predominantly in thecytoplasma of the undifferentiated stem cell.

In yet other embodiments, at least 75% of the undifferentiated stemcells express the at least one marker when the at least one marker isABCG2 or p53. In certain aspects, the undifferentiated stem cells arenegative for HLA-DR. In one embodiment, the tissue of neural crestorigin is dental pulp. In yet other aspects, the undifferentiated stemcells from tissue of neural crest origin are immature dental pulp stemcells (IDPSCs).

In another aspect, the present invention provides a method of treating aneurological disease or condition comprising systemically administeringto a subject a pharmaceutical composition comprising undifferentiatedstem cells from tissue of neural crest origin expressing at least onesafety marker selected from the group consisting of ABCG2, inactivenestin, and p53. In some aspects, the undifferentiated stem cells of thepharmaceutical composition further express at least one neuroepithelialstem cell marker selected from the group consisting of BDNF, NT3, NT4,NT5, and p75.

In yet another embodiment, the present invention is directed to a methodof treating a neurological disease or condition comprising systemicallyadministering to a subject a pharmaceutical composition comprisingundifferentiated stem cells from tissue of neural crest originexpressing at least one neuroepithelial stem cell marker selected fromthe group consisting of BDNF, NT3, NT4, NT5, and p75.

In certain embodiments, the undifferentiated stem cells of thepharmaceutical composition further express at least one safety markerselected from the group consisting of ABCG2, inactive nestin, p53, andSOX2.

In other aspects, the subject is intravenously administered thepharmaceutical composition. In some embodiments, the neurologicaldisease or condition is treated by the population of undifferentiatedstem cells crossing the blood/brain barrier and inducing neurogenesis.In one aspect, the neurological disease or condition is treated by theundifferentiated stem cells inducing neurogenesis viadopamine-associated neurogenesis. In another aspect, thedopamine-associated neurogenesis is through self-differentiation of theundifferentiated stem cells or activation of migration anddifferentiation of intrinsic stem cells by the undifferentiated stemcells.

In certain embodiments, the undifferentiated stem cells of thepharmaceutical composition provide neurotrophic factors andimmunoprotective factors. In other embodiments, the undifferentiatedstem cells of the pharmaceutical composition provides systemicneuroprotection. In one embodiment, the undifferentiated stem cells areautologous and/or allogeneic to the subject.

In certain aspects, the neurological disease or condition is aneurodegenerative disease or condition. The neurodegenerative disease orcondition may be selected from the group consisting of Parkinson'sdisease (PD), multiple sclerosis, amyotrophic lateral sclerosis (ALS),stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatousneuropathy, Alzheimer's disease, and Huntington's disease (HD).

In some aspects, the method comprises systemically administering thepharmaceutical composition to the subject, wherein the subject isdiagnosed with early HD, supports the natural neuroprotective mechanismin the subject. In other aspects, the method comprises systemicallyadministering the pharmaceutical composition to the subject, wherein thesubject is diagnosed with PD, repairs lost dopaminergic neurons in thesubject. In another embodiment, the neurological disease or condition isselected from the group consisting of autism, schizophrenia, stroke, andischemia. In other embodiments, the neurological disease or condition isselected from the group consisting of a motor disorder and a convulsivedisorder.

In certain aspects, the subject is administered a single administrationof the pharmaceutical composition. In one embodiment, the subject isadministered a single intravenous injection of the pharmaceuticalcomposition. In yet other embodiments, the subject is administered afirst and a second administration of the pharmaceutical composition.

In other embodiments, the subject is administered a first and a secondintravenous injection of the pharmaceutical composition. In someaspects, the second administration or intravenous injection of thepharmaceutical composition takes place at least 7 days after the firstadministration or intravenous injection.

In one aspect, the method further comprises measuring the amount of DAreceptor in the subject. In another aspect, the method comprisesmeasuring the amount of DA receptor in the subject comprises imaging thesubject to detect DA receptor. In one aspect, the DA receptor isreceptor D2.

The present invention is further illustrated by the following examplesthat should not be construed as limiting. The contents of allreferences, patents, and published patent applications cited throughoutthis application, as well as the Figures, are incorporated herein byreference in their entirety for all purposes.

EXAMPLES Example 1. Characterization of Early and Late Harvests IDPSCsand Derivation of Neural and Glial Cells from the Early and Late HarvestIDPSCs Characterization of Early and Late Harvests IDPSCs

In order to characterize the properties of the hIDPSC, from the early(n=8) and late (n=4) harvests (Table 1), flow cytometric analyzes of themesenchymal markers CD13, CD105, CD73, CD90, CD44 was performed. FACSexperiments were performed with 2×10⁵ cells. Cells were washed twicewith PBS (without calcium and magnesium) and the tested antibodies wereadded for 15 minutes at room temperature. The cells were then washedtwice with cold PBS and analyzed with a Becton-Dickinson flow cytometer.The fluorescence of PE (FL2), FITC (FL1), APC (FL4) were detected in 575nm, 53 nm, and 600 nm emission wavelengths, respectively.

TABLE 1 List of cells used in the FACS experiments Batch Number HarvestNumber (H) Passage Number (P) Early Harvests: 1 0 3 6 0 3 10 0 3 11 0 317 0 3 22 0 3 24 0 3 26 0 4 Late Harvests: 11 13 3 11 16 9 24 13 3 26 102

Cells from both early and late harvests expressed high levels ofmesenchymal markers. Both populations were negative for HLA-DR andHLA-ABC antigen expression which allows for allogenic transplantation ofthese populations of cells. Both populations were double immunopositivefor mesenchymal stem cell markers, such as, CD13 and CD44 and others, aswell as expressed nestin, P75 (CD271), neuroepithelial stem cellmarkers, and nerve growth factor (NGF) (see FIGS. 1 and 2A-2L and Table2) and they were negative for CD146 and HLA-ABC.

After mutiharvest of DP tissue and explant culture, IDPSCs demonstratecapacity to form colonies (FIG. 3). The colony forming assay (CFU-F)assay was performed in triplicate at T20, P3 using 480 cells seeded ineach plate, at day 8 multiple colonies colonies appeared andapproximately 100 colonies were formed in each plate (FIG. 3). Colonyforming capacity is one of the principal characteristics of stem cell.Therefore, we conclude that this capacity was maintained when the cellswere obtained using the disclosed multiharvest organ and tissue explantmethod. Additionally, the proliferative activity of LP IDPSC wasevaluated as shown on FIG. 4, and these cells demonstrated a very highproliferative rate.

TABLE 2 Comparison of the cell marker expression from the hIDPSC derivedfrom the same donor by FACS analysis. % of Fluorescence Markers H0P3H13P3 H16P9 CD105 99.4 99.76 99.6 CD13 99.5 99.1 99.3 CD73 95.1 99.8885.3 CD90 99.9 99.9 99.7 CD44 99.12 99.45 96.4 HLA-DR 0.8 3.03 0.4HLA-ABC 0.2 0.1 0.3 NGF 18.7 55.96 49.5 Nestin 54.5 66.57 30 ABCG2 1.88ND 8.1 ABCB1 24.8 ND 45.6

Table 2 compares the cell marker expression from different harvests ofhIDPSC derived from the same donor (i.e., H0P3=first harvest;H13P3=later harvest; H16P9=last harvest). Late harvest populations hadgreater levels of NGF than the early harvest population. Expression ofadenosine triphosphate binding cassette (ABC) transporters was alsotested in the cells. ABC transporters are involved in the activetransport of an extremely diverse range of substrates across biologicalmembranes. These transporters are commonly implicated in the developmentof multidrug resistance and are also involved in numerous physiologicaland homeostatic processes, including lipid transport, cell migration anddifferentiation. Moreover there is evidence that ABC transporters serveas phenotypic markers and functional regulators of stem cells (Bunting2002). Both early and late harvests populations expressed ABCB1 protein,the product of MDR1 gene, but expression was higher in the late harvest.According to Islam et al. (2005), ABCB1 is expressed in human fetalneural stem/progenitor cells (hNSPCs).

FACS analysis show that LP of IDPSCs (batch #11) comprises approximately80% cells that express BDNF and DARPP 32, while EP is negative for thesemarkers (data not shown) and very low number of the cells, which expressD2 (FIG. 3). To further characterize hIDPSC early and late harvests,total brain-derived neurotrophic factor (BDNF) levels represented by theamount of BNDF in medium was determined using ELISA (Table 3). BDNFlevels were quantified by using a human BDNF Quantikine ELISA kitaccording to the manufacturer's protocol (R&D Systems, Minneapolis,Minn.). Cells (1×10⁶) from different harvests were inoculated in 75 cmplastic flasks. The supernatants were harvested approximately 4 daysafter inoculation. The results were expressed as the BDNF concentration.BDNF was secreted in all cell subsets, but the levels were 4-10 foldshigher in the late harvests.

TABLE 3 Total BDNF levels in early and late harvests of hIDPSC Harvest(H) and Batch number Passage (P) Number BDNF levels (pg/ml) 11 H0 P3 1324 H10 P2 154 26 H13 P3 43Comparison with Other MSCs Shows that hIDPSCs Secrete Much More BDNF.

The average level of BDNF secreted by 1×10⁶ hIDPSCs is 6589 pg, which ismany times higher than other types of MSCs that secrete BNDF, such asthe MSCs of Gothelf et al. in 2014 (Clin Transl Med. 2014 3:21). Gothelfet al. induced bone marrow-derived MSCs (BM-MSC) to differentiate intoneurotrophic factor-secreting cells (BM-MSC-NTF) by incubating theBM-MSCs for 72 hours in medium containing 1 mM dibutyryl cyclic 15 AMP(cAMP), 20 ng/ml human Basic Fibroblast Growth Factor (hbFGF), 5 ng/mlhuman platelet derived growth factor (PDGF-AA), and 50 ng/ml humanHeregulin β1. Although the induction medium nearly doubled BDNFsecretion (827 pg BNDF/10⁶ BM-MSC compared to 1640 pg BNDF/10⁶BM-MSC-NTF cells), hIDPSCs still secreted four times more BDNF thanBM-MSC-NTF. Accordingly, the hIDSPCs have much greater neuroprotectivepotential than bone marrow-derived MSC induced to secrete neurotrophicfactors.

Expression of Oct4, Nanog, Sox2 and p53

It is known that MSCs generally express pluripotent markers such asOct4, Nanog and Sox2 at low levels as described in the literature (Jianget al., 2002; Guillot et al., 2007). We showed that hIDPSC express verylow levels of such markers in comparison with human embryonic stem cellsand even induced pluripotent stem cells obtained from hIDPSCs (see FIG.5). More importantly, we demonstrated that hIDPSC express a high levelof p53. The tumor suppressor gene p53 is well known as a masterregulator that helps keeps cancer at bay. Blocking the p53 pathwayvastly improves the ease and efficiency of transforming differentiatedcells into induced pluripotent stem cells (Dolgin, 2009).

Derivation of Neural and Glial Cells from the Early and Late HarvestsIDPSCs

The neuronal system consists of two classes of neural precursor cells:neuronal NPCs that differentiate into neurons and glial NPCs thatdifferentiate into glia. Both neuronal and glial NPCs descend from thesame neuroectodermal precursor. A third class of neural precursor cells,neuroglioblast, was also suggested. This third class of cells includeradial glial cells also can act as neuronal precursors and only later,after neurogenesis, do they shift towards an exclusive generation ofastrocytes.

The ability to distinguish whether a population of cells in cell therapyare neuronal NPSs or glial NPCs is of extreme importance for developingan efficient cell therapy strategy for treating neurodegenerativediseases, which mainly involve the damage or loss of both glia andneurons. It is possible to test known cell populations for the potentialto differentiate into neurons or glia by inducing these cells todifferentiate.

The capacity of EP (early population) and LP (late population) IDPSC toproduce neurons and glias was tested by inducing neuronaldifferentiation in EP and LP IDPSC at early (P2) and late passages (P7)according to the previously described protocol (Kerkis et al., 2006)(FIG. 6). After 7 days, the cells were collected and analyzed by flowcytometry using GFAP (glial fibrillary acidic protein) andbeta-III-tubulin antibodies, respectively. A significant differenceexists in the number of cells that express these markers between EP(B-E, left) and LP (B-E, right), which were established following adental pulp (DP) harvesting protocol. On the other hand, no significantdifference in expression of both proteins was detected between differentpassages (P2 and P7) obtained following enzymatic digestion, (FIG. 6).Surprisingly, IDPSCs can be neuronal and glial NPCs. Early DP harvesting(EP IDPSC) leads to isolation of neural progenitor cells committedmainly to glial differentiation while late DP harvesting (LP IDPSC)leads to isolation of neural progenitor cells committed mainly toneuronal differentiation.

Thus DP harvesting is important for establishing a population of NPCswith the potential to develop into neurons and glia. SHED, which arestem cells from human deciduous teeth, cannot be categorized as an earlypopulation or late population because they are stem cells isolated fromdental pulp cells without DP harvesting. The single SHED populationcontains neuron-committed and not glial-committed progenitors. In Miuraet al. (2003) neuronal differentiation of SHED resulted in increasedexpression of beta-III-tubulin, GAD, and NeuN while the expression ofnestin, GFAP, CNPase, and NFM remained the same after the induction ofdifferentiation (see FIG. 41 of Miura).

Example 2. Expression of CD146 and CD13 in Early Phase (EP) and LatePhase (LP) hIDPSC

CD146 and CD13 expression were analyzed by flow cytometry in EP-hIDPSCand LP-hIDPSC. The results in FIG. 7 show that CD13 was expressed in 52%of EP-hIDPSC and 95% of LP-hIDPSC. These results demonstrate that invitro DP harvesting and hIDPSC passing produce increased quantities ofhIDPSC expresssing CD13 and lacking expression of CD146.

Example 3. Comparison of IDPSC and SHED

MSCs from different sources (e.g. bone marrow and adipose tissue) canrespond differently to different stimuli (Fraser J K et al., 2006).Culture conditions (e.g., media supplemented with either human serum orfetal calf serum (FCS), or serum-free) may also affect thedifferentiation potential of even MSCs of the same origin (Lindroos etal., 2011; Lizier et al., 2012). It is very probable that thedifferences in the differentiation efficiencies are extremely reflectiveof the heterogeneity of MSC populations (i.e., the presence of distinctsubpopulations) (Ho et al., 2008; Tormin et al., 2009; Mareddy et al.,2009; Rada et al., 2011). Different isolation and culture protocols usedby different groups may account for the predominance of a particular MSCsubpopulation with a distinct differentiation potential [Ho et al.,2008; Pevsner-Fischer et al., 2011; Rada et al., 2011).

SHED and IDPSCs have different methods of isolation and come fromdifferent stem cell niches. So it is unsurprising that SHED and IPSCsalso have different expression of stem cell markers (see Table 4). SHEDoriginated from perivascular environment and STRO-1 and CD146 positivecells were found to be located around blood vessels of the remnant pulpby immunohistochemical staining. Only a minor proportion (9%) of ex vivoexpanded SHED stained positive for the STRO-1 antibody using FACS.

TABLE 4 Differences between SHED and IDPSCs SHED IDPSC Perivascularniche Perivascular niche Nerve plexus Subodontoblastic plexus nicheCell-free and cell-rich zones whole dental pulp (DP) minced pulpEnzymatic digestion: 1 hour Stem cell migration Can be isolated one timeDP transferrable up to 30 times from the same DP to result in 30isolations Culture medium: Alpha Culture medium: Dulbecco's modificationof Eagle's medium modified Eagle's medium (DMEM)/ (GIBCO/BRL)supplemented with: Ham's F12 (1:1) supplemented with: 20% FCS 15% fetalbovine serum 100 μM l-ascorbic acid 2- 100 U/ml penicillin phosphate 100g/ml streptomycin 2 mM l-glutamine 2 mM L-glutamine 100 units/mlpenicillin 2 mM nonessential amino acids 100 μg/ml streptomycinSingle-cell suspension Outgrowth Use of cell strainer Assess only toouter layer of Assess to outer and inner part of DP DP and very closelayers Principal markers: Principal markers: Perivascular Mesenchymalstem cells (MSC) Embryonic stem cells (ES cells) Neuronal precursorsPerivascular Osteogenic differentiation Not required required BMP-4Neurogenic differentiation Not required required EGF, FGF, and rat serumChondrogenic differentiation Not required required TGF-β3 and bFGF orTGF-β High passages are needed in DP multiple transfer ensure sufficientorder to obtain number of SHED IDPSC number at low passages sufficientfor cell therapy

The requirements for inducing differentiation are also different betweenSHED and IDPSCs. For example, to induce neuronal differentiation, SHEDneed EGF 20 ng/ml (BD Bioscience), FGF 40 ng/ml (BD Bioscience) and 3%rat serum. They need four weeks in neural inductive culture in order toshow neural morphology and to increase expression of neuronal markers.

In part because of these differences, IDPSCs had advantages over SHEDregarding neurogenesis. In one study, SHED were injected into thedentate gyrus of the hippocampus of immunocompromised mice. The datademonstrated that SHED were able to survive for more than 10 days inmice hippocampus and to express NFM, which were expressed also byundifferentiated SHED (Miura et al., 2003). In another study,pre-differentiated SHED (SHED-derived spheres created by a combinationof EGF and bFGF for 7 days in vitro) were transplanted into Parkinsonianrats. The cell suspension (200,000/μL) was injected into 2 DA-depletedstriatum sites in rats (2.5 per site). Modest differentiation into DAneurons was observed (Wang et al, 2010). In a third study, SHED wereinjected in injured brain of postnatal day 5 mice, which were inducedwith in perinatal hypoxia-ischemia (HI) that has high rates ofneurological deficits and mortality. Cyclosporine A was used to protectengrafted cells from the xenogeneic host immune response, neverthelesseight weeks after transplantation the engrafted SHED, had no or fewcells differentiated into neurons, oligodendrocytes, or astrocytes(Yamagata et al. 2013).

The common theme across all three experiments is that SHED wereadministrated together with Cyclosporine A. Cyclosporine A is shown todecreases the size of the ischemic brain infarct in rats and to protectsagainst synaptic dysfunction and cell death in rodent models oftraumatic brain infarct as well as to protects striatal neurons frommitochondrial dysfunction in Huntington disease (Matsomoto et al., 1999;Albensi et al. 2000; Leventhal et al., 2003). Therefore, benefitsobserved in Parkinsonian rats and HI, cannot be purely attributed toSHED but also to Cyclosporine A intervention.

Example 4. Comparison with Other Therapeutic Stem Cells for theTreatment of Neurological Conditions

As shown in Table 5, hIDPSCs from Avita International LTD asadvantageous over other therapeutic stem cells on the market or inclinical trial. Avita International LTD's hIDPSCs have a good safetyprofile with low risk of immunogenicity and has low cost of production,as they can be cryopreserved.

TABLE 5 Comparison table modified from Maxim Research. BrainStorm CellAvita Therapeutics NeuralStem Kadimastem International Company (ticker)Inc. (BCLI) Inc. (CUR) (KDST) LTD Cell Source Autologous MSC Allogenic;8- hESCs (embryo) hIDPSCs from from bone week-old fetal and iPSCs(adult) dental pulp marrow spinal cord- derived cells ModificationsInduction of No Induction to No neurotrophic differentiate into factorsecretion astrocyte precursor cells Cell Safety Profile Good with lowLess safe with Less safe with Good with low risk of risk of unwantedrisk of unwanted risk of immunogenicity differentiation differentiationimmunogenicity (teratoma) and/or (teratoma) and/or risk of rejectionrisk of rejection Immunosuppression Not required Required Required Notrequired Cryopreservation Not yet - Cell can be Cells can be Cell can bestudying the expanded and frozen in expanded and feasibility of frozendifferentiated frozen cryopreservation state of MSCNCs during earlyphase expansion Clinical Trials Compassionate Phase I/II begins Not yetin clinical On going Phase Care: Phase I/II in 2014 trials I (Brazil)complete (Israel); (Mexico); Phase Phase II II ends in underway (US)4Q2014 (US) Cost High Low Low Low

Example 5. Certificate of Analysis of IDPSCs (Cellavita) Used forSterile IV Injection

Certificate of analysis (Table 6) of a representative batch of IDPSCsused for IV injection into animal models confirm the characterizationresults of IDPSCs.

TABLE 6 Method of analysis Characteristics Specification Morphologicaltest Morphology Normal fibroblast like morphology under invertedmicroscope inspection Cell viability via Viability >95% Trypan Blueexclusion PCR Mycoplasma test Mycoplasma detection Undetectable CFU Cellforming units assay >5 colonies LAL Endotoxin detection ≤2 Eu/kg bodyweight/dose Bacteriostatic and Sterility Undetectable Fungistaticactivity Gram stain technique Microbial contamination UndetectableMTT/or XTT Cell proliferation rate Cell number at least double in 24hours FACS analysis (MSC Phenotype analysis Positive for CD73, CD105,CD44 markers) Negative for CD45, HLA-ABC Cytokine and growth Cytokineand neuronal Positive for NGF, or/and BDNF, IL8 factors release assayfactors analysis FACS analysis Neuronal markers Positive for SOX2,or/and Nestin

Example 6. Identification of the Parameters for Safe SystemicAdministration of a Stem Cell Treatment

IDPSC shows Oct4 nuclear localization (FIG. 8A-B). While a majority ofIDPSCs have Nanog in the cytoplasm of cells (FIG. 8C-D), very rare cellsdemonstrate nuclear localization as well. The intracellular localizationof Sox2 in IDPSCs is mainly nuclear (FIG. 8E-G), though several cellscan show cytoplasmic localization too. Interestingly, we can observe thesymmetrical division (FIG. 8D-F) when Nanog and Sox2 expression inobserved in both daughter cells, and observe asymmetric division whenafter division the daughter cells do not express these markers or losesthe characteristic of stem cells and becomes a less potent progenitor ora differentiated cell (FIG. 8E-F).

Our data demonstrate that in contrast to pluripotent stem cells, IDPSCare classified as MSC or adult stem cells. The intracellularlocalization of Nanog indicates that the protein is mostly inactive.This is a dramatic difference between pluripotent stem cells and adultstem cells, which express pluripotent stem cells markers. These cellsare more immature than classic MSC and can differentiate to widerspectrum of the mature cells, but they are not able to produce teratomadue to the inactive state of Nanog. Our data on symmetric and asymmetricdivision clearly demonstrate that these cells mimic asymmetric neuralstem cells division (FIG. 9).

Teratomas formation is an essential tool in determining the pluripotencyof any pluripotent cells, such as embryonic or induced pluripotent stemcells (ES and iPS cells). Established a consistent protocol forassessment of teratoma forming ability of the cells, was used in ourstudies, similar to protocol published recently by Gropp et al., 2012.Our and recently published methods are based on subcutaneousco-transplantation of defined numbers of undifferentiated mouse or humanES and iPS cells and Matrigel into immunodeficient mice. Our method wasshown to be highly reproducible and efficient when 10⁶ cells (differentfrom Gropp et al., 2012, which used 10⁵ cells) of mouse ES cells andhuman iPS cells were used. In 100% of cases we observed teratomaformation in a large number of animals and in long follow-up (up to 6months). We also used these methods for bio-safety analysis of otheradult MSC, such as those derived from dental pulp of deciduous teeth,umbilical cord, and adipose tissue.

Principal Criterion for Teratoma Assay

We evaluated next criterion for a teratoma assay: sensitivity andquantitativity; definitive cell number and single cell suspensionproduction; immunophenotyping of studied cell in respect of expressionon pluripotent cell markers and karyotype; co-transplantation of studiedcells together with Matrigel. The cells were transplanted subcutaneously(s.c) into NOD/SCID mice, which allows for simple monitoring of teratomadevelopment.

The development of tumors was monitored from 4 month (˜16 weeks).Histological criteria for teratomas is the differentiation ofpluripotent cells into the cells derived from three germ layers. Suchstudy usually was performed by pathologist.

For adult/mesenchymal stem cells any type or any changes on normaltissue integrity in the site of cell injection were taken inconsideration.

Application of the Teratoma Criterion A. THE EXPERIMENTAL SYSTEM (S):

a. Mouse embryonic stem cells

b. Mouse 3T3 fibroblasts, permanent mouse cell line Balbc 3T3 cell line,clone A31

c. Human iPS-IDPSC

d. Human ES cells

e. Human IDPSCs

We used aforementioned method in diverse studies to characterizedifferent mouse ES cell lines pluripotency established by us as well asto confirm ES cells pluripotency at high 25 or more passages and forcharacterization of sub-clones obtained from mouse ES cell lines(Sukoyan et al., 2002; Carta et al., 2006; Kerkis et al., 2007;Lavagnolli et al., 2007; Hayshi et al., 2010).

Additionally, this method was used to characterize the pluripotency ofiPS cells derived from immature dental pulp stem cells (IDPSC) in morerecent publication of our group (Beltrão-Braga et al., 2011). In thispublication the human IDPSC were used as a control for iPS-IDPSCs. Weshowed that iPS-IDPSCs formed nice teratomas with tissues originatedfrom all three germ layers, while hIDPSC were not able to produce anytype of teratomas or any other type of neoplasms. In addition,iPS-IDPSCs expressed Nanog in nucleus, and hIDPSCs did not.

Results

Disclosed multiharvest explant like culture used for the isolation of apopulation of immature dental pulp stem cells (IDPSC), results inexpression of embryonic stem cell markers Oct-4, Nanog, SSEA-3, SSEA-4,TRA-1-60 and TRA-1-81 as well as several mesenchymal stem cell markersduring at least 15 passages while maintaining the normal karyotype andthe rate of expansion characteristic of stem cells. The expression ofthese markers was maintained in subclones obtained from these cells.Moreover, in vitro these cells can be induced to undergo uniformdifferentiation into smooth and skeletal muscles, neurons, cartilage,and bone under chemically defined culture conditions. It is important tomentioned that IDPSC although have a small size and cytoplasm poor incell organelles differ from naïve pluripotent cells presenting typicalmesenchymal-fibroblast like morphology. Therefore IDPSC are ofmesenchymal type, in contrast to ES and iPS cells, which are ofepithelial type (FIG. 8). The principle difference between MSC and ES oriPS cells that MSC are migrating and plastic anchoring, they synthetizeextracellular matrix and are cell junction free cells.

B. THE EXPERIMENTAL SYSTEMs:

-   -   a. three different IDPSC primary cultures at early (n=10) and        late passages (n=10)    -   b. Human primary fibroblast

In addition, this method was validated using dog fetal stem cells frombone marrow, liver, yolk sac, allantois and amniotic liquid which alsoexpress pluripotent markers.

The IDPSC are composed by population of MSC with a variable number ofstem cells expressing pluripotent markers (1-25% of cells) (Lizier etal., 2012). These cells were transplanted into NOD/SCID mice (n=20) andthe development of tumors was monitored from 4 month (˜16 weeks). Anytype of changes on normal tissue integrity in the site of cell injectionwere taken in consideration. This protocol was adapted for thepopulation of IDPSC, especially with respect to the number of cellsused, which was calculated on the basis that 20% of IDPSC expresspluripotent markers. In our previous tests with ES and iPS cells we used10⁶ cells, while to test IDPSC and control cells teratogenicity 5×10⁶cells were used. After 4 months, even if macroscopically, the tumorswere not observed, the mice were sacrificed and frozen cuts wereobtained from diverse organs, such as brain, lung, kidney, spleen, liverand were analyzed by pathologist.

Although presence of DNA of IDPSC within all studied organs were found,no tumor formation or any morphological changes were observed.

Example 7. Identification of Parameters for Effective SystemicAdministration of a Stem Cell Treatment Cell Culture Conditions toEstablish Proper Population of Stem Cells.

Culture conditions, such as culture medium and adhesive surface, canaffect gene expression of the cells. Such genes include ABCG2 andVimentin, which are two genes that can indicate suitability of the cellsin culture for therapeutic use, particularly systemic cellular systemslike the present invention. Most suitable culture medium form tested isDMEM/F12 basal medium supplemented with 5-10-15% of FBS, antibiotics,and Glutamate, and the cells should be cultured without an adhesionlayer (e.g. without extracellular matrix (ECM) or scaffold) such thatthe cells adhere directly to the culture dish or beads plastic. Cellsthat were grown with epithelial growth media conditions turn intoepithelial-like cells. Using various xeno-free medium will requiregrowth factors supplementation and selection of appropriate ECM coatingcan be useful for scale up of current cells into 3D culture conditionsincluding bioreactors, such as Terumo hollofiber bioreactor,Eppendorf-New Brunswick bioreactors with beads, etc. The link of ABCG2expression and undifferentiation status of cells is shown in FIGS. 10and 11, where demonstrated that once ABCG2 not expressed due to changedculture medium or coating layer, then—cells have clear more fibroblastor epithelial cells-like morphology. Another surprising finding was thata typical medium routinely used in the prior art for maintenance orinduction of embryonic stem cells, namely Dulbeccos Modified EagleMedium (DMEM) serum knockout medium KOSR (KSFM), is not advantageous forgenerating or maintaining pluripotent cells derived from hDPSC. Asdemonstrated in FIG. 11, use of this medium with and without fibronectincontaining scaffold/ECM matrix coating or scaffold resulted in thedifferentiation of hIDPSCs into fibroblast-like (FIG. 11) or epitheliallike cells. In contrast to the use of Dulbeccos Modified Eagle Medium(DMEM) alone, it was found that Dulbeccos Modified Eagle Medium (DMEM)or Neurobasal medium (NB) if supplemented with B27 and, optionally,supplemented with FGF and/or EGF, leads to the formation of neuronallike leneages. Exemplary protocols for differentiation into cells of theneural lineages have also been described in previous patentapplications, for example, International Application no. PCT/IB14/59850and U.S. patent application Ser. No. 14/2140,016.

Differentiation into Corneal Cells

Material and Methods

De-Epithelialization of Amniotic Membrane as a PotentialFibronectin-Containing Scaffold for hIDPSC Cell Culture

Amniotic membrane (AM) was obtained from placenta of donor and stored at−8° C. (Covre J L at al 2011). Prior AM use, it was thawed at roomtemperature and washed in three times in PBS. Next, AM was removed fromnitrocellulose membrane and washed again. In order to remove theepithelia, AM was incubated with EDTA for two hours. Then, the epitheliawere removed mechanically. The AM becomes transparent following theepithelia removal. Completely transparent AM was transferred on inserts(Covre J L at al 2011 and Melo G B at al 2007).

IDPSC Culture

Human IDPSC, (2n=46, XX) were isolated from dental pulp of deciduousteeth and characterized previously (Kerkis et al. 2006). hIDPSC weremaintained in Dulbecco's-modified Eagle's medium (DMEM)/Ham's F12 (1:1;Invitrogen, Carlsbad, Calif.), supplemented with 15% fetal bovine serum(FBS; Hyclone, Logan, Utah), 100 units/mL penicillin (Gibco, GrandIsland, N.Y.), 100 μg/mL streptomycin (Gibco), 2 mM L-glutamine (Gibco),and 2 mM nonessential amino acids (Gibco). The culture medium waschanged daily, and the cells were replaced every 3 days. After theyreached 80% confluence, they were washed twice in sterilephosphate-buffered saline (PBS; Gibco; 0.01 M, pH 7.4), enzymaticallytreated with 0.25% trypsin/EDTA (Invitrogen), and seeded onto amnioticmembrane previously prepared.

Culture Media

To select the best culture media for cultivate IDPSC on AM, we testedthe following culture media: A) The first was supplemental hormonalepithelial medium (SHEM), a combination of Dulbecco's Modified Eagle'sMedium/Ham's F-12 nutrient mixture (DMEM/F12; Invitrogen, Gibco CellCulture, Portland, Oreg.; 1:1) containing 1.05 mM calcium supplementedwith 5 μg/ml crystalline bovine insulin (Sigma Aldrich, St. Louis, Mo.),30 ng/ml cholera-toxin (Calbiochem, San Diego, Calif.), 2 ng/mlepidermal growth factor (EGF, R & D Systems, Inc., Minneapolis, Minn.),0.5% dimethyl sulfoxide (DMSO, Sigma Aldrich), 0.5 μg/ml hydrocortisone,5 ng/ml sodium selenite, and 5 μg/ml apo-transferrin, and supplementedwith 10% fetal bovine serum (FBS). All reagents were obtained fromInvitrogen Corporation (Grand Island, N.Y.), except those indicated inthe text. B) The second was keratinocyte serum-free medium (KSFM)containing 0.09 mM calcium supplemented with 30 mg/ml pituitary bovineextract, 0.2 ng/ml EGF, 10% FBS, and ampicillin/streptomycin. C) Thethird was Epilife medium (Cascade Biologics, Portland, Oreg.),containing 0.06 mM calcium supplemented with 1% “human corneal growthsupplement” (Cascade Biologics), containing 0.2% pituitary bovineextract, 5 g/ml bovine insulin, 0.18 mg/ml hydrocortisone, 5 μg/mlbovine transferrin, 0.2 ng/ml EGF, added 1% penicillin G sodium(Penicillin G sodium 10,000 g/ml, streptomycin sulfate 25 mg/ml,amphotericin B in 0.85% NaCl), and 5% FBS. D) Knockout media

Antibodies

Mouse anti-human monoclonal antibodies: ABCG2 (Chemicon) andcytoplasmic/nuclear monoclonal antibodies: mouse anti-cytokeratin 3/12(K3/12) (RDI, Flanders, N.J., USA), reacts with human and rabbit. Mouseanti-human IDPSC antibody was obtained as described (Kerkis et al.,2006) and successfully used by us in previous studies (Fonseca et al.,2009; Monteiro et al., 2009).

Immunofluorescence Staining

Cells were grown on glass cover-slips up to 70% confluence and also,were grown on AM, washed in PBS (Gibco) and fixed overnight with 4%paraformaldehyde (Sigma). Coverslips were washed three times in trisbuffered saline (TBS), containing 20 mm Tris-HCl pH 7.4 (Vetec, Duque deCaxias, R J, Brazil), 0.15 m NaCl (Dinâmica Reagent, São Paulo, SP,Brazil), and 0.05% Tween-20 (Sigma). Permeabilization was performedusing 0.1% Triton X-100 for 15 min (Santa Cruz Biotechnology). Cellswere washed three times and incubated for 30 min in 5% bovine serumalbumin (Sigma) in PBS pH 7.4 (Gibco). Primary antibodies were added for1 h on each slide at different dilutions (ABCG2 and K3/12 (1:100), andanti-hIDPSC (1:1000)), which were incubated at room temperature.Following washing in TBS (three times), cells were incubated in the darkfor 1 h with secondary anti-mouse antibody-conjugated fluoresceinisothiocyanate (FITC) at a dilution of 1:500. Microscope slides weremounted in antifade solution (Vectashield mounting medium, VectorLaboratories, Hercules, Calif., USA) with 4′,6-diamidino-2-phenylindole(DAPI) and analysed using a confocal microscope. Control reactions wereincubated with PBS instead of primary antibody, followed by washing andincubation with respective secondary antibody. All experiments have beendone in triplicate.

Results Expression of Undifferentiated LSCs and Differentiated CornealCells Proteins in IDPSCs Grown in Different Culture Media on PlasticSubstrate

The expression pattern of ABCG2 protein (ATP-binding cassette sub-familyG member 2), which are commonly used for LSCs characterization and CK3(cytokeratin 3) and cytokeratin 12 that encodes the type I intermediatefilament chain and both expressed in corneal epithelia were analyzed.FIG. 12 depicts that IDPSC had differential response in respect ofexpression of studied proteins when cultured in distinct culture mediumduring 7 days. The IDPSCs grown on plastic surfaces did not expressABCG2 when cultured in SHEM, KSFM, Epilife and DMEM/KO (FIG. 10 A1-A4),this protein was expressed in IDPSCs only when they were cultured inbasal culture medium (FIG. 10 A5). Interestingly, that IDPSCs culturedin SHEM and DMEM/KO, after seven days changed their morphologyfibroblast like (FIG. 10 A5) to epithelial like (FIGS. 10 B2 and B4) andstart to express CK3/12, while IDPSC cultured in Epilife and KSFM andDMEM/F12 did not start to express K3/12 (FIG. 10 B1, B3, B5).

Expression of Undifferentiated LSCs and Differentiated Vimentin Markersin IDPSCs Grown in Different Culture Media on AM

Next, the expression of these markers and additionally vimentin wasverified in IDPSC grown on AM during 7 days (FIG. 11). Epilife wasexcluded from this study due to very low survival of the cells (lessthen 50%), when grown in this medium and low adherence of the cells onAM in combination with Epilife. Vimentin expression was observed in allsamples (FIG. 11 A-A3), it was positive in IDPSCs cultured in DMEM/F12and SHEM (FIG. 11 A and A2) and showed weak positivity with IDPSCscultured in KSFM and DMEM/KO (FIG. 11 A2 and A3). ABCG2 antibody showedstrong immunopositivity with IDPSC cultured in SHEM and DMEM/F12 (FIG.11 B and B1) and did not express in IDPSC cultured in KSFM (FIG. 11 B2)and showed weak immunoreactivity with IDPSC cultured in DMEM/KO (FIG. 11B3). IDPSCs did not react with IDPSCs cultured in DMEM/F12 e KSFM (FIG.11 C and C4) and showed very weak immunopositivity with K3/12 whencultured in SHEM and DMEM/KO (FIG. 11 C1 and C3).

Example 8. Preclinical Pharmacology Studies

FIG. 12 summarizes the preclinical pharmacology studies, which aimed atexamining the different clinical applications of the investigationalproduct CELLAVITA™ (stem cells). Although many of the studies wereconducted to investigate the pharmacological efficacy of the cells forvarious indications, they are all demonstrate the safety profile of theproduct as well as of the proposed intravenous administration.

Example 9. Product Description and Specifications

Table 7 depicts CELLAVITA⋅ (stem cells) specifications.

TABLE 7 Drug Product Release Monograph Method of AnalysisCharacteristics Specification Appearance- Morphology Normal fibroblastMorphological like morphology test under inverted microscope inspectionCell viability Viability >95% via Trypan Blue exclusion Cell doublingsCell doublings number At least doubling of cell number in 24 hours CFUCell forming units assay >5 colonies Sterility Microbial contaminationNo growth detected (21CFR/EP/USP) after 14 days Endotoxins Less than orequal to <0.005 EU/mg (LAL) 1.0 EU/mg A280 protein A280 protein PCRMycoplasma Mycoplasma detection Undetectable test Culture - no growthdetected Impurities FACS analysis Allogeneic marker Negative to HLAclass II FACS analysis HSC marker Negative to CD34 FACS analysisPhenotype analysis MSC Positive to CD73, CD105 FACS analysis Phenotypeanalysis Positive to NGF, neuronal factors nestin Assay ELISA assayNeuronal factors Positive to BDNF

Analytical Procedure Safety QC-Mycoplasma Test

Mycoplasma tests are performed regularly during cultivation of hIDPSCwith an in-house RT-PCR test (EZ-PCR Biological Industries, Israel)according to the manufacturer's protocol.

Safety Characteristics—Karyotype Analysis

Karyotype analysis have been performed in order to demonstrate karyotypestability and this data are already published (Kerkis et al., 2006;Beltrão-Braga, 2011; Lizier et al., 2012).

Safety and Identity QC-Flow Cytometric Analysis of Cell Surface Antigens

Immunostaining of cell surface markers was carried out with monoclonalantibodies against various surface antigen markers: HLA-DR-FITC,CD44-FITC, CD45-APC, CD105-PE, CD73-FITC, CD90-APC (eBioscience CA,USA), SOX2-PE, Nestin-PE, Tubulin-APC, NGF-PE (R&D systems, MN, USA).2×105 cells were used for the FACS experiments. Cells were washed twicewith PBS (w/o Ca and Mg) and suspended in 50 μl PBS. Cells were thenincubated with antibodies for 15 min at room temperature. The cells werewashed twice with PBS and analyzed with a Becton-Dickinson flowcytometer. The fluorescence of PE (FL2), FITC (FL1), APC (FL4) wasdetected at 575 nm, 530 nm and 600 nm emission wave lengths,respectively.

Activity Bioassay QC-ELISA Assay

BDNF levels were quantified by using a human BDNF Quantikine ELISA kit,according to the manufacturer's protocol (R&D Systems, MN, USA).

1×10⁶ cells from different harvests were inoculated in 75-cm2 plasticflasks. The supernatants were harvested approximately 4 days afterinoculation. The results were expressed as the BDNF concentration.

Batch Analysis

Table 8 depicts batch Number 001H1 -30 P1-5. F analysis.

TABLE 8 Batch Number 001H1-30/P1-5/F Method of Analysis CharacteristicsSpecification Result Characteristics Appearance- Morphology Normalfibroblast like Confirms Morphological test morphology under invertedmicroscope inspection Cell viability via Trypan Viability >95% ConfirmsBlue exclusion Cell doublings Cell doublings number At least doubling ofcell Confirms number in 24 hours CFU Cell forming units assay >5colonies Confirms Safety Sterility (21CFR/EP/USP) Microbialcontamination No growth detected after Confirms 14 days Endotoxins (LAL)Less than or equal to 1.0 <0.005 EU/mg A280 Confirms EU/mg A280 proteinprotein PCR Mycoplasma test Mycoplasma detection Undetectable ConfirmsCulture - no growth detected FACS analysis Allogeneic marker Negative toHLA-DR Confirms FACS analysis HSC marker Negative to CD34 ConfirmsIdentity: mesenchymal stem cell markers and neuronal markers FACSanalysis Phenotype analysis MSC Positive to CD13, CD73, Confirms CD105FACS analysis Phenotype analysis Positive to NGF, nestin Confirmsneuronal factors Activity Bioassay ELISA assay Neuronal factors Positiveto BDNF Confirms

Stability

Avita performed non GMP, non GLP studies regarding hIDPSC stability. Forthis purpose a single master cell bank, which may mitigate variabilityof the final batch, was established. It was composed by 5 batches, eachderived from Dental Pulp of one individual. The cells were produced asdescribed in FIG. 13. The time line of stability studies of hIDPSC ispresented on FIG. 14.

The expression of stem cell markers, dynamics of cell proliferation, anddifferentiation capacity of hIDPSC derived from four batches beforecryopreservation as well as migration and biodistribution in differentorgans after injection into Nude mice were studied. CELLAVITA™ (stemcells) showed that under standard culture conditions these cells atpassage 6 from four independent batches express surface markers ofmesenchymal stem cells (MSC) such as CD105, CD73, and CD13.Nevertheless, they lack the expression of CD45, CD34, CD14, CD43, and ofHLA-DR. These cells were able to undergo spontaneous and induced invitro differentiation into osteoblasts, adipocytes and chondroblasts,muscle cells, and into neurons in vitro. After transplantation intonormal mice, these cells showed significant engraftment in liver,spleen, brain and kidney, among others.

Stability Program Development

Past experience showed that both the initial cell Poll (primary cells)and its final blend (after P5 expansion and mixing of all transfers) arestable when cryopreserved at −192° C.

Example 10. Huntington's Disease Animal Model Experiments HuntingtonDisease (HD)—as a Model of Neurodegeneration.

Huntington's disease (HD) is an inherited disease of the brain thatdamages certain brain cells. The disease damages some of the nerve cellsin the brain, causing deterioration and gradual loss of function ofthese areas of the brain. This can affect movement, cognition(perception, awareness, thinking, judgment) and behavior. There aretypical involuntary movements called chorea, manifested by muscle,spontaneous and transient contractions. This symptom is present in over90% of patients with this disease. Over time, the patient's voluntarymovements become slower and they showed severe difficulties inequilibrium. Often the difficulty in words articulating (dysarthria) andin food swallowing (dysphagia) is noted. The patient may also presentmuscle rigidity, dementia and psychiatric disorders such as depressionand delusions.

HD and Neuronal Cell Loss.

HD is characterized by a progressive loss of medium spiny neurons,predominantly the GABAergic neurons, in the basal ganglia. Moreover, HDis associated with severe striatal D1 and D2 receptor loss and taking inconsideration that recently it was reported that disregulation ofdopamine receptor D2 as a sensitive measure for Huntington diseasepathology in model mice (Crook et al., 2012; Chen et al., 2013). HDbecomes most prominent in the neostriatum, commonly referred to as thestriatum, which also includes the caudate nucleus and putamen. Striatalatrophy in 95% of HD brains with a mean volumetric decrease of 58% wasrevealed during postmortem analysis (Lange et al., 1976; Vonsattel andDiFiglia, 1998). A volumetric loss of up to 29% in the cerebral cortex,28% in the thalamus, and 29-34% in the telencephalic white matter in wasalso observed in HD patients (De la Monte et al., 1988). Additionally,in HD patients a total brain volume was be reduced by 19% when comparedto healthy control brains (Halliday et al., 1998).

Immune System and HD.

Today, consistent evidences exist about a key role of neuroinflammationin the development of several neurodegenerative diseases. Thecontribution of inflammation to neurodegeneration in HD is stronglysuggested. Thus, an activation of the immune system in HD was clearlyproven by the elevated expression of cytokines such as IL-6 in mousemodels and in symptomatic as well as presymptomatic patients. Activationof CNS innate immune cells in HD occurs through microglia andastrocytes, which are directly, implicated in the pathogenesis ofseveral neurodegenerative diseases.

HD and Nerve Growth Factors.

Several studies demonstrate that wild-type htt protein increasesbrain-derived neurotrophic factor (BDNF) expression in CNS cells,whereas the mutated htt protein leads to down-regulation ofbrain-derived neurotrophic factor (BDNF), resulting in insufficientneurotrophic support and neuronal cell death (Zuccato et al., 2001).

Use of Cellavita hIDPSCs on Preclinical Model

Different, chemical models (quinolinic acid, QA; 3-nitropropionic acid,3-NP) and genetic models (R6/2-J2; N171-82Q, R6/2) of HD were used inprevious publications. We used in our non-limiting example a classicalHD-like symptoms induction model by systemic administration of 3-NP. Theprimary goals of preclinical safety evaluation are: 1) to identify aninitial safe dose and subsequent dose escalation schemes in humans; 2)to identify potential target organs for toxicity and for the study ofwhether such toxicity is reversible; 3) to identify safety parametersfor clinical monitoring; 4) to identify IDPSC in rat's brain.

The HD in our study was induced with 3-NP, which is an irreversibleinhibitor of succinate dehydrogenase that inhibits both the Krebs cycleand Complex II and systemic administration of 3-NP to both rats andprimates can produce selective striatal lesions that are a consequenceof secondary excitotoxic mechanisms [95-96]. These lesions accuratelyreplicate a number of motor and neuropathological symptoms observed inHD patients. Systemic administration of 3-NP results in differentialsparing of striatal NADPH-diaphorase and large cholinergic neurons witha significant loss of striatal GABAergic neurons activity of theelectron transport chain.

We used in our preclinical study three-month-old Wistar rat males withstarting bodyweight of between 300 g and 350 g. HD was induced withdaily intraperitoneal injection of 20 mg/kg of 3-NP (Sigma-Aldrich) for4 days. The human IDPSC were isolated according to the protocol alreadyestablished for Kerkis and colleagues (2006). The cells were expanded topassage 4. The cells were immunopositive for MSCs markers such as CD105,CD90, and CD73; pericyte markers such as CD146; and neural crest stemcells marker such as CD271. The cells were negative for CD45 (bloodcells marker) and HLA II (major histocompatibility complex: humanleukocyte antigen class II molecules). All procedures were developed inthe presence and under supervision of veterinarian specialized in neuralsystem diseases.

A. Short-Term Action of hIDPSC in an Experimental Rat Model Induced with3-NP of HD.

In order to observe the track and biodistribution of IDPSC in thestriatum and in other brain compartments they were previously stainedwith Vybrant (green-dye Invitrogen, Carlsbad, Calif., USA; V12883).After 24 hours of induction of HD with 3-NP acid, a total of 1×106 IDPSCwere transplanted intravenously (caudal vein), and after 4 days (pilotstudy) or after 35 days (Group I study), the animals were euthanized.The brain were collected for histological and immunohistochemicalanalysis (FIGS. 15 and 16).

To evaluate the process of neurodegeneration induced by 3-NP and theeffect of IDPSC transplantation on this process in experimental groupsthe global biomarkers in FIG. 17 were used.

Results: Pilot Study

FIG. 18 demonstrates hIDPSC engraftment throughout the striatum andcortex parenchymal tissue. Tissues were evaluated byimmunohistochemistry using the specific anti-human cells nuclei antibody(brown) and the anti-hIDPSC antibody (green). hIDPSC was co-localizedwith CD73 (red), a marker for human MSC producing as a result yellowcolor. (2) effect on neurogenesis induction marked by striatal GABAergicneurons that were immunostained in brown, as well as (3) DA neuronsburst shown by high magnification showed expression of receptor D2(brown) in neurons of striatum, while (4) Collagen 1 demonstrates inbrown the area which was lesioned by 3-NP-a mimicking of HD-likestriatum lesion.

After the induction of HD with 3-NP acid, the mice showed similarfunctional and anatomical characteristics with human's symptoms of HD:

1. most of the animals had lesions in the striatum.2. all animals, which received 3-NP showed a reduction in body weight,were lethargic and demonstrated depressive symptoms 4 days after HDinduction.3. four days after transplantation of IDPSC there was no significantdifference in weight between the animals treated with IDPSC and controlgroup (not treated)4. both groups showed lethargic and depressive behavior.5. four days after IDPSCs transplantation, they were distributedthroughout of subcortical part of the forebrain-striatum (FIG. 19).

At that moment hIDPSC showed double positive immunostaining foranti-IDPSC antibody CD73 and CD105 demonstrating that 4 days aftertransplantation most of the cells were still undifferentiated. hIDPSCwere mainly localized in the parenchyma of the striatum and close tocapillaries (FIG. 20).

Thus IDPSC transplanted via IV in HD rats induced by 3-NP were able tocross BBB and to migrate into lesioned area. These cells demonstratedsignificant engraft in parenchyma and around capillaries. Four daysafter transplantation, the cells are still undifferentiated; however afew human cells that present neuron-like morphology were also observed.

Results: Group I Study

The aim of the study was to identify the IDPSC in rat's brain 30 daysafter IV injection. Thirty days after IDPSC injection they were observedin cortex and mainly in striatum close to capillaries, typicallocalization of brain pericytes (FIG. 21). Additional serial cutobtained from rat's brain demonstrates neuron like morphology of IDPSClocalized in parenchyma (FIG. 22). Unexpectedly the IDPSC were found inSubventricular zone (SVZ), which is considered stem cell niche ofneurons in adult brain (FIG. 23). Other surprising unexpected resultthat was obtained is a robust production of DARPP32 positive neurons inrats, which received hIDPSC transplantation. In contrast this was notobserved in control groups (FIG. 24). It is important to note thatDopamine- and cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP-32), wasidentified initially as a major target for dopamine and protein kinase A(PKA) in striatum. The regulation of the state of DARPP-32phosphorylation provides a mechanism for integrating informationarriving at dopaminoceptive neurons, in multiple brain regions, via avariety of neurotransmitters, neuromodulators, neuropeptides, andsteroid hormones (Svenningsson et al., 2004). HD is associated withsevere striatal D1 and D2 receptor loss and taking in consideration thatrecently it was reported that dysregulation of dopamine receptor D2 as asensitive measure for Huntington disease pathology in model mice (Crooket al., 2012; Chen et al., 2013), therefore we used this marker toevaluate possible effect of IDPSC in 3-NP induced rats. Surprisingly, weobserved significant difference in receptor D2 expression in rats, whichreceived IDPSC in comparison with untreated groups, a few of expressionof receptor D2 cells can be observed in the striatum of control animals.Therefore we suggested three score system for this protein expression(FIG. 25), which can be quantified also.

B. Longer Term Action of hIDPSC in an Experimental Rat Model Inducedwith 3-NP of HD.

We performed two new experiments (Group II and III) that followed nextexperimental design (FIG. 26) and aimed at several IDPSC transplantationand elevated cell number. Clinical markers observed included weight lossand extent of motor deterioration. The extent of motor deteriorationcould be determined by detecting dystonia, lethargy, hind limb weakness,ventral and lateral recumbancy, or upregulation of indh (i.e.,upregulation of motor performance deficits) in HD. FIG. 27 present anexample scoring system for evaluating motor deterioration. Clinicalevaluation of all studied animals after induction of HD is presented inTable 9. FIGS. 28-31 shows the weight chances of animals in the pilotstudy, Group II study, and Group III study. In the longer term studies,animals treated with IDPSCs had higher body weight than untreatedanimals.

TABLE 9 Summary clinical evaluation of all four experiments after theinduction of HD using 3-NP. Number Number of of hIDPSC Behavioralchanges Groups Animals transplants after 3NP induction Survival Pilot 251 IV Body weight loss; lethargy Normal life span I 20 1 IV Body weightloss; lethargy Normal life span II 20 — — 16 deaths IIa 20 1 IV Bodyweight loss; lethargy 2 deaths III 20 2 IV Body weight loss; lethargy; 8deaths gait abnormalities; deficits on rotarod; hind limb stiffness; andventral recumbency with hind limb extended (15 days)

Example 11. 3-Nitropropionic Acid (3-NP) Rat Model of Huntington DiseaseEthical Issue

All studies were approved by the ethics committee of the Nuclear andEnergy Research Institute (Instituto de Pesquisas Energéticas eNucleares—IPEN), University of São Paulo, São Paulo, Brasil. Protocolsconcerning the maintenance, care, and handling of experimental animalsare in accordance with all Brazilian current legislation and withinternationally recognized norms and protocols. All staff working withexperimental animals were fully accredited as a staffresearcher/technician and were properly trained in the use of animalsfor experimental scientific purposes in accordance with currentBrazilian regulations

Main Goal

The research group tested the neuroprotective and/or neural tissueremodeling effects of hIDPSC in a 3-NP chemical model of Huntington'sdisease.

Animal Model

Systemic administration of the mitochondrial toxin 3-nitropropionic acid(3-NP) serves as a chemical model of Huntington's disease in rodents andnon-human primates and has been used to test potential drug therapies.3-NP is an irreversible mitochondrial succinate dehydrogenase (SDH)inhibitor that causes cell death mainly in the striatum and also inGABAergic medium spiny projection neurons and spiny interneurons.Because of its ability to cross the blood-brain barrier, 3-NP can beadministered systemically, causing selective neurodegeneration of thestriatum or the entire corpus striatum. Depending on the drug regimen,3-NP administration can simulate different stages of Huntington'sdisease. Intraperitoneal injections of two 3-NP doses lead tohyperkinetic symptoms in mice in the early stages of disease, whereasfour or more doses result in hypoactivity in the late stages of disease(Beal et al., 1993; Brouillet et al., 1995; Yang et al., 2008; Borloganet al., 1997).

It should be noted that the 3-NP-treated animals (chemical model) has animportant limitation if compared to transgenics. In 3-NP model, thestriatum lesion can regenerate spontaneously, after 10-12 days becauseof the presence of normal intrinsic neuronal precursors and an absenceof genetic background which provides constant neurodegeneration.Therefore, difference in motor and functional improvements betweenexperimental and control groups can be observed before spontaneousneuroregeneration.

Brief Protocol of hIDPSC Transplantation

Lewis rats (n=124) weighing 350-450 g were injected 20 mg/kg 3-NPintraperitoneally (IP) once daily for four days. The animals were keptunder a light/dark cycle for 12 h and given free access to food andwater. Rats were injected IP with 3-NP to induce brain injuries. Next,they were anesthetized and injected into the caudal vein with either oneor three doses of 1×10⁶ each in 250 μl of saline solution or 1×10⁷ in300 μl of saline solution hIDPSCs per animal, which corresponds to0.35×10⁶ and to 3.5×10⁶ per kg, respectively. Multiple doses wereadministered 30 days apart (FIG. 32).

Each treatment group was paired with a control group that receivedsaline solution only (‘untreated’). Thus, animals were grouped into fivegroups as shown in Table 10.

TABLE 10 Groups and number of the animals used in the present study.Animals Total composed Groups Treatment number Deaths this study 1 (n =40) Treated = 1 × 10⁶ hIDPSCs in a single 19 2 17 administration (n =19) Untreated = saline solution (n = 20) 21 0 20 2 (n = 40) Treated = 1× 10⁶ hIDPSCs in three 19 5 14 administrations (n = 19) Untreated =saline solution (n = 21) 21 9 12 3 (n = 21) Treated = 1 × 10⁷ hIDPSCs ina single 10 0 10 administration (n = 10) Untreated = saline solution (n= 11) 11 0 11 4 (n = 23) Treated = 1 × 10⁷ hIDPSCs in three 14 5 9administrations (n = 14) Untreated = saline solution (n = 9) 9 3 6 5 (n= 10) Control = no administration of 3-NP, 10 0 10 saline solution, orhIDPSCs (n = 10)

Functional Analysis Semi-Quantitative Neurological Scale

Ambulatory abilities were assessed twice a week by one blinded observerfor each experimental group using the quantitative neurological scaleadapted from Ludolph et al., (1991). This scale measures the ambulatorybehavior (scored 0-4) of rats on a flat wooden surface as follows: 0:normal behavior; 1: general slowness; 2: incoordination and gaitabnormalities; 3: upper limb paralysis or impairment, inability to move;and 4: inability to leave the lying position.

At baseline, all rats (30) in both groups exhibited normal behavior withno marked gait abnormality before treatment with 3NP, thus receiving ascore 0. At the end 3NP administration (4 days) end of the of 3NPinduction, a total of the 76 rats presented general slowness (score 1);2 rats presented difficult to move to move (score 2); 20 rats exhibitedincapacity to move resulting from forelimb and hindlimbs impairment(score 3); 24 rats presented recumbence and consequently death (score4). After 24 hours HIDPSC transplantation, the rats treated with3NP+hIDPSC (both doses) performed better compared to rats treated with3NP. However, 5-days after hIDPSC transplantation the rats exhibitedbetter improvement after HDPSC transplantation. Total of 27 ratspresented normal score (score 0). Furthermore 20 rats presented score 1,3 score 2 and 2 score 3 and no rats presented score 4 after HIDPSCtransplantation (Table 12). While control group (3NP+saline solution) 38rats presented score 1, 1 score 2 and 5 score 3 and 1 rat presentedscore 4 (Table 11).

TABLE 11 Neurological rating scale scores after 5 days end 3NP treatment(4 days). Scores are for rats in the control group (3NP + salinesolution). Group Score 0 Score 1 Score 2 Score 3 Score 4 GI 0 16 0 0 0GII 0 9 0 3 0 GIII 0 10 0 1 0 GIV 0 3 1 1 1 TOTAL 4 38 1 5 1

TABLE 12 Neurological rating scale scores after 5 days end 3NP treatment(4 days). Scores are for rats in the treatment group (3NP + hIDPSC).Group Score 0 Score 1 Score 2 Score 3 Score 4 GI 8 11 0 0 0 GII 10 3 0 10 GIII 7 3 0 0 0 GIV 2 3 3 1 0 TOTAL 27 20 3 2 0

Table 13 depicts neurological score of control group (3NP+salinesolution) and hIDPSC group (3NP+hIDPSC transplant) after 3NP treatment(4 days of administration), 1 day and 5 days after 3NP induction andafter HIDPSC transplantation. Normal behavior with no gait abnormalities(score 0); general slowness (score 1); incoordination and gaitalterations (score 2); inability to move either the hind limbs orforelimbs (score 3); and inability to leave the lying position. Thislast group eventually died (score 4). Group 1=Treated=1×10⁶ hIDPSCs in asingle administration; Group 2=Treated=1×10⁶ hIDPSCs in threeadministrations; Group 3=Treated=1×10⁷ hIDPSCs in a singleadministration Group 4=Treated=1×10⁷ hIDPSCs in three administrations.

TABLE 13 Neurological scors of various groups of rats. neuro- neuro-neuro- logical logial dose and logical score score HIDPSC and score AF 1AF 5 Animal Treatment frequency AF 3NP DAY DAYS GROUP I  1 3NP + SAL GI1 1 1  2 3NP + SAL GI 1 1 1  3 3NP + SAL GI 1 1 1  4 3NP + SAL GI 1 1 1 5 3NP + SAL GI 1 1 1  6 3NP + HIDPSC GI 1 1 1  7 3NP + HIDPSC GI 1 1 1 8 3NP + HIDPSC GI 1 1 1  9 3NP + HIDPSC GI 1 1 1 10 3NP + HIDPSC GI 1 11 11 3NP + SAL GI 1 1 1 12 3NP + SAL GI 1 1 1 13 3NP + SAL GI 1 1 1 143NP + SAL GI 1 1 1 15 3NP + SAL GI 1 1 1 16 3NP + HIDPSC GI 1 1 1 173NP + HIDPSC GI 1 1 1 18 3NP + HIDPSC GI 1 1 1 19 3NP + HIDPSC GI 1 1 120 3NP + HIDPSC GI 1 1 1 64 3NP + SAL GI 1 1 1 65 3NP + SAL GI 1 1 1 663NP + SAL GI 1 1 1 67 3NP + SAL GI 3 3 1 68 3NP + HIDPSC GI 1 0 0 693NP + HIDPSC GI 1 0 0 70 3NP + HIDPSC GI 1 0 0 71 3NP + SAL GI 1 1 1 723NP + SAL GI 1 1 1 73 3NP + SAL GI 1 1 1 74 3NP + SAL GI 1 1 1 75 3NP +SAL GI 1 1 1 76 3NP + HIDPSC GI 1 1 1 77 3NP + HIDPSC GI 1 0 0 78 3NP +HIDPSC GI 4 4 death 79 3NP + HIDPSC GI 1 0 0 80 3NP + HIDPSC GI 1 0 0 813NP + HIDPSC GI 1 0 0 82 3NP + HIDPSC GI 1 0 0 83 3NP + HIDPSC GI 4death GROUP II 21 3NP + SAL GII 4 4 death 22 3NP + SAL GII 3 3 3 233NP + SAL GII 3 death 24 3NP + SAL GII 3 4 death 25 3NP + SAL GII 4 4death 26 3NP + HIDPSC GII 3 3 3 27 3NP + HIDPSC GII 4 death 28 3NP +HIDPSC GII 4 4 death 29 3NP + HIDPSC GII 3 3 1 30 3NP + HIDPSC GII 3 3 131 3NP + SAL GII 4 4 3 32 3NP + SAL GII 4 4 death 33 3NP + SAL GII 4 4death 34 3NP + SAL GII 4 4 death 35 3NP + SAL GII 3 3 death 36 3NP + SALGII 3 3 3 37 3NP + HIDPSC GII 3 death 38 3NP + HIDPSC GII 4 4 death 393NP + HIDPSC GII 3 3 1 40 3NP + HIDPSC GII 4 4 death  21A 3NP + SAL GII4 4 death  22A 3NP + SAL GII 1 1 1  23A 3NP + SAL GII 1 1 1  24A 3NP +SAL GII 1 1 1  25A 3NP + SAL GII 1 1 1  26A 3NP + HIDPSC GII 1 0 0  27A3NP + HIDPSC GII 1 0 0  28A 3NP + HIDPSC GII 1 0 0  29A 3NP + HIDPSC GII1 0 0  30A 3NP + HIDPSC GII 1 0 0  31A 3NP + SAL GII 1 1 1  32A 3NP +SAL GII 1 1 1  33A 3NP + SAL GII 1 1 1  34A 3NP + SAL GII 1 1 1  35A3NP + SAL GII 1 1 1  36A 3NP + HIDPSC GII 1 0 0  37A 3NP + HIDPSC GII 10 0  38A 3NP + HIDPSC GII 1 0 0  39A 3NP + HIDPSC GII 1 0 0  40A 3NP +HIDPSC GII 1 0 0 GROUP IV 84 3NP + SAL GIII 1 1 1 85 3NP + SAL GIII 1 11 86 3NP + SAL GIII 1 1 1 87 3NP + SAL GIII 1 1 1 88 3NP + SAL GIII 1 11 89 3NP + HIDPSC GIII 1 0 0 90 3NP + HIDPSC GIIl 1 0 0 91 3NP + HIDPSCGIII 1 0 0 92 3NP + SAL GIII 1 1 1 93 3NP + SAL GIII 1 1 1 94 3NP + SALGIII 1 1 1 95 3NP + SAL GIII 1 1 1 104  3NP + SAL GIII 3 3 3 96 3NP +SAL GIII 1 0 1 97 3NP + HIDPSC GIII 1 0 1 98 3NP + HIDPSC GIII 1 0 1 993NP + HIDPSC GIII 2 2 1 100  3NP + HIDPSC GIII 1 0 0 101  3NP + HIDPSCGIII 1 0 0 102  3NP + HIDPSC GIII 1 0 0 103  3NP + HIDPSC GIII 1 0 0GROUP III 41 3NP + HIDPSC GIV 4 4 death 42 3NP + HIDPSC GIV 3 3 1 433NP + SAL GIV 3 3 death 44 3NP + HIDPSC GIV 3 3 0 45 3NP + SAL GIV 4 4death 46 3NP + HIDPSC GIV 4 4 2 47 3NP + HIDPSC GIV 3 3 1 48 3NP +HIDPSC GIV 4 4 3 49 3NP + HIDPSC GIV 4 4 death 50 3NP + SAL GIV 4 4death 51 3NP + HIDPSC GIV 4 4 2 52 3NP + SAL GIV 4 4 4 53 3NP + SAL GIV3 3 3 54 3NP + HIDPSC GIV 4 4 death 55 3NP + HIDPSC GIV 4 4 death 563NP + HIDPSC GIV 3 3 1 57 3NP + SAL GIV 3 3 2 58 3NP + HIDPSC GIV 4 4 259 3NP + HIDPSC GIV 3 3 death 60 3NP + SAL GIV 1 1 1 61 3NP + SAL GIV 11 1 62 3NP + HIDPSC GIV 1 0 0 63 3NP + SAL GIV 1 1 1

Histopathological and Immunohistological Analysis

Histopathological and immunohistological analyses were conducted 7, 30,and 90 days after hIDPSC injection; animals were perfused with 4%paraformaldehyde (prepared in PBS, 0.1 mol/L). Tissue fragments weredehydrated in a decreasing ethanol series (75, 95, and 100%) and stainedusing Nissl staining with 0.1% cresyl violet. Two antibodies, such as,anti-human nuclei and anti-hIDPSC (1:1000, Abcam Plc) were used todetermine the presence of hIDPSC in rat brain. To evaluate theneuroprotective and neuroreparative effects of hIDPSC, anti-GABAergicmedium spiny neurons DARPP32 (1:1000, Abcam Plc), dopamine D2 (1:800),and BDNF (1:500) antibodies were used.

hIPDSC Engraftment in Rat Brain

One of the most relevant findings of the study was that hIDPSCs weredetected in the cortex and corpus striatum, indicating that they wereable to cross the blood-brain barrier and migrate to the site of injury(FIG. 33). In FIG. 33, optical cuts demonstrate at different depth offocus (A1-A4) the presence of IDPSC stained with Vybrant (green), andnuclei are stained with PI (red). The cells demonstrate capillarypredominant association and different morphological types: neuron-likecells and pericytes. On A2, A3, and A4 two pericytes at differentlocations along capillary can be observed, and both present similarmorphology. On A4 embranchment of axons is shown. Neuron nuclei arelight with nucleolus, and the difference with perycite nuclei, which arestrongly stained, can be observed. Blue is the artificial color ofconfocal microscope. Microscopy was with epifluorescence+DigitalInterference Contrast (DIC), and the scale bar=10 μm.

In addition, four days after hIDPSC administration, a few cells werepositive for specific MSC antibodies (anti-CD73 and anti-CD105),indicating that some cells were still undifferentiated at that time(FIG. 34). Nevertheless, hIDPSC-derived neuron-like cells and pericytes(perivascular cells from microvessels) were also observed in the sameperiod (FIG. 33).

In FIG. 34 the optical cut demonstrates IDPSC stained with Vybrant(green) and positively reacted with anti-IDPSC antibody (red).Superposition of both produce yellow color. The cell demonstrate nearcapillary localization. Two markers for MSC were used: CD73 and CD105demonstrating positive reaction with IDPSC. A confocal microscope withepifluorescence+Digital Interference contrast (DIC) was used. Scalebar=A=5 μm; B=10 μm; C=20 μm; D=5 μm

Thirty days after hIDPSC transplantation, a few hIDPSCs were observed inthe cortex and a large number of cells were observed in the corpusstriatum, along the capillaries (FIG. 35). Serial cuts obtained fromrat's brain demonstrates neuron like morphology of IDPSC localized inparenchyma (FIG. 35). Additionally, neuron-like and fibroblast-likecells were also observed, confirming that hIDPSCs undergodifferentiation (FIG. 36). Unexpectedly the IDPSC were found also inSubventricular zone (SVZ), which is considered a stem cell niche ofneurons in the adult brain (FIG. 35).

Neuroprotective and Neuroreparative Effects

3-NP-induced striatal lesions were determined by neuron loss using Nisslstaining and DARPP32 expression (FIG. 37 and FIG. 38, respectively).Nissl stains are used to identify neuron structures in the brain andspinal cord (FIG. 37), whereas DARPP32 is a cytoskeleton markerexpressed in GABAergic neurons and prevalent in the striatum of healthymammals (FIG. 38). Using these two markers, neuron loss in the corpusstriatum was scored as follows:

Score 1 (severe): severe neuron loss, with areas of degradation, loss ofDARPP32 immunostaining in the lateral striatum with little or no cellsin the central striatum;

Score 2 (moderate): moderate neuron loss with “dark neurons” (dead orapoptotic neurons) and few DARPP32+ cells; and

Score 3 (mild): no neuron loss and intense DARPP32 immunostaining (Viset al., 2001).

3-NP-treated animals showed complete or partial neuron loss in thestriatum compared to controls (no 3-NP or hIDPSC). The two experimentalgroups (treated and untreated) presented different scores for neuronalloss in the striatum relative to controls. However, morphometrichistological analysis revealed that most hIDPSC-treated animals hadscores 3 and 2, whereas most untreated animals (3-NP+saline solution)had neuron loss scores of 2 and 1 (FIG. 38). No animal had visibleatrophy (FIG. 37 and FIG. 38).

FIG. 39 depicts neuronal growth in the striatum of rats after hIDPSC.Administration of hIDPSC resulted in a neuroreparative effect inhIDPSC-treated animals by (A) Nissl staining and (B) DARPP32 expression.(C) Number of animals showing neuron recovery after hIDPSCadministration compared to Controls. Most hIDPSC-treated animals(3-NP+hIDPSC) had scores 3 and 2 (moderate and mild) whereas mostuntreated animals (3 NP+saline) had scores 2 and 1 (severe andmoderate).

We also observed that DARPP32 expression was higher in hIDPSC-treatedanimals than in untreated animals (FIG. 40) indicating neuronregeneration. Optical cuts in FIG. 40 demonstrate that neuron positivelyreacted with DARPP32.

It is reported that dysregulation of dopamine receptor D2 is a sensitivemeasurement for HD pathology in model mice (Crook et al., 2012). Asurprising, unexpected result was obtained in respect to a robustproduction of DARPP32 positive neurons in rats, which received hIDPSCtransplantation. In contrast this was not observed in control groups(FIG. 38). It is important to note that dopamine- and cAMP-regulatedneuronal phosphoprotein (DARPP-32), was identified initially as a majortarget for dopamine and protein kinase A (PKA) in striatum. Theregulation of the state of DARPP-32 phosphorylation provides a mechanismfor integrating information arriving at dopaminoceptive neurons, inmultiple brain regions, via a variety of neurotransmitters,neuromodulators, neuropeptides, and steroid hormones (Svenningsson etal., 2004). HD is associated with severe striatal D1 and D2 receptorloss and taking in consideration that recently it was reported thatdysregulation of dopamine receptor D2 as a sensitive measure forHuntington disease pathology in model mice (Crook et al., 2012; Chen etal., 2013), therefore we used this marker to evaluate possible effect ofIDPSC in 3-NP induced rats.

Surprisingly, we observed significant differences in receptor D2expression in rats, which received IDPSC in comparison with untreatedgroups, a few of expression of receptor D2 cells can be observed in thestriatum of control animals (FIG. 41).

Reduced BDNF's mRNA and protein levels have been observed in thecerebellum, caudate putamen, striatum, and cerebral cortex of HDpatients (Adachi et al., 2014). In the current study, BDNF expressionwas observed in the striatum, caudate, putamen, and subventricular zoneof hIDPSC-treated animals 7 and 30 days after hIDPSC administration(FIG. 40). BDNF expression in the subventricular zone indicates thathIDPSC promoted neurogenesis. No BDNF expression was observed inuntreated animals (3-NP+saline).

Co-localization of hIDPSC was observed with the motor neuron markerDARRP32, suggesting that hIDPSCs differentiate into mature neurons.DARPP32 expression was detected in the striatum of hIDPSC-treatedanimals 30 days after hIDPSC administration in this 3-NP model of HD(FIG. 41). These data indicate that hIDPSCs differentiate into GABAergicspiny neurons in vivo. It should be noted that integration ofneurotransmitter and neuromodulator signals in the striatum plays acentral role in basal ganglia functions. Moreover, DARPP32 is a keyplayer in the integration of GABAergic medium spiny neurons in responseto dopamine and glutamate (Fernandez et al., 2006).

Histological and immunohistochemical analyses revealed that hIDPSCs wereable to cross the blood-brain barrier and reach different areas affectedby HD, including the striatum and cortex. Morphometric histologicalanalysis revealed that most hIDPSC-treated animals showed mild neuronloss in the striatum compared to untreated animals (3-NP+saline).Moreover, hIDPSCs showed neuroprotective and neuroreparative effects, asrevealed by the upregulation of BDNF, DARPP32, and D2 receptorexpression, which are downregulated in Huntington's disease (Van Dellenet al., 2000; Crook and Housman, 2012).

TABLE 14 NUMBER OF NUMBER OF NUMBER OF NUMBER OF ANIMALS PER DEATHS PERANIMALS PER DEATHS PER GROUP GROUP GROUP GROUP ANIMALS 3NP + 3NP + 3NP +3NP + HIDPSC 3NP + HIDPSC COMPOSED GROUP SAL GROUP SAL GROUP GROUP GROUPTHIS STUDY GI (n = 40) 19 0 21 2 38 GII (n = 40) 21 9 19 5 26 GIII (n =21) 11 0 10 0 21 GIV (n = 23) 9 3 14 5 15 Control Group 10 10 GV (n =10) TOTAL 60 12 64 12 110

Safety

The following physiological parameters were recorded during theexperimental period for treated and untreated animals: body weight andfeed and water intake. Fewer deaths were observed among hIDPSC-treatedanimals than 3-NP-injected rats, indicating that hIDPSC administrationis safe. In addition, the results suggest that hIDPSC administrationimproved overall survival by protecting animals from the neurotoxiceffects of 3-NP (Table 14). Table 14. The number of survived versus deadanimals.

The primary study assessing safety of hIDPSC was the 3-nitropropionicacid (3-NP) rat model of HD study. In this study, two different celldoses were injected: 1×10⁶ and 1×10⁷ cell/transplant or 3×106 cell/kgand 3×107 cell/kg, respectively. 3-NP-treated rats received a single IVinjection or a total of three IV injections at one month intervals ofthe cells.

Seven deaths occurred in 3-NP induced animals which received 3×106cell/kg, and 5 deaths occurred in animals receiving 3×107 cell/kg. Inplacebo groups (3-NP induced without the cell transplantation) samenumber (12) of animals died. All rats that died presented with extremelysevere disease manifestation; the deaths occurred within 5 days of 3-NPadministration. No additional deaths occurred with repeated hIDPSCdoses. Based on these data, probable cause of all early deaths was 3-NPtoxicity. Because no deaths occurred after repetitive hIDPSCtransplantation, this supports the safety of hIDPSC transplantation(Table 14).

Patients with Huntington's disease often exhibit progressive weight lossdespite adequate or high-energy intake. Weight loss may be an indicatorof 3-NP neurotoxicity caused by decreased energy metabolism (Saydoff etal., 2003; Colle et al., 2013). No significant weight loss was observedin 3-NP-treated animals four days after 3-NP administration. However 30days after hDPSC transplant, the hDPSC group (1×10⁶ cells dose)exhibited significantly weight gain when compared with untreated group(3NP). Thus, hIDPSC attenuated weight loss (p=0.01) (FIG. 42).

HD is a clinically debilitating disease for which there is no availabletherapy to stop or reverse disease progression. One major obstacleencountered by many therapeutics to treat HD, is that it is aneurodegenerative disorder and some targeted systemically delivereddrugs would be unable to reach their target; passage of drugs to thebrain is regulated by the blood-brain barrier (BBB). The BBB is a highlyselective permeability barrier that separates the circulating blood fromthe extracellular fluid surrounding the nervous system. Treatment withcell-based therapeutics, therefore, would seem to require localizeddelivery bypassing the BBB (i.e. injection through the selectivepermeability barrier) since cells do not generally cross the BBB.

Extensive studies show that hIDPSCs have mesenchymal stem cell (MSC)attributes, can secrete immunomodulating and neurotropic factors. Inaddition, histological and immunohistochemical analyses in validated HDrat model reveal that hIDPSCs are able to cross the BBB and reachdifferent areas affected by HD, including the striatum and cortex.Morphometric histological analysis reveals that most hIDPSC-treatedanimals show mild neuron loss in the striatum compared to untreatedanimals. Moreover, hIDPSCs show neuroprotective and neuroreparativeeffects by upregulating BDNF, DARPP32, and D2 receptor expression, whichare downregulated in Huntington's disease (Van Dellen et al., 2000;Crook and Housman, 2012).

Finally, studies evaluating the safety profile of hIDPSCs show they donot form teratomas, they do not exhibit chromosomal aberration, and theyare able to form human/mouse chimeras. Since the studies suggest hIDPSCsare safe and efficacious in the treatment of HD, we propose to usehIDPSCs to treat HD.

Example 12. Neuroprotection Effect of hIDPSC on Brain. Short andLong-Term Effect of hIDPSC on BDNF Expression in Rat HD Model (Inducedby 3-NP) after their Systemic Administration (Intravenous Route)

Introduction Neurotrophic factors, such as brain-derived neurotrophicfactor (BDNF), are essential contributors of central nervous systemneuron function. BDNF plays an important role in neuronal survival andgrowth, serves as a neurotransmitter modulator, and participates inneuronal plasticity, which is essential for learning and memory. BDNF isalso that support differentiation, maturation, and survival of neuronsin the nervous system and shows a neuroprotective effect. BDNFstimulates and controls growth of new neurons from neural stem cells(NSC). In Huntington's disease decreased levels of BDNF are associatedwith neuronal loss. Studies demonstrate their reduced availability indiseased brains, thus suggesting that they play an important role inneurological disorders and, in particular, in HD. Under non-pathologicconditions, BDNF is synthesized in the cortex, the substantia nigra parscompacta, the amygdala, and in the thalamus. All these regions supplythe striatum with BDNF. In HD, the deficit of BDNF in the striatum maybe due to reduced BDNF gene transcription in the cerebral cortex orreduced BDNF vesicle transport (or both). The decrease in BDNFexpression observed in HD impairs dopaminergic neuronal function, whichmay be associated with HD motor disturbances. As a result, many studieshave been carried out to examine whether increasing BDNF levels may helptreat HD⁽¹⁻⁷⁾.

Material and Methods

Chemical HD Model.

Lewis rats weighing 350-450 were injected 20 mg/kg 3 nitropropionic(3-NP) intraperitoneally (Sigma Aldrich) once daily for four days. Theanimals were kept under a light/dark cycle for 12 h and given freeaccess to food and water. Rats were injected with 3-NP to induce braininjuries. After 3NP administration reduction of BDNF expression occursin cortex, hippocampus and striatum.

hIDPSC Transplantation.

Animals were anesthetized and injected intravenously with one dose of1×10⁶ of hIDPSC in 200 μL of PBS (Phosphate buffered saline) into thecaudal vein. Control animal received 200 μL of PBS only following thesame route.

Immunohistochemistry

Expression of BDNF was analyzed using anti-human anti-BDNF (Santa Cruz)antibody and immunohistochemistry assay. HD animals induced with 3-NPand treated with hIDPSC or with placebo were sacrificed 4 and 30 daysafter the cells transplantation, brain were isolated and respectivebrain compartments were dissected, fixed in 4% paraformaldehyde in PBSand included in paraffin. Paraffin slides were deparaffinized using theroutine technique. Then, the slides were incubated with ammoniahydroxide (Sigma-Aldrich) for 10 min and washed four times in distilledwater for five min each. Antigen retrieval of the slides was performedusing a pH 6.0 buffer of sodium citrate (Sigma-Aldrich), in a water bathset at 95° C. for 35 min. The slides were blocked with hydrogen peroxide(Sigma-Aldrich) for 15 min and incubated overnight at 4° C. withpolyclonal anti-human BDNF Antibody (N-20) in rabbit, diluted 1:500 inBSA (Sigma-Aldrich). Then, the slides were rinsed three times with PBSfor five min each and Anti-Rabbit AP (SC-2057) diluted 1:100 in PBS(both anti-bodies from Santa Cruz Biotechnologies, Dallas, Tex., U.S.A)were added for 40 min at room temperature. Afterward, the slides werewashed three times in PBS for five min each. Finally, permanent fast redsystem (Abcam, Boston, Mass., USA) was applied to produce brownstaining. Immunostained sections were counterstained with hematoxylin(Sigma-Aldrich), to be observed under a light microscope (Axio Observer;Zeiss, Jena, Germany).

Results

Short Term Effect of hIDPSC Transplantation: Expression of BDNF Justafter HD Induction by 3-NP in Rats and 4 Days after hIDPSCTransplantation.

FIG. 43 demonstrates innumerous BDNF positive cells (here and furtherbrown color) in rat cortex (FIG. 43 1a and 1b) and in striatum (FIG. 431e and 1f), known as a NSC niche. A few of these cells is observed inhippocampus (FIG. 43 1c and 1d). However, these cells showed morphologysimilar with neuronal progenitor and not mature neurons. 3-NP treatedanimals which received saline solution (PBS) did not show any BDNFsecreting cells (FIG. 43 2a to 2f).

Long Term Effect of hIDPSC Transplantation: Expression of BDNF Justafter HD Induction by 3-NP in Rats and 30 Days after hIDPSCTransplantation.

FIG. 44 demonstrates innumerous morphologically mature neurons in thecortex that secret BDNF (FIG. 44 1a and 1b). In hippocampus BDNFsecreting cells are also present (FIG. 44 1c and 1d) and many of BDNFexpressing cells were observed in striatum (FIG. 44 1e and 1f). Incontrol group BDNF secreting was not still observed (FIG. 44 2a to 2f).

CONCLUSION

In present study, the expression of BDNF by a number of cells wasdetected in the cortex and striatum, but in only a few cells in thehippocampus in four groups each composed by at least 10 animals. Twogroups were composed by 3-NP animals and BDNF expression was analyzed 4days (FIG. 43) and 30 days (FIG. 44) after hIDPSC transplantation. Twocontrol groups were composed by 3-NP animals which received PBS only andwere analyzed after 4 (FIG. 43) and 30 days (FIG. 44), respectively.These data suggest neuroprotective effect of hIDPSC which act throughBDNF expression induction by intrinsic rat stem cells in the brain of3-NP treated rats soon after transplantation and this effect influencedsurvival and differentiation intrinsic rat NSC into mature neurons.Additionally, transplantation of hIDPSC provide neuronal regeneration 30days after transplantation (FIG. 44)

Previous studies tightly link BDNF lack in the striatum to HDpathogenesis. At present, drugs developed to treat HD able to amelioratesymptoms and do not delay the disease progression. Thus, restoring ofstriatal BDNF levels in the striatum may have therapeutic potential onHD. Examples 10 and 11 demonstrate also improved behavioral phenotypesin hIDPSC treated HD animals. This result support indication that BDNFexpression may overcome functional deficits observed in HDpatients^(6,7).

Example 13. Veterinary Treatment of Multiple Sclerosis-Like CanineDistemper Virus (CDV) Disease in Dogs

CDV in dogs is a well-defined virus-induced demyelination model with anetiology similar to etiology of multiple sclerosis. Functional recoveryshown in the example disclosed herein suggests that IDPSC inducegliogenesis under CDV pathophysiological conditions that is correlatedwith our previous disclosure of expression of p75 neurotrophin receptor,a marker for Schwann cells, in hIDPSCs cultured by Cellavita method;or/and induce immunoprotection mechanism to provide functional recovery.Over twenty dogs tested, see results in tables. (Similar recoveryresults are not shown here were found in a few horses that weresuccessfully treated by IDPSC from symptoms similar measles-like viraldisease).

Table 15 below briefly shows that most of patients have symptomsrecovery; only one patient had no effect at all. Most of the patientshad symptoms of recovery after second transplantation while somepatients had demonstration of trends to recovery already after firsttransplantation. Over 90% demonstrated partial recovery after 3^(rd)transplantation. About 50% demonstrated full recovery after thirdtransplantation.

TABLE 15 Neurological conditions of the 20 dogs before and after IDSPCtransplantation Basal level (before Results (after transplantation)Patient transplantation) 1st Transplantation 2nd Transplantation 3rdTransplantation 1 Inability to stand and Inability to stand andInability to stand and Inability to stand and bear weight severe bearweight light ataxia bear weight moderate bear weight moderate ataxia andparaparesis of forelimb and ataxia and paraparesis ataxia andparaparesis in both limbs. moderate ataxia of hind of limbs of limbslimb 2 Quadriplegia Inability to stand and Inability to stand and Normalmarch bear weight light ataxia bear weight light of forelimb and ataxiaand paraparesis paralysis of hind limb of limbs 3 Quadriplegia Inabilityto stand and Normal march of Normal march bear weight light forelimb andminimum ataxia and paraparesis ataxia and paraparesis of hind limb ofhind limb 4 Inability to stand and Ability to stand and Ability to standand Normal march bear weight and bear weight moderate bear weightminimal paraparesis in of hind ataxia and paraparesis ataxia andparaparesis limb of hind limb of hind limb 5 Inability to stand andInability to stand and Ability to stand and Normal march bear weightsevere bear weight moderate bear weight falta de ataxia and paraparesisand paraparesis of hind equilibrio in both limbs. limb 6 Inability tostand and Inability to stand and Inability to stand and Inability tostand and bear weight severe bear weight moderate bear weight moderatebear weight moderate ataxia and paraparesis ataxia of forelimb andataxia of and ataxia of and in both limbs severe of hind limb andparaparesis of limbs paraparesis of limbs paraparesis of limbs 7Inability to stand and Ability to stand and Ability to stand and Abilityto stand and when stands bear bear weight moderate bear weight moderatebear weight moderate weight with severe to light ataxia and to lightataxia and to light ataxia and ataxia and paraparesis paraparesis ofhind paraparesis of hind paraparesis of hind of hind limb limb limb limb8 Paraplegia of hind Ability to stand and Normal march Normal march limbbear weight and light ataxia and paraparesis of hind limb 9 Paraplegiaof hind Inability to stand and Inability to stand and Normal march limbbear weight moderate bear weight minimal ataxia and paraparesis ataxiaand paraparesis of hind limb of hind limb 10 Inability to stand andInability to stand and Inability to stand and Normal march bear weightsevere bear weight m light bear weight minimal ataxia and paresis inataxia and paraparesis ataxia and paraparesis both limbs. of limbs oflimbs 11 Paraplegia of hind Inability to stand and Inability to standand Normal march limb bear weight moderate bear weight m light ataxiaand paraparesis ataxia and paraparesis of hind limb of hind limb 12Inability to stand and Inability to stand and Inability to stand andNormal march bear weight severe bear weight moderate bear weight m lightataxia and paraparesis ataxia and paraparesis ataxia and paraparesis inboth limbs. of limbs of limbs 13 Paraplegia of hind stand and bearweight Normal march Normal march limb light ataxia and paraparesis oflimbs 14 Inability to stand and Inability to stand and Inability tostand and Inability to stand and bear weight severe bear weight moderatebear weight moderate bear weight moderate ataxia and paraparesis ataxiaand paraparesis ataxia and paraparesis ataxia and paraparesis in bothlimbs. of limbs of limbs of limbs 15 Quadriplegia Inability to stand andInability to stand and Inability to stand and bear weight severe bearweight moderate bear weight moderate ataxia and paresis in ataxia andparesis in ataxia and paresis in both limbs both limbs both limbs 16Inability to stand and Inability to stand and Ability of stand andAbility of stand and bear weight severe bear weight moderate bear weightand bear weight and ataxia and paraparesis ataxia and paresis in walkingwith circle walking with circle of limbs both limbs march march 17Inability to stand and stand and bear weight Inability to stand andInability to stand and bear weight severe moderate to light bear weightand light bear weight moderate ataxia and paraparesis ataxia andparaparesis ataxia and paraparesis ataxia and paresis in of limbs oflimbs of limbs both limbs 18 Inability to stand and Inability to standand Inability to stand and Inability to stand and bear weight severebear weight moderate bear weight moderate bear weight moderate ataxiaand paresis in ataxia and paresis in ataxia and paresis in ataxia andparesis in both limbs. both limbs both limbs both limbs 19 Inability tostand and Inability to stand and Inability to stand and Inability tostand and bear weight severe bear weight moderate bear weight moderatebear weight moderate ataxia and paresis in ataxia and paresis in ataxiaand paresis in ataxia and paresis in both limbs both limbs both limbsboth limbs 20 Inability to stand and Inability to stand and Inability tostand and Inability to stand and bear weight moderate bear weightmoderate bear weight light bear weight moderate ataxia and paresis inataxia and paresis in ataxia and paresis in ataxia and paresis in bothlimbs. both limbs both limbs both limbs

TABLE 16 Patients' description and times of administration of stem cellsand amount of the cells used for dog Age Weight Number of cells PatientBreed (months) Sex (kg) per one transplant 1 mongrel 24 M 20 4 × 10⁶ 2mongrel 8 M 7 4 × 10⁶ 3 mongrel 15 F 3 6 × 10⁶ 4 mongrel 17 F 8 4 × 10⁶5 mongrel 18 M 8 4 × 10⁶ 6 mongrel 12 M 4 4 × 10⁶ 7 poodle 24 F 8 4 ×10⁶ 8 poodle 14 M 17 4 × 10⁶ 9 mongrel 20 F 15 6 × 10⁶ 10 mongrel 21 M25 6 × 10⁶ 11 mongrel 21 F 28 4 × 10⁶ 12 mongrel 19 M 19 4 × 10⁶ 13Labrador 19 F 25 6 × 10⁶ retriever 14 poodle 24 F 6 4 × 10⁶ 15 German 22F 23 4 × 10⁶ shepherd 16 pinscher 36 M 4 4 × 10⁶ 17 mongrel 36 M 3 4 ×10⁶ 18 American 41 F 26 6 × 10⁶ pitbull 19 mongrel 30 F 27 6 × 10⁶ 20Labrador 28 F 29 4 × 10⁶ retriever

Example 14. Batch Release Process for Industrial Scale-Up ofMultiharvest Organ and Tissue Explant Culture of hIDPSC—CELLAVITA™ (StemCells) Product by Late Population Method Nomenclature

CELLAVITA™ (stem cells) is the bulk material prior to final formulation.CELLAVITA™ (stem cells) is referred to as Drug Substance (DS).CELLAVITA™ (stem cells) for IV infusion is referred to as Drug Product(DP). The Process for the CELLAVITA™ (stem cells) Substance initiates atdonor screening and testing and finishes prior to final formulation andcryopreservation of the cell stock. Preparation of the Drug Productinvolves formulation of the CELLAVITA™ (stem cells) substance withadditional excipients.

General Properties

In one embodiment, CELLAVITA™ (stem cells) are stem cells expressingneural crest/mesenchymal stem/progenitor cell markers, such as CD13,CD105 (Endoglin), CD73, CD29 (integrin b-1), CD44, and nestin (Kerkis etal., 2009; Kerkis et al., 2006) obtained using multiharvest organ andtissue explant culture.

In another embodiment, CELLAVITA™ (stem cells) are MSC-like cells, whichpossess all basic properties of these cells. The cells are defined inaccordance with minimal criteria for defining multipotent mesenchymalstromal cells established by the Mesenchymal and Tissue Stem CellCommittee of the International Society for Cellular Therapy. Thisdefinition includes being plastic-adherent when maintained in standardculture conditions, expressing CD105, CD73 and CD90, and lack expressionof CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surfacemolecules, and ability to differentiate to osteoblasts, adipocytes andchondroblasts in vitro (Dominici et al., 2006).

Manufacturing Method of Investigational Product CELLAVITA™ (Stem Cells)

Only healthy teeth of children aged 6-12 years may be used for thecultivation of Cellavita™. Children's legal guardians answer aneligibility questionnaire about the child's health and blood samples arecollected for serological testing to detect infectious diseases, asrecommended by the European Commission guidelines for donor eligibility(COMMISSION DIRECTIVE 2006/17/EC). The mandatory testing includes testsfor HIV-1 and -2 (Anti-HIV-1 and -2), HTLV-1 and -2, HBV (specificallyHBsAg, Anti-HBc), HCV (specifically anti-HCV-Ab), and Treponema pallidum(syphilis) (COMMISSION DIRECTIVE 2006/17/EC).

Only healthy teeth without dental diseases such as dental caries arecollected after natural loss or surgical extraction. To avoidunnecessary testing, only donors whose teeth have viable pulp forcultivation (a process determined in the laboratory after two weeks ofcell culture) are asked to return to the center for the donoreligibility test (blood collection).

Tooth Collection, Container, Transportation

Immediately after spontaneous exfoliation, the tooth are immersed into 3mL of sterile transporting solution composed of DMEM (Dulbecco'sModified Eagle Medium) and 500 mM Gentamycin in a 15 mL sterilecentrifuge tube. The tooth are stored at 4° C. and processed within48-72 hours.

Pulp Isolation and Washing Procedure

A freshly exfoliated deciduous tooth from a healthy subject is washedrepeatedly in sterile solution containing 50% pen/strep solution (100units/mL penicillin, 100 units/mL streptomycin) and 50% PhosphateBuffered Saline (PBS). Dental pulp is removed from the tooth with theaid of a sterile needle.

Selection of Viable Pulps as a Raw Material for hIDPSC Stem CellExpansion

Freshly obtained dental pulp (DP) is washed in a solution containing 3%Pen/strep solution (100 units/mL penicillin, 100 units/mL streptomycin).Initial plating and viability testing of the dental pulp is performed indental pulp Maintenance Medium supplemented with 15% fetal bovine serum(FBS, Hyclone), 100 units/mL penicillin, 100 units/mL streptomycin, 2 mML-glutamine, and 2 mM nonessential amino acids. This procedure usuallytakes up to one week. Once the DP is considered to be viable, it isharvested and the hIDPSC is passaged. The resulting hIDPSC iscryopreserved under GTP conditions for future clinical research

Description of the Proposed Manufacturing Process

In one aspect, the production process comprises the steps illustrated inFIG. 48 which demonstrates the initial process of CELLAVITA™ (stemcells) isolation and batch formulation. The vertical pathway shows theprocess of dental pulp mechanical transfer (harvest) of earlypopulation-hIDPSC (isolated from dental pulp before 5 harvests) and latepopulation—hIDPSC (isolated from dental pulp after 5 harvests). Thehorizontal pathway shows the traditional enzymatic method of cellcultures when cells are replaced through repetitive passages. The finalbatch product is a sum of hIDPSC obtained from dental pulp harvests andpassages (no more then 5).

In another aspect, the production process comprises the stepsillustrated in FIG. 48 and/or FIG. 49. The production process includesCELLAVITA™ (stem cells) isolation and batch formation. The verticalpathway shows the process of dental pulp (DP) mechanical transfer(harvest) for early population-hIDPSC isolated from dental pulp before 5harvests and late population—hIDPSC isolated from DP after 5 DPharvests; the horizontal pathway shows traditional enzymatic method ofcells culturing, when cells are replaced through repetitive passages.Final batch—product is a sum of hIDPSC obtained from DP harvest andpassages (no more then 5).

The production of CELLAVITA™ (stem cells) is performed in a state of theart clean room facility according to GMP regulations. In one embodiment,this production process follows the steps outlined in FIG. 50.

hIDPSC Harvesting

When the semi-confluent colony formation of hIDPSC is detected aroundthe dental pulp explant, DP is transferred into a new cell culturevessel for continued growth in DP Maintenance Medium.

hIDPSC Passaging hIDPSC is washed with sterile PBS, removed with TrypLEsolution and centrifuged.

The pellet is resuspended in DP Maintenance Medium and thereafter isseeded in the tissue culture flask (Passage 1-P1). When the cells reachabout 80% confluency they are passed to the new flask (Passage 2-P2).Cells are incubated in a humidified 5% CO₂ incubator.

Safety Tests Prior to Freezing hIDPSC from P5 are maintained in culturefor at least 3-5 days in order to collect cell conditioned medium forsterility and mycoplasma testing.

Sterility test are performed by ISO, GMP certified methodologies.

Mycoplasma testing is performed using an in-house RT-PCR test (EZ-PCRBiological Industries) and by ISO, GMP certified.

Freezing and Storage

The hIDPSC freezing protocol is adapted to the standard freezingrepository protocol-hIDPSC from P5 is transferred into 2 mLcryopreservation vials containing 1 mL of freezing media, composed of:90% FBS and 10% DMSO (GMP/US pharmaceutical grade). 1×106 cells per vialare cryopreserved.

Cryopreservation vials are placed inside a Nalgene Cryo loC FreezingContainer filled with isopropyl alcohol and are placed at −80° C.overnight. Thereafter, vials are transferred to the vapor phase of aliquid nitrogen storage tank and their locations recorded.

Control of Materials

Table 17 depicts the process, which used for the control of materials.

TABLE 17 Control of Materials Concentration Source/Country ManufacturingReagent at Use of Origin Manufacturer Step Deciduous Tooth 1 toothBrazil NA Raw material Dulbecco Modified 500 mL Beit Haemek, BiologicalTransporting Eagle Medium-F12 Israel Industries (BI) solution (DMEM-F12)Dulbecco's 500 mL Beit Haemek, Biological Sterile solution PhosphateBuffered Israel Industries (BI) Saline without Calcium and Magnesium(DPBS) Gentamycin 500 mM Beit Haemek, Biological Sterile solution IsraelIndustries (BI) Fetal Bovine Serum 90% Washington HyClone Maintenancemedium; freezing media. L-Glutamine Solution  2 mM Beit Haemek,Biological Maintenance Israel Industries (BI) medium Penicillin- 100,000U/mL Beit Haemek, Biological Sterile solution Streptomycin penicillinand Israel Industries (BI) Solution 100 mg/mL streptomycin Non-essential 2 mM Beit Haemek, Biological Maintenance amino acids Israel Industries(BI) medium TrypLE 1X Gibco Cell-dissociation enzymes DMSO 10% SigmaCryopreservation

Example 15. In Vivo Tumorigenicity

The formation of teratomas is an essential tool in determining thepluripotency of any pluripotent cells, such as embryonic or inducedpluripotent stem cells (ES and iPS cells). A protocol adapted from theprotocol described by Gropp et al., 2012, was used for the assessment ofthe teratoma forming ability of the cells. The method described hereinis based on the subcutaneous co-transplantation of defined numbers ofundifferentiated mouse or human ES and iPS cells and Matrigel intoimmunodeficient mice. The novel method used was shown to be highlyreproducible and efficient when 10⁶ cells (different from Gropp et al.,2012, which used 10⁵ cells) of mouse ES cells and human iPS cells wereused. In 100% of cases teratoma formation was observed in a large numberof animals and in long follow-up (up to 6 months). The method was alsoused to assess the bio-safety of other adult MSC types, such as thosederived from dental pulp of deciduous teeth, umbilical cord, and adiposetissue.

We observed the derivation of induced pluripotent stem cells fromhIDPSC. The pluripotency of hIDPSC derived iPS cells were tested throughteratoma formation, while human embryonic stem (ES) cells and hIDPSCwere used as control. Routine protocol for teratoma production for EScells was used (Hentze et al., 2009). Following this protocol 10⁶ ofcells of each line: hIDPSC-iPS cells, ES cells and hIDPSC wereinoculated in the rear leg muscle of 4-week-old male, SCID. In animals,which were inoculated with hIDPSC-iPS cells or ES cells teratomaformation was observed after three months. However, hIDPSCs, which wereused as a negative control in this study and were inoculated in 10animals, did not produce teratomas neither after three month nor aftersix months of follow-up. Five of these animals were maintained aliveduring one year and even after this time teratomas formation was notobserved.

Histologically, teratoma formation in pluripotent stem cells requiresthe development of tissues derived from the three germ layers. Foradult/mesenchymal stem cells, any alterations in the integrity of normaltissue at the site of transplantation were considered. After six months,animals, which were inoculated with hIDPSCs and did not produceteratomas, were killed and histological specimens of the brain, lung,kidney, spleen, and liver were analyzed of the animals. The presence ofDNA from hIDPSCs was confirmed in all aforementioned organs but no tumorformation or any morphological alterations were observed. Thus, weestablished the safety of cell regeneration by investigational productCELLAVITA™ (stem cells) regarding tumor formation and risk of immunerejection.

Additionally, as shown in the aforementioned studies using hIDPSC inanimal models of spinal cord injury, cranial bone defects, total limbalstem cell deficiency (TLSCD), muscular dystrophy, and osteonecrosis ofthe femoral head (ONFH), no teratoma formation and/or risk of immunerejection were observed (Costa et. al., 2008; Kerkis et al., 2008;Monteiro et al., 2009; Gomes et al., 2010; Feitosa et al., 2010; Almeidaet al., 2011).

FIG. 51 summarizes additional already published preclinical studies,which support the safety of investigational product CELLAVITA™ (stemcells).

Example 16. Principal Criterion for Teratoma Assay

We evaluated the next criterion for a teratoma assay: sensitivity andquantitativity; definitive cell number and single cell suspensionproduction; immunophenotyping of studied cell in respect of expressionon pluripotent cell markers and karyotype; co-transplantation of studiedcells together with Matrigel. The cells were transplanted subcutaneously(s.c) into NOD/SCID mice, which allows for simple monitoring of teratomadevelopment.

The development of tumors was monitored from 4 month (˜16 weeks).Histological criteria for teratomas is the differentiation ofpluripotent cells into the cells derived from three germ layers. Suchstudy usually was performed by pathologist.

For adult/mesenchymal stem cells any type or any changes on normaltissue integrity in the site of cell injection were taken inconsideration.

Application of the Teratoma Criterion A. The Experimental System(s):

a. Mouse embryonic stem cells

b. Mouse 3T3 fibroblasts, permanent mouse cell line Balbc 3T3 cell line,clone A31

c. Human iPS-IDPSC

d. Human ES cells

e. Human IDPSCs

We used aforementioned method in diverse studies to characterizedifferent mouse ES cell lines pluripotency established by us as well asto confirm ES cells pluripotency at high 25 or more passages and forcharacterization of sub-clones obtained from mouse ES cell lines(Sukoyan et al., 2002; Carta et al., 2006; Kerkis et al., 2007;Lavagnolli et al., 2007; Hayshi et al., 2010).

Additionally, this method was used to characterize the pluripotency ofiPS cells derived from immature dental pulp stem cells (IDPSC) in morerecent publication of our group (Beltrão-Braga et al., 2011). In thispublication the human IDPSC were used as a control for iPS-IDPSCs. Weshowed that iPS-IDPSCs formed nice teratomas with tissues originatedfrom all three germ layers, while hIDPSC were not able to produce anytype of teratomas or any other type of neoplasms. In addition,iPS-IDPSCs expressed Nanog in nucleus, and hIDPSCs did not.

Results

Disclosed multiharvest explant like culture used for the isolation of apopulation of immature dental pulp stem cells (IDPSC), results inexpression of embryonic stem cell markers Oct-4, Nanog, SSEA-3, SSEA-4,TRA-1-60 and TRA-1-81 as well as several mesenchymal stem cell markersduring at least 15 passages while maintaining the normal karyotype andthe rate of expansion characteristic of stem cells. The expression ofthese markers was maintained in subclones obtained from these cells.Moreover, in vitro these cells can be induced to undergo uniformdifferentiation into smooth and skeletal muscles, neurons, cartilage,and bone under chemically defined culture conditions. It is important tomentioned that IDPSC although have a small size and cytoplasm poor incell organelles differ from naïve pluripotent cells presenting typicalmesenchymal-fibroblast like morphology. Therefore IDPSC are ofmesenchymal type, in contrast to ES and iPS cells, which are ofepithelial type. The principle difference between MSC and ES or iPScells that MSC are migrating and plastic anchoring, they synthetizeextracellular matrix and are cell junction free cells.

B. The Experimental System(s):

a. IDPSC three different primary cultures at early (n=10) and latepassages (n=10)

b. Human primary fibroblast

In addition, this method was validated using dog fetal stem cells frombone marrow, liver, yolk sac, allantois and amniotic liquid which alsoexpress pluripotent markers.

The IDPSC are composed by population of MSC with a variable number ofstem cells expressing pluripotent markers (1-25% of cells) (Lizier etal., 2012). These cells were transplanted into NOD/SCID mice (n=20) andthe development of tumors was monitored from 4 month (˜16 weeks). Anytype of changes on normal tissue integrity in the site of cell injectionwere taken in consideration. This protocol was adapted for population ofIDPSC, especially in respect of cell number used, which was calculatedon the basis that 20% of IDPSC express pluripotent markers. In ourprevious tests with ES and iPS cells we used 10⁶ cells, while in to testIDPSC and control cells teratogenicity 5×10⁶ cells were used. After 4month, even if macroscopically the tumors were not observed, the micewere sacrificed and frozen cuts were obtained from diverse organs, suchas brain, lung, kidney, spleen, liver and were analyzed by pathologist.

Although the presence of DNA of IDPSCs within all studied organs wasfound, no tumor formation or any morphological changes were observed.

REFERENCES

-   1. Altman J and Das G D. Post-natal origin of microneurones in the    rat brain. Nature 1965; 207: 953-956-   2. Bachoud-Levi A C, Gaura V, Brugieres P, et al. Effect of fetal    neural transplants in patients with Huntington's disease 6 years    after surgery: a long-term follow-up study. Lancet Neurol 2006; 5:    303-09.-   3. Baker S A, Baker K A and Hagg T. Dopaminergic nigrostriatal    projections regulate neural precursor proliferation in the adult    mouse subventricular zone. Eur J Neurosci 2004; 20: 575-579-   4. Brito et al., Imbalance of p75NTR/TrkB protein expression in    Huntington's disease: implication for neuroprotective therapies.    Cell Death and Disease (2013) 4, e595; doi:10.1038/cddis.2013.116-   5. Lescaudron L, Unni D, Dunbar G L. Autologous adult bone marrow    stem cell transplantation in an animal model of huntington's    disease: behavioral and morphological outcomes. Int J Neurosci 2003;    113:945-956.-   6. Vatzey E M, Chen K, Hughes S M, Connor B: Transplanted adult    neural progenitor cells survive, differentiate and reduce motor    function impairment in a rodent model of Huntington's disease. Exp    Neurol 2006; 199:384-396.-   7. C. Uboldi, A. Doring, C. Alt, P. Estess, M. Siegelman, and B.    Engelhardt, “L-Selectin-deficient SJL and C57BL/6 mice are not    resistant to experimental autoimmune encephalomyelitis,” European    Journal of Immunology, vol. 38, no. 8, pp. 2156-2167, 2008.-   8. B. Engelhardt, “Immune cell entry into the central nervous    system: involvement of adhesion molecules and chemokines,” Journal    of the Neurological Sciences, vol. 274, no. 1-2, pp. 23-26, 2008.-   9. S. Kim, K. A. Chang, J. Kim et al., “The preventive and    therapeutic effects of intravenous human adipose-derived stem cells    in Alzheimer's disease mice,” PLoS ONE, vol. 7, no. 9, Article ID    e45757, 2012.-   10. D. Jeon, K. Chu, S. Lee et al., “A cell-free extract from human    adipose stemcells protects mice against epilepsy,” Epilepsia, vol.    52, no. 9, pp. 1617-1626, 2011.-   11. Mullen R J1, Buck C R, Smith A M. NeuN, a neuronal specific    nuclear protein in vertebrates. Development. 1992 September;    116(1):201-11.-   12. Shuo Liu, Dritan Agalliu, Chuanhui Yu and Mark Fisher. The Role    of Pericytes in Blood-Brain Barrier Function and Stroke. Current    Pharmaceutical Design, 2012, 18, 3653-3662.-   13. De Miguel M P, Fuentes-Julián S, Blázquez-Martinez A, Pascual C    Y, Aller M A, Arias J, Arnalich-Montiel F. Immunosuppressive    properties of mesenchymal stem cells: advances and applications.    Curr Mol Med. 2012 June; 12(5):574-91.-   14. Le Blanc K, Ringdén O. Mesenchymal stem cells: properties and    role in clinical bone marrow transplantation. Curr Opin Immunol.    2006 October; 18(5):586-91. Epub 2006 Aug. 1.-   15. Karen English Mechanisms of mesenchymal stromal cell    immunomodulation. Immunol Cell Biol 91: 19-26; advance online    publication, Oct. 23, 2012; doi:10.1038/icb.2012.56-   16. Matthew D Griffin, Aideen E Ryan, Senthilkumar Alagesan, Paul    Lohan, Oliver Treacy and Thomas Ritter Anti-donor immune responses    elicited by allogeneic mesenchymal stem cells: what have we learned    so far? Immunol Cell Biol 91: 40-51; advance online publication,    Dec. 4, 2012; doi:10.1038/icb.2012.67-   17. Svenningsson P, Nishi A, Fisone G, Girault J A, Nairn A C,    Greengard P. DARPP-32: an integrator of neurotransmission. Annu Rev    Pharmacol Toxicol. 2004; 44:269-96.-   18. Crook Z R, Housman D E. Dysregulation of dopamine receptor D2 as    a sensitive measure for Huntington disease pathology in model mice.    Proc Natl Acad Sci USA. 2012 May 8; 109(19):7487-92. doi:    10.1073/pnas.1204542109. Epub 2012 Apr. 23.-   19. Chen J Y, Wang E A, Cepeda C, Levine M S. Dopamine imbalance in    Huntington's disease: a mechanism for the lack of behavioral    flexibility. Front Neurosci. 2013 Jul. 4; 7:114. doi:    10.3389/fnins.2013.00114. eCollection 2013.-   20. Parent M, Bédard C, Pourcher E. Am J Neurodegener Dis. 2013 Sep.    18; 2(3):221-7.-   21. Hoglinger G U, Rizk P, Muriel M P, Duyckaerts C, Oertel W H,    Caille I and Hirsch E C. Nat Neurosci 2004; 7: 726-735).-   22. Wernig M, et al. Proc Natl Acad Sci USA. 2008; 105:5856-5861;    Caiazzo M, et al. Nature. 2011; 476:224-227;-   23. Lindvall, 0. & Kokaia, Z., J Clin Invest., 2010 120, 29.-   24. Calissano P, Matrone C, Amadoro G: Nerve growth factor as a    paradigm of neurotrophins related to Alzheimer's disease. Dev    Neurobiol 2010, 70:372-383.-   25. M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H,    Nagatsu T: Brain-derived growth factor and nerve growth factor    concentrations are decreased in the substantia nigra in Parkinson's    disease. Neurosci Lett 1999, 270:45-48;-   26. Gauthier L R, Charrin B C, Borrell-Pages M, Dompierre J P,    Rangone H, Cordelieres F P, De Mey J, MacDonald M E, Lessmann V,    Humbert S, Saudou F: Huntingtin controls neurotrophic support and    survival of neurons by enhancing BDNF vesicular transport along    microtubules. Cell 2004, 118:127-138;-   27. Strand A D, Baguet Z C, Aragaki A K, Holmans P, Yang L, Cleren    C, Beal M F, Jones L, Kooperberg C, Olson J M, Jones K R: Expression    profiling of Huntington's disease models suggests that brain-derived    neurotrophic factor depletion plays a major role in striatal    degeneration. J Neurosci 2007, 27:11758-11768;-   28. Wictorin K, Bjorklund A, Williams L R, Varon S, Gage F H:    Amelioration of cholinergic neuron atrophy and spatial memory    impairment in aged rats by nerve growth factor Nature 1987,    329:65-68-   29. Sukoyan M A, Kerkis A Y, Mello M R, Kerkis I E, Visintin J A,    Pereira L V. Establishment of new murine embryonic stem cell lines    for the generation of mouse models of human genetic diseases. Braz J    Med Biol Res. 2002 May; 35(5):535-42.-   30. Carta L, Pereira L, Arteaga-Solis E, Lee-Arteaga S Y, Lenart B,    Starcher B, Merkel C A, Sukoyan M, Kerkis A, Hazeki N, Keene D R,    Sakai L Y, Ramirez F. Fibrillins 1 and 2 perform partially    overlapping functions during aortic development. J Biol Chem. 2006    Mar. 24; 281(12):8016-23-   31. Kerkis A, Fonseca S A, Serafim R C, Lavagnolli T M, Abdelmassih    S, Abdelmassih R, Kerkis I. In vitro differentiation of male mouse    embryonic stem cells into both presumptive sperm cells and oocytes.    Cloning Stem Cells. 2007 Winter; 9(4):535-48.-   32. Lavagnolli T M, Fonseca S A, Serafim R C, Pereira V S, Santos E    J, Abdelmassih S, Kerkis A, Kerkis I. Presumptive germ cells derived    from mouse pluripotent somatic cell hybrids. Differentiation. 2009    September-October; 78(2-3):124-30-   33. Hayashi M A, Guerreiro J R, Cassola A C, Lizier N F, Kerkis A,    Camargo A C, Kerkis I. Long-term culture of mouse embryonic stem    cell-derived adherent neurospheres and functional neurons. Tissue    Eng Part C Methods. 2010 December; 16(6):1493-502.-   34. Lima B L, Santos E J, Fernandes G R, Merkel C, Mello M R, Gomes    J P, Soukoyan M, Kerkis A, Massironi S M, Visintin J A, Pereira L V    A new mouse model for marfan syndrome presents phenotypic    variability associated with the genetic background and overall    levels of Fbn1 expression. PLoS One. 2010 Nov. 30; 5(11):e14136.-   35. Beltrão-Braga P C, Pignatari G C, Maiorka P C, Oliveira N A,    Lizier N F, Wenceslau C V, Miglino M A, Muotri A R, Kerkis I.    Feeder-free derivation of induced pluripotent stem cells from human    immature dental pulp stem cells. Cell Transplant. 2011;    20(11-12):1707-19.-   36. Bunting K D ABC transporters as phenotypic markers and    functional regulators of stem cells. Stem Cells. 2002; 20(1):11-20.-   37. Islam M O et al. Characterization of ABC transporter ABCB1    expressed in human neural stem/progenitor cells. FEBS letters. 2005    579(17): 3473-3480.-   38. Mead B, Logan A, Berry M, Leadbeater W, Scheven B A.    Intravitreally transplanted dental pulp stem cells promote    neuroprotection and axon regeneration of retinal ganglion cells    after optic nerve injury. Invest Ophthalmol Vis Sci. 2013;    54:7544-7556.-   39. Mead B, Logan A, Berry M, Leadbeater W, Scheven B A.    Paracrine-mediated neuroprotection and neuritogenesis of axotomised    retinal ganglion cells by human dental pulp stem cells: comparison    with human bone marrow and adipose-derived mesenchymal stem cells.    PLoS One. 2014 Oct. 7; 9(10).-   40. Martens W, Sanen K, Georgiou M, Struys T, Bronckaers A, et al.    Human dental pulp stem cells can differentiate into Schwann cells    and promote and guide neurite outgrowth in an aligned    tissue-engineered collagen construct in vitro. (2013) The FASEB    Journal.-   41. Sakai K, Yamamoto A, Matsubara K, Nakamura S, Naruse M, Yamagata    M, Sakamoto K, Tauchi R, Wakao N, Imagama S, Hibi H, Kadomatsu K,    Ishiguro N, Ueda M. Human dental pulp-derived stem cells promote    locomotor recovery after complete transection of the rat spinal cord    by multiple neuro-regenerative mechanisms. J Clin Invest. 2012; 122:    80-90.-   42. Rampon C, Weiss N, Deboux C, Chaverot N, Miller F, Buchet D,    Tricoire-Leignel H, Cazaubon S, Baron-Van Evercooren A, Couraud P O.    Molecular mechanism of systemic delivery of neural precursor cells    to the brain: assembly of brain endothelial apical cups and control    of transmigration by CD44. Stem Cells. 2008 July; 26(7):1673-82.-   43. Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F, Murphy M,    O'Brien T, Ritter T. Immunogenicity of allogeneic mesenchymal stem    cells. J Cell Mol Med. 2012; 16:2094-2103.-   44. Weinger J G, Weist B M, Plaisted W C, Klaus S M, Walsh C M, Lane    T E. MHC mismatch results in neural progenitor cell rejection    following spinal cord transplantation in a model of viral-induced    demyelination. Stem Cells. 2012 November; 30(11):2584-950-   45. Bifari F, Pacelli L, Krampera M. Immunological properties of    embryonic and adult stem cells. World J Stem Cells. 2010; 2:50-60.-   46. Bertram L, McQueen M B, Mullin K, Blacker D, Tanzi R E. (2007)    “Systematic meta-analyses of Alzheimer disease genetic association    studies: the AlzGene database.” Nat Genet 39(1): 17-23.-   47. Jared B. Vasquez, a David W. Fardo, b and Steven Estusa,* ABCA7    expression is associated with Alzheimer's disease polymorphism and    disease status. Neurosci Lett. Nov. 27, 2014-   48. Yamagata et al. Human Dental Pulp-Derived Stem Cells Protect    Against Hypoxic-Ischemic Brain Injury in Neonatal Mice. Stroke.    2013; 44:551-554.-   49. Albensi, B. C., Sullivan, P. G., Thompson, M. B., Scheff, S. W.    & Mattson, M. P. Cyclosporine ameliorates traumatic brain    injury-induced alterations of hippocampal synaptic plasticity. Exp.    Neurol. 162, 385-389 (2000).-   50. Matsumoto, S., Friberg, H., Ferrand-Drake, M. & Wieloch, T.    Blockade of the mitochondrial permeability transition pore    diminishes infarct size in the rat after transient middle cerebral    artery occlusion. J. Cereb. Blood Flow Metab. 19, 736-741 (1999).-   51. Leventhal L, Jeffrey H. Kordower Cyclosporine A Protects    Striatal Neurons from Mitochondrial Dysfunction. Immunosuppressant    Analogs in Neuroprotection. 2003, pp 159-174.-   52. Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J.,    Larson, B. L., Semprun-Prieto, L., Delafontaine, P., Prockop, D.    J., 2009. Intravenous hMSCs improve myocardial infarction in mice    because cells embolized in lung are activated to secrete the    anti-inflammatory protein TSG-6. Cell Stem Cell 5 (1), 54-63.-   53. Grigoriadis N, Lourbopoulos A, Lagoudaki R, Frischer J m,    Polyzoidou E, Touloumi O, Simeonidou C, Deretzi G, Kountouras J,    Spandou E, Kotta K, Karkavelas G, Tascos N, Lassmann H (2011)    Variable behavior and complications of autologous bone marrow    mesenchymal stem cells transplanted in experimental autoimmune    encephalomyelitis. Experimental neurology 230: 78-89.-   54. E. Y. Snyder. The risk of putting something where it does not    belong: Mesenchymal stem cells produce masses in the brain    Experimental Neurology 230 (2011) 75-77.-   55. Dagur P K, McCoy J P Jr. Endothelial-binding, proinflammatory T    cells identified by MCAM (CD146) expression: Characterization and    role in human autoimmune diseases. Autoimmun Rev. 2015 May;    14(5):415-22.-   56. Ryu J K, Kim J, Cho S J, Hatori K, Nagai A, Choi H B, et al.    Proactive transplantation of human neural stem cells prevents    degeneration of striatal neurons in a rat model of Huntington    disease. Neurobiol Dis. 2004; 16:68-77.-   57. Zuccato C, Ciammola A, Rigamonti D, Leavitt B R, Goffredo D,    Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription    in Huntington's disease. Science. 2001; 293(5529): 493-8.-   58. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in    neurodegenerative diseases. Nat Rev Neurol. 2009; 5(6):311-22.-   59. Altar C A, Cai N, Bliven T, Juhasz M, Conner J M, Acheson A L,    et al. Anterograde transport of brain-derived neurotrophic factor    and its role in the brain. Nature. 1997; 389(6653):856-60.-   60. Baguet Z C, Gorski J A, Jones K R. Early striatal dendrite    deficits followed by neuron loss with advanced age in the absence of    anterograde corticalbrain-derived neurotrophic factor. J Neurosci.    2004; 24(17):4250-8.-   61. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor    in Huntington's disease. Prog Neurobiol. 2007; 81(5-6):294-330.-   62. Baydyuk M, Xu B. BDNF signaling and survival of striatal    neurons. Front Cell Neurosci. 2014; 8:254.

What is claimed is:
 1. A method of treating a neurological disease or condition, comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs, wherein the hIDPSCs express CD44 and CD13.
 2. The method of claim 1, wherein the hIDPSCs lack expression of CD146, HLA-DR, and HLA-ABC.
 3. The method of claim 1, wherein at least 80% of the hIDPSCs secrete BDNF and DARPP-32.
 4. The method of claim 1, wherein the hIDPSCs express ABCG2.
 5. The method of claim 1, wherein the pharmaceutical composition is intravenously administered.
 6. The method of claim 5, wherein the pharmaceutical composition is comprises 10⁴-10¹⁰ hIDPSCs.
 7. The method of claim 1, wherein the neurological disease or condition is a neurodegenerative disease.
 8. The method of claim 7, wherein the neurodegenerative disease is caused by neuronal loss in the striatum, the subventricular zone (SVZ), or the cerebral cortex, accumulation of protein aggregation in the brain, synaptic dysfunction, or combinations thereof.
 9. The method of claim 8, wherein the neurodegenerative disease is Huntington's disease (HD).
 10. The method of claim 9, wherein the subject is diagnosed with early HD.
 11. A method of promoting neuronal growth and repair, reducing neuronal loss, or both in the central nervous system (CNS) of a subject, comprising administering to the subject a pharmaceutical composition comprising hIDPSCs, wherein the hIDPSCs express CD44 and CD13.
 12. The method of claim 11, wherein administration of the pharmaceutical composition is systemic.
 13. The method of claim 11, wherein the hIDPSCs lack expression of CD146, HLA-DR, and HLA-ABC.
 14. The method of claim 11, wherein at least 80% of the hIDPSCs secrete BDNF and DARPP-32.
 15. The method of claim 11, wherein the hIDPSCs express ABCG2.
 16. A method of increasing expression of dopamine- and cAMP-regulated neuronal phosphoprotein (DARPP-32), dopamine receptor D2, brain-derived neurotrophic factor (BDNF), or combinations thereof in the central nervous system (CNS) of a subject, comprising administering to the subject a pharmaceutical composition comprising hIDPSCs, wherein the hIDPSCs express CD44 and CD13.
 17. The method of claim 16, wherein administration of the pharmaceutical composition is systemic.
 18. The method of claim 16, wherein the hIDPSCs lack expression of CD146, HLA-DR, and HLA-ABC.
 19. The method of claim 16, wherein at least 80% of the hIDPSCs secrete BDNF and DARPP-32.
 20. The method of claim 16, wherein the hIDPSCs express ABCG2. 